0001117480-21-000025.txt : 20211104 0001117480-21-000025.hdr.sgml : 20211104 20211104121442 ACCESSION NUMBER: 0001117480-21-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 211378994 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 10-Q 1 cmrx-20210930.htm 10-Q cmrx-20210930
false2021Q3000111748012/31http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent00011174802021-01-012021-09-30xbrli:shares00011174802021-10-31iso4217:USD00011174802021-09-3000011174802020-12-31iso4217:USDxbrli:shares0001117480cmrx:ContractAndGrantMember2021-07-012021-09-300001117480cmrx:ContractAndGrantMember2020-07-012020-09-300001117480cmrx:ContractAndGrantMember2021-01-012021-09-300001117480cmrx:ContractAndGrantMember2020-01-012020-09-300001117480us-gaap:LicenseMember2021-07-012021-09-300001117480us-gaap:LicenseMember2020-07-012020-09-300001117480us-gaap:LicenseMember2021-01-012021-09-300001117480us-gaap:LicenseMember2020-01-012020-09-3000011174802021-07-012021-09-3000011174802020-07-012020-09-3000011174802020-01-012020-09-300001117480us-gaap:CommonStockMember2020-12-310001117480us-gaap:AdditionalPaidInCapitalMember2020-12-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001117480us-gaap:RetainedEarningsMember2020-12-310001117480us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100011174802021-01-012021-03-310001117480us-gaap:CommonStockMember2021-01-012021-03-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001117480us-gaap:RetainedEarningsMember2021-01-012021-03-310001117480us-gaap:CommonStockMember2021-03-310001117480us-gaap:AdditionalPaidInCapitalMember2021-03-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001117480us-gaap:RetainedEarningsMember2021-03-3100011174802021-03-310001117480us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000011174802021-04-012021-06-300001117480us-gaap:CommonStockMember2021-04-012021-06-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001117480us-gaap:RetainedEarningsMember2021-04-012021-06-300001117480us-gaap:CommonStockMember2021-06-300001117480us-gaap:AdditionalPaidInCapitalMember2021-06-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001117480us-gaap:RetainedEarningsMember2021-06-3000011174802021-06-300001117480us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001117480us-gaap:CommonStockMember2021-07-012021-09-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001117480us-gaap:RetainedEarningsMember2021-07-012021-09-300001117480us-gaap:CommonStockMember2021-09-300001117480us-gaap:AdditionalPaidInCapitalMember2021-09-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001117480us-gaap:RetainedEarningsMember2021-09-300001117480us-gaap:CommonStockMember2019-12-310001117480us-gaap:AdditionalPaidInCapitalMember2019-12-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001117480us-gaap:RetainedEarningsMember2019-12-3100011174802019-12-310001117480us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100011174802020-01-012020-03-310001117480us-gaap:CommonStockMember2020-01-012020-03-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001117480us-gaap:RetainedEarningsMember2020-01-012020-03-310001117480us-gaap:CommonStockMember2020-03-310001117480us-gaap:AdditionalPaidInCapitalMember2020-03-310001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001117480us-gaap:RetainedEarningsMember2020-03-3100011174802020-03-310001117480us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000011174802020-04-012020-06-300001117480us-gaap:CommonStockMember2020-04-012020-06-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001117480us-gaap:RetainedEarningsMember2020-04-012020-06-300001117480us-gaap:CommonStockMember2020-06-300001117480us-gaap:AdditionalPaidInCapitalMember2020-06-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001117480us-gaap:RetainedEarningsMember2020-06-3000011174802020-06-300001117480us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001117480us-gaap:CommonStockMember2020-07-012020-09-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001117480us-gaap:RetainedEarningsMember2020-07-012020-09-300001117480us-gaap:CommonStockMember2020-09-300001117480us-gaap:AdditionalPaidInCapitalMember2020-09-300001117480us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001117480us-gaap:RetainedEarningsMember2020-09-3000011174802020-09-30cmrx:product0001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-09-300001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-09-300001117480us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001117480us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001117480us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-12-310001117480us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001117480us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2020-12-310001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001117480us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001117480us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001117480cmrx:ExpenseReimbursementMembercmrx:BARDAMember2011-02-012021-09-010001117480cmrx:BARDAMembercmrx:FeesMember2011-02-012021-09-01cmrx:segment0001117480cmrx:BARDAMember2011-02-012021-09-01cmrx:contractcmrx:grant0001117480cmrx:OncoceuticsIncMembercmrx:FederalGovermentMember2021-09-300001117480cmrx:OncoceuticsIncMembercmrx:PrivateFoundationsMember2021-09-300001117480cmrx:OncoceuticsIncMemberus-gaap:GrantMember2021-09-300001117480cmrx:OncoceuticsIncMemberus-gaap:GrantMember2021-07-012021-09-300001117480cmrx:OncoceuticsIncMemberus-gaap:GrantMember2021-01-012021-09-300001117480cmrx:SymBioPharmaceuticalsMember2019-10-012019-10-310001117480cmrx:SymBioPharmaceuticalsMember2019-09-300001117480cmrx:SymBioPharmaceuticalsMember2019-10-012019-10-310001117480us-gaap:CorporateBondSecuritiesMember2021-09-300001117480us-gaap:USTreasurySecuritiesMember2021-09-300001117480us-gaap:CommercialPaperMember2021-09-300001117480us-gaap:CorporateBondSecuritiesMember2020-12-310001117480us-gaap:USTreasurySecuritiesMember2020-12-31cmrx:securityxbrli:pureutr:sqft0001117480cmrx:RefundableAgreementsMembercmrx:BARDAMember2021-09-300001117480cmrx:RefundableAgreementsMembercmrx:BARDAMember2020-12-310001117480cmrx:PublicStockOfferingMember2021-01-202021-01-2000011174802021-01-200001117480cmrx:PublicStockOfferingMember2021-01-200001117480us-gaap:OverAllotmentOptionMember2021-01-200001117480us-gaap:OverAllotmentOptionMember2021-01-202021-01-200001117480cmrx:The2013PlanMember2021-01-012021-09-300001117480cmrx:The2013PlanMember2021-01-012021-01-010001117480cmrx:The2013PlanMember2021-09-300001117480cmrx:The2013PlanMember2021-07-012021-09-300001117480cmrx:The2013PlanMember2020-07-012020-09-300001117480cmrx:The2013PlanMember2020-01-012020-09-300001117480cmrx:The2013EmployeeStockPurchasePlanMember2021-09-300001117480cmrx:The2013EmployeeStockPurchasePlanMember2021-01-012021-09-300001117480cmrx:The2013EmployeeStockPurchasePlanMember2021-01-012021-01-010001117480cmrx:The2013EmployeeStockPurchasePlanMember2021-07-012021-09-300001117480cmrx:The2013EmployeeStockPurchasePlanMember2020-07-012020-09-300001117480cmrx:The2013EmployeeStockPurchasePlanMember2020-01-012020-09-300001117480us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001117480us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001117480us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001117480us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001117480us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001117480us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001117480us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001117480us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001117480srt:ScenarioForecastMember2021-01-012021-12-31cmrx:extension0001117480cmrx:BARDAMember2011-02-012011-02-280001117480cmrx:BARDAMember2021-07-012021-09-300001117480cmrx:BARDAMember2020-07-012020-09-300001117480cmrx:BARDAMember2021-01-012021-09-300001117480cmrx:BARDAMember2020-01-012020-09-300001117480cmrx:CantexPharmaceuticalsMember2019-07-260001117480cmrx:SymBioPharmaceuticalsMember2019-09-012019-09-300001117480cmrx:OharaPharmaceuticalCoLtdMember2019-12-310001117480cmrx:OncoceuticsIncMembercmrx:SanjiuMedicalPharmaceuticalCoLtdMember2020-12-012020-12-310001117480cmrx:OncoceuticsIncMember2021-01-072021-01-070001117480cmrx:OncoceuticsIncMember2021-09-300001117480cmrx:OncoceuticsIncMember2021-01-070001117480cmrx:OncoceuticsIncMember2020-10-012020-12-310001117480srt:ScenarioForecastMemberus-gaap:SubsequentEventMember2021-10-012021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
(Mark One)
 
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
 
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                  to                
 
Commission file number: 001-35867
 
CHIMERIX, INC.
(Exact Name of Registrant as Specified in Its Charter)  
Delaware 33-0903395
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
  
2505 Meridian Parkway, Suite 100
  
Durham, North Carolina
 27713
(Address of Principal Executive Offices) (Zip Code)
 
(919) 806-1074
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareCMRXThe Nasdaq Global Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x   No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  o
 
Accelerated filer o
Non-accelerated filer ☒
 
Smaller reporting company ☒
 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No x
 
As of October 31, 2021, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 86,862,426.


CHIMERIX, INC.
 
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2021
 
INDEX
  
 Page
 
 

Unless otherwise mentioned or unless the context indicates otherwise, as used in this prospectus, the terms “Chimerix,” “the Company,” “we,” “us” and “our” refer to Chimerix, Inc., a Delaware corporation. We have obtained a registered trademark for Chimerix® and TEMBEXA® in the United States. All other trademarks or trade names referred to in this Quarterly Report on Form 10-Q are the property of their respective owners.


2


PART I - FINANCIAL INFORMATION
 
ITEM 1.    CONSOLIDATED FINANCIAL STATEMENTS
 
CHIMERIX, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited) 
 September 30, 2021December 31, 2020
ASSETS  
Current assets:  
Cash and cash equivalents$26,174 $46,989 
Short-term investments, available-for-sale96,384 31,973 
Accounts receivable53 340 
Inventories1,595 — 
Prepaid expenses and other current assets4,327 2,356 
Total current assets128,533 81,658 
Long-term investments2,035 — 
Property and equipment, net of accumulated depreciation264 214 
Operating lease right-of-use assets2,509 2,825 
Other long-term assets60 26 
Total assets$133,401 $84,723 
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities:  
Accounts payable$1,792 $1,283 
Accrued liabilities10,498 7,250 
Note payable14,000 — 
Total current liabilities26,290 8,533 
Lease-related obligations2,525 2,814 
Total liabilities28,815 11,347 
Stockholders’ equity:  
Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding as of September 30, 2021 and December 31, 2020
— — 
Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2021 and December 31, 2020; 86,848,426 and 62,816,039 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively
87 63 
Additional paid-in capital950,597 785,673 
Accumulated other comprehensive loss, net— — 
Accumulated deficit(846,098)(712,360)
Total stockholders’ equity104,586 73,376 
Total liabilities and stockholders’ equity$133,401 $84,723 
 
The accompanying notes are an integral part of the consolidated financial statements.



3


CHIMERIX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Revenues:
Contract and grant revenue$105 $1,591 $1,928 $4,158 
Licensing revenue2 18 5 94 
Total revenues107 1,609 1,933 4,252 
Operating expenses:    
Research and development13,820 10,018 39,480 27,545 
General and administrative4,887 3,151 13,431 9,466 
Acquired in-process research and development— — 82,890 — 
Total operating expenses18,707 13,169 135,801 37,011 
Loss from operations(18,600)(11,560)(133,868)(32,759)
Other income:
Interest income and other, net40 149 130 912 
Net loss(18,560)(11,411)(133,738)(31,847)
Other comprehensive loss:    
Unrealized gain (loss) on debt investments, net11 (97)— (2)
Comprehensive loss$(18,549)$(11,508)$(133,738)$(31,849)
Per share information:    
Net loss, basic and diluted$(0.21)$(0.18)$(1.59)$(0.51)
Weighted-average shares outstanding, basic and diluted86,335,357 62,242,456 84,277,555 62,009,941 
  
The accompanying notes are an integral part of the consolidated financial statements.

 
4


CHIMERIX, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(in thousands)
(unaudited) 
Common Stock
SharesAmountAdditional
Paid-in Capital		Accumulated Other
Comprehensive
Gain (Loss)		Accumulated
Deficit		Total 
Stockholders’
Equity (Deficit)
Balance, December 31, 202062,816,039 $63 $785,673 $— $(712,360)$73,376 
Share-based compensation— — 2,584 — — 2,584 
Exercise of stock options710,132 1 3,529 — — 3,530 
Employee stock purchase plan purchases259,837 — 330 — — 330 
RSU stock issuance168,752 — — — — — 
Issuance of common stock related to asset acquisition8,723,769 9 43,436 — — 43,445 
Issuance of common stock, net of issuance costs of $7.2 million
13,529,750 13 107,829 — — 107,842 
Comprehensive loss:
Unrealized loss on investments, net— — — (43)— (43)
Net loss— — — — (97,415)(97,415)
Total comprehensive loss(97,458)
Balance, March 31, 202186,208,279 $86 $943,381 $(43)$(809,775)$133,649 
Share-based compensation— — 3,112 — — 3,112 
Exercise of stock options41,465 — 119 — — 119 
Comprehensive loss:
Unrealized gain on investments, net— — — 32 — 32 
Net loss— — — — (17,763)(17,763)
Total comprehensive loss(17,731)
Balance, June 30, 202186,249,744 $86 $946,612 $(11)$(827,538)$119,149 
Share-based compensation— — 3,431 — — 3,431 
Exercise of stock options74,588 — 130 — — 130 
Employee stock purchase plan purchases283,094 1 424 — — 425 
RSU stock issuance241,000 — — — — — 
Comprehensive loss:
Unrealized loss on investments, net— — — 11 — 11 
Net loss— — — — (18,560)(18,560)
Total comprehensive loss(18,549)
Balance, September 30, 202186,848,426 $87 $950,597 $— $(846,098)$104,586 

5


Common Stock
SharesAmountAdditional
Paid-in Capital		Accumulated Other
Comprehensive
Gain (Loss)		Accumulated
Deficit		Total 
Stockholders’
Equity (Deficit)
Balance, December 31, 201961,590,013 $62 $778,693 $35 $(668,838)$109,952 
Share-based compensation— — 1,326 — — 1,326 
Employee stock purchase plan purchases177,193 — 229 — — 229 
RSU stock issuance163,133 — — — — — 
Comprehensive loss:
Unrealized loss on investments, net— — — (46)— (46)
Net loss— — — — (10,420)(10,420)
Total comprehensive loss(10,466)
Balance, March 31, 202061,930,339 $62 $780,248 $(11)$(679,258)$101,041 
Share-based compensation— — 1,391 — — 1,391 
Exercise of stock options242,079 — 578 — — 578 
Comprehensive loss:
Unrealized gain on investments, net— — — 141 — 141 
Net loss— — — — (10,016)(10,016)
Total comprehensive loss(9,875)
Balance, June 30, 202062,172,418 $62 $782,217 $130 $(689,274)$93,135 
Share-based compensation— — 1,282 — — 1,282 
Exercise of stock options20,592 1 62 — — 63 
Employee stock purchase plan purchases159,879 — 197 — — 197 
RSU stock issuance276,833 — — — — — 
Comprehensive loss:
Unrealized loss on investments, net— — — (97)— (97)
Net loss— — — — (11,411)(11,411)
Total comprehensive loss(11,508)
Balance, September 30, 202062,629,722 $63 $783,758 $33 $(700,685)$83,169 

6


CHIMERIX, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited) 
 Nine Months Ended September 30,
 20212020
Cash flows from operating activities:  
Net loss$(133,738)$(31,847)
Adjustments to reconcile net loss to net cash used in operating activities:
  
Depreciation of property and equipment143 309 
Amortization of discount/premium on investments648 (268)
Share-based compensation 9,127 4,000 
Fair value of common stock issued related to asset acquisition43,445 — 
Note payable related to asset acquisition14,000 
Gain on sale of investments(2)(1)
Gain on sale of equipment— (10)
Lease-related amortization314 (47)
Changes in operating assets and liabilities:  
Accounts receivable288 855 
Inventories(1,595)— 
Prepaid expenses and other assets(2,005)1,284 
Accounts payable and accrued liabilities3,468 (1,268)
Net cash used in operating activities(65,907)(26,993)
Cash flows from investing activities:  
Purchases of property and equipment(193)(60)
Proceeds from sale of property and equipment— 10 
Purchases of short-term investments(105,355)(58,895)
Purchases of long-term investments(9,594)— 
Proceeds from sales of short-term investments2,007 1,498 
Proceeds from maturities of short-term investments45,850 104,602 
Net cash (used in) provided by investing activities(67,285)47,155 
Cash flows from financing activities:  
Proceeds from exercise of stock options3,780 641 
Proceeds from employee stock purchase plan754 426 
Proceeds from issuance of common stock, net of commissions107,843 — 
Net cash provided by financing activities112,377 1,067 
Net (decrease) increase in cash and cash equivalents(20,815)21,229 
Cash and cash equivalents:
Beginning of period46,989 16,901 
End of period$26,174 $38,130 
 
The accompanying notes are an integral part of the consolidated financial statements.

 
 
7


CHIMERIX, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
 
Note 1. The Business and Summary of Significant Accounting Policies
 
Description of Business

Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Our two most advanced clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in Phase 3 development as a potential first-line therapy in acute myeloid leukemia (AML).

Basis of Presentation

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of the Company’s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year. 

Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.
 
For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.
 
The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:
 
•Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
•Level 2 — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.
•Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

At September 30, 2021 and December 31, 2020, the Company had cash equivalents including money market funds, whose value is based on quoted market prices. At September 30, 2021 and December 31, 2020, the Company had short-term investments, including U.S. Treasury securities, whose value is based on quoted market prices. At September 30, 2021, the Company had long-term investments including U.S. Treasury securities, whose value is based on quoted market prices. Accordingly, these securities are classified as Level 1.
 
8


At September 30, 2021, the Company had short-term investments, including commercial paper, and corporate bonds, and on December 31, 2020, the Company had short-term investments including corporate bonds. As quoted prices are not available for these securities, they are valued using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security’s credit rating, prepayment assumptions and other factors such as credit loss assumptions. Accordingly, these securities are classified as Level 2.
 
There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company's investments, please refer to Note 2, "Investments."
 
Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):
 
Fair Value Measurements
September 30, 2021
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$20,165 $20,165 $— $— 
          Total cash equivalents20,165 20,165 — — 
Short-term investments
     U.S. treasury securities7,534 7,534 — — 
     Commercial paper51,277 — 51,277 — 
     Corporate bonds37,573 — 37,573 — 
          Total short-term investments96,384 7,534 88,850 — 
Long-term investments
     U.S. treasury securities2,035 2,035 — — 
          Total long-term investments2,035 2,035 — — 
               Total assets$118,584 $29,734 $88,850 $— 
Fair Value Measurements
December 31, 2020
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$1,503 $1,503 $— $— 
          Total cash equivalents1,503 1,503 — — 
Short-term investments
     U.S. treasury securities28,715 28,715 — — 
     Corporate bonds3,258 — 3,258 — 
          Total short-term investments31,973 28,715 3,258 — 
               Total assets$33,476 $30,218 $3,258 $— 
  
Inventories

The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories.

9


At September 30, 2021, the Company’s inventory is related to TEMBEXA, which is being manufactured for the treatment of smallpox and potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.

The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The Company's inventories at September 30, 2021 consisted of $1.6 million of work-in-process and no finished goods.

The Company’s assessment of market value requires the use of estimates regarding the net realizable value of its inventory balances, including an assessment of excess or obsolete inventory. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. The Company determines excess or obsolete inventory based on multiple factors, including an estimate of the future demand for its products, product expiration dates and current sales levels. The Company’s assumptions of future demand for its products are inherently uncertain and if the Company were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that the Company reports in a particular period. In addition, the Company's inventory may experience expiration of its shelf-life stability. During the nine months ended September 30, 2021, the Company did not record a reserve for inventory as the Company assumes TEMBEXA will be sold to the US government under a procurement contract with Biomedical Advanced Research and Development Authority (BARDA) or could be sold to other governmental agencies. Should no procurement contract be secured in the future, the Company may reserve part or all of our inventory balance, which would be included in cost of sales.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):
September 30, 2021December 31, 2020
Accrued research and development expenses$3,276 $1,375 
Accrued compensation4,502 4,473 
Accrued legal expenses213 651 
Other accrued liabilities2,507 751 
Total accrued liabilities$10,498 $7,250 

Revenue Recognition

Policy

The Company’s revenues generally consist of (i) contract and grant revenue - revenue generated under federal and private foundation grants and contracts, and (ii) collaboration and licensing revenue - revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.

Biomedical Advanced Research and Development Authority (BARDA)

In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees over the performance of one base segment and four option segments. Exercise of each option segment was solely at the discretion of BARDA. The Company assessed the services in accordance with the authoritative guidance and concluded that there was a potential of five separate contracts (one base segment and four option segments) within this agreement, each of which had a single performance obligation. All option segments (one through four) were exercised, as well as the base segment. The transaction price for each segment, based on the transaction price as defined in
10


each segment contract, was allocated to the single performance obligation for each contract. The transaction price was recognized over time by measuring the progress toward complete satisfaction of the performance obligation. For reimbursable expenses, this occurred as qualifying research activities were conducted based on invoices from company vendors. For the fixed fee, the progress toward complete satisfaction was estimated based on the costs incurred to date relative to the total estimated costs per the terms of each contract. The Company typically invoiced BARDA monthly as costs were incurred. Any amounts received in advance of performance were recorded as deferred revenue until earned. The base segment and first option segment were completed prior to adoption of ASC 606. The second and third option segments were completed on August 20, 2020. The fourth option segment was completed on September 1, 2021 and the contract has expired in accordance with its terms.

Grant Revenue

Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. As a result of its acquisition of Oncoceutics, Inc. (Oncoceutics), the Company became the beneficiary of two federal grant programs and two grant programs with private foundations, of which the federal grant programs ended in the third quarter of 2021. At September 30, 2021, the Company has a deferred revenue balance of $0.2 million related to these grants. Additionally, for the three and nine months ended September 30, 2021, the Company recognized $18,000 and $0.4 million of grant revenue related to these grants, respectively.

SymBio Pharmaceuticals

On September 30, 2019, the Company entered into a license agreement with SymBio Pharmaceuticals Limited (SymBio) under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. The Company assessed the agreement in accordance with the authoritative guidance and concluded that the SymBio contract includes multiple performance obligations. The SymBio contract has one fixed transaction amount of a $5.0 million upfront payment received in October 2019 and several variable transaction amounts, up to $180 million, due to the Company at certain regulatory and commercial milestones, along with low double-digit percent royalties based on net sales of TEMBEXA. All variable transaction amounts are fully constrained, therefore the allocated transaction price is $5.0 million. The majority of the transaction price of the contract has been allocated to the combined performance obligation of the granting of the license to TEMBEXA and associated technology transfer which was recognized when the technology transfer was completed in the fourth quarter of 2019. The revenue from regulatory and commercial milestones and royalties from net sales will be recognized upon the occurrence of the triggering events or when those transaction amounts are no longer fully constrained.
 
Research and Development Prepaids and Accruals

As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.

The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
 
Basic and Diluted Net Loss Per Share of Common Stock 

Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net loss per share of common stock is computed by dividing net loss by
11


the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three and nine months ended September 30, 2021 and 2020.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Segments

The Company operates in only one segment, pharmaceuticals.

Impact of Recently Issued Accounting Standards

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements.

Note 2. Investments
 
The following tables summarize the Company's debt investments (in thousands):
 September 30, 2021
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$37,579 $1 $(7)$37,573 
U.S. treasury securities9,568 2 (1)9,569 
Commercial paper51,272 7 (2)51,277 
Total investments$98,419 $10 $(10)$98,419 
 December 31, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$3,256 $2 $— $3,258 
U.S. treasury securities28,717 1 (3)28,715 
Total investments$31,973 $3 $(3)$31,973 
 
12


The following tables summarize the Company's debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):

September 30, 2021
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
Corporate bonds$27,554 $(7)$— $— $27,554 $(7)
Commercial paper10,491 (2)— — 10,491 (2)
U.S. treasury securities7,034 (1)— — 7,034 (1)
Total$45,079 $(10)$— $— $45,079 $(10)
Number of securities with unrealized losses16 — 16 
December 31, 2020
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
U.S. treasury securities$16,598 $(3)$— $— $16,598 $(3)
Total$16,598 $(3)$— $— $16,598 $(3)
Number of securities with unrealized losses6 — 6 

The Company periodically reviews available-for-sale debt investments for other-than-temporary declines in fair value below the cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company’s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. At September 30, 2021, the Company did not intend to sell, and was not more likely than not to be required to sell, the available-for-sale debt investments in an unrealized loss position before recovery of the cost basis of the securities, which may be at maturity. There were no such declines in value for the three and nine months ended September 30, 2021 and 2020. Unrealized gains and losses on debt investments are recorded to unrealized (loss) gain on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.

The following table summarizes the scheduled maturity for the Company's debt investments at September 30, 2021 (in thousands):
Maturing in one year or less$96,384 
Maturing after one year through two years2,035 
     Total debt investments$98,419 
 
Note 3. Commitments and Contingencies
 
Leases

The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company's sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company's discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company's operating leases as of September 30, 2021 was 4.84 years.

13


Expense related to leases is recorded on a straight-line basis over the lease term. Lease expense under operating leases, including common area maintenance fees, totaled approximately $0.2 million and $0.2 million, respectively, for the three months ended September 30, 2021 and 2020 and approximately $0.5 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.

The discount rate implicit within the Company's leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of September 30, 2021, the operating lease liabilities reflect a weighted-average discount rate of 7.89%.

The following table sets forth the operating lease right-of-use assets and liabilities as of September 30, 2021 (in thousands):
Assets
Operating lease right-of-use assets $2,509 
Liabilities
Operating lease short-term liabilities (recorded within Accrued liabilities)$416 
Operating lease long-term liabilities (recorded within Lease-related obligations)2,525 
     Total operating lease liabilities$2,941 

Operating lease payments over the remainder of the lease terms are as follows (in thousands):
Years Ending December 31,As of September 30, 2021
2021 (1)$97 
2022715 
2023736 
2024759 
2025781 
All remaining years467 
Total future minimum rental payments$3,555 
     Less amount of lease payments representing interest614 
Total present value of lease payments$2,941 

(1)The Company entered into the Ninth Amendment of its lease for the Company's headquarters in Durham, North Carolina, which extended the term of the lease by 65 months to July 31, 2026. As part of the amendment, the Company is entitled to receive a rent abatement of the first five months of the new lease term which began on March 1, 2021. Additionally, the Ninth Amendment grants the Company a refurbishment allowance, which the Company expects to receive in 2021 after the refurbishment has been completed.

As of December 31, 2020, operating lease payments over the remainder of the lease terms were as follows (in thousands):
Years Ending December 31,As of December 31, 2020
2021$260 
2022715 
2023736 
2024759 
2025781 
Thereafter467 
Total future minimum rental payments$3,718 
     Less amount of lease payments representing interest792 
Total present value of lease payments$2,926 

For the three months ended September 30, 2021 and 2020, the Company made lease payments of approximately $122,000 and $181,000, respectively, and for the nine months ended September 30, 2021 and 2020, the Company made lease payments of approximately $292,000 and $538,000, respectively.

14


Sublease

The Company subleased 3,537 square feet of its office space under a non-cancelable operating lease that expired in February 2021. For the three and nine months ended September 30, 2021, the Company recognized $0 and approximately $12,000 of income, respectively, and for the three and nine months ended September 30, 2020, the Company recognized approximately $18,000 and $53,000 of income, respectively, in Interest income and other, net on the Consolidated Statement of Operations and Comprehensive Loss. As this lease has terminated, there are no future minimum rentals payments to be received.

Significance of Revenue Source

The Company is the recipient of federal research contract funds from BARDA, the primary source of the Company's contract and grant revenue. Periodic audits are required under the Company’s BARDA agreement and certain costs may be questioned as appropriate under the BARDA agreement. At September 30, 2021 and December 31, 2020, the Company had recorded a provision for potential refundable amounts of $52,000 and $38,000, respectively.
 
Note 4. Equity Transactions and Share-based Compensation

Common Stock

On January 20, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 11,765,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share (the Common Stock). The price to the public in this offering was $8.50 per share, and the Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $7.99 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,764,750 additional shares of Common Stock at the public offering price. The net proceeds to the Company from this offering were approximately $107.8 million, as the Underwriters’ option to purchase additional shares was exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on January 25, 2021.

Stock Options

The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increases on January 1 of each calendar year by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. On January 1, 2021, the common stock reserved for issuance under the 2013 Plan was automatically increased by 2.5 million shares. As of September 30, 2021, there was a total of 2.2 million shares reserved for future issuance under the 2013 Plan. The Company issued approximately 75,000 and 826,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2021, respectively. The Company issued 21,000 and 263,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2020, respectively.

Employee Stock Purchase Plan

The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of its designated affiliates. The Company has reserved a total of 3.9 million shares of common stock to be purchased under the ESPP, of which 2.3 million shares remained available for purchase as of September 30, 2021. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, by the lesser of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 422,535 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b). On January 1, 2021, the common stock reserved for issuance under the ESPP was automatically increased by an additional 422,535 shares.

The ESPP provides for an automatic reset feature to start participants on a new twenty-four month participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the twenty-four month offering period. Eligible employees may authorize an amount up to 15% of their salary to purchase common stock at the lower of a 15% discount to the beginning price of their offering period or a 15% discount to the ending price of
15


each six-month purchase interval. The Company issued approximately 283,000 and 160,000 shares of common stock pursuant to the ESPP during the three months ended September 30, 2021 and 2020, respectively. The Company issued approximately 543,000 and 337,000 shares of common stock pursuant to the ESPP during the nine months ended September 30, 2021 and 2020, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the “look-back” option and were determined using a Black-Scholes option pricing model.

Restricted Stock Units

The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company's common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company's common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued 241,000 shares and approximately 410,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2021, respectively. The Company issued 277,000 shares and approximately 440,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2020, respectively.

Stock-based Compensation

For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Research and development expense$1,853 $625 $4,995 $2,090 
General and administrative expense1,578 657 4,132 1,910 
          Total share-based compensation expense$3,431 $1,282 $9,127 $4,000 

Note 5. Income Taxes
 
The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the nine month period ended September 30, 2021, and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740.

Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable.
 
At September 30, 2021, the Company had no unrecognized tax benefits that would reduce the Company’s effective tax rate if recognized.

Note 6. Significant Agreements
     
Biomedical Advanced Research and Development Authority (BARDA)

In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, BARDA agreed to reimburse the Company, plus pay a fixed fee, for the research and development of TEMBEXA as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections. The contract consists of an initial performance period, referred to as the base performance segment, plus up to four extension periods, referred to as option segments, of which all have been exercised. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees.

The fourth option segment ended on September 1, 2021 and the contract has expired in accordance with its terms. For the three months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $0.1 million and $1.6
16


million, respectively, and for the nine months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $1.6 million and $4.2 million, respectively.

Cantex Pharmaceuticals, Inc.

In July 2019, the Company entered into a License and Development Agreement with Cantex Pharmaceuticals, Inc. (Cantex) pursuant to which the Company acquired exclusive worldwide rights to develop and commercialize, for any and all uses, a glycosaminoglycan compound known as DSTAT, which is currently being studied for the treatment of acute myeloid leukemia. Under the terms of the license agreement, the Company is responsible for, and bears the future costs of, worldwide development and commercialization of DSTAT. In connection with the transaction, Cantex assigned to the Company all of its rights under its DSTAT supply agreements, including its bulk API agreement with Scientific Protein Laboratories LLC (SPL), including subsequent amendments, pursuant to which SPL will exclusively produce DSTAT for the Company through December 2040.

The license agreement obligates the Company to pay Cantex regulatory milestone payments of up to $202.5 million upon receipt of product approvals in the United States, the European Union and Japan, and sales milestone payments of up to $385.0 million upon achievement of specified net sales levels. The Company also agreed to pay Cantex tiered royalties based on percentages of net sales beginning at 10% and not to exceed the high-teens.

SymBio Pharmaceuticals

On September 30, 2019, the Company entered into a license agreement with SymBio under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. Under the terms of the license agreement, SymBio will be responsible for, and bear the future costs of, worldwide development and commercialization of TEMBEXA in the licensed indications. Either party may terminate the license agreement upon the occurrence of a material breach by the other party (subject to standard cure periods). SymBio may also terminate the license agreement without cause on a country-by-country basis upon ninety days' prior notice.

In exchange for the license to SymBio under the Company's TEMBEXA rights, the Company received an upfront payment of $5.0 million in October 2019. In addition, the Company is eligible to receive up to $180.0 million in clinical, regulatory and commercial milestones worldwide, as well as low double-digit percent royalties based on net sales of TEMBEXA. Since entering into the license agreement in September 2019, the Company has recognized all of the $5.0 million upfront payment.

Ohara Agreement

In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan.

CR Sanjiu Agreement

In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in China.

Note 7. Oncoceutics Acquisition

On January 7, 2021, the Company, Ocean Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (Merger Sub), Oncoceutics and Fortis Advisors, LLC solely in its capacity as representative of the securityholders of Oncoceutics (the Securityholders’ Representative), entered into an Agreement and Plan of Merger (the Merger Agreement). Concurrently with the execution of the Merger Agreement, Merger Sub merged with and into Oncoceutics (the Merger) whereupon the separate corporate existence of Merger Sub ceased, with Oncoceutics continuing as the surviving corporation of the Merger as a wholly-owned subsidiary of the Company.

17


As consideration for the Merger, the Company (a) paid an upfront cash payment of approximately $25.0 million, subject to certain customary adjustments, (b) issued an aggregate of 8,723,769 shares of the Company's common stock, (c) issued a promissory note to the Securityholders' Representative in the principal amount of $14.0 million (the Seller Note), to be paid in cash, subject to the terms and conditions of the Merger Agreement and the Seller Note, upon the one year anniversary of the closing of the Merger, and (d) agreed to make contingent payments up to an aggregate of $360.0 million based on the achievement of certain development, regulatory and commercialization events as set forth in the Merger Agreement, as well as additional tiered royalty payments based upon future net sales of ONC 201 and ONC 206 products, subject to certain reductions as set forth in the Merger Agreement, and a contingent payment in the event the Company receives any proceeds from the sale of a rare pediatric disease priority review voucher based on Oncoceutics' products. The closing payment may be adjusted after the closing, pursuant to procedures set forth in the Merger Agreement, in connection with the finalization of the cash, transaction expenses, debt and working capital amounts at closing. As of September 30, 2021, the Company has recorded an estimated liability of $0.2 million related to closing payment adjustments. Additionally, as of September 30, 2021, the Company has recorded an estimated receivable of $0.6 million related to the repayment of certain severance amounts due from the Oncoceutics' shareholders.

The Company accounted for the Oncoceutics acquisition as an asset acquisition as the majority of the value of the assets acquired related to the ONC201 acquired in-process research and development (IPR&D) asset. In accordance with Accounting Standards Codification (ASC) Subtopic 730-10-25, Accounting for Research and Development Costs, the up-front payments to acquire a new drug compound, as well as future milestone payments when paid or payable, are immediately expensed as acquired IPR&D in transactions other than a business combination provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Therefore, the portion of the purchase price that was allocated to the IPR&D assets acquired was immediately expensed. Other assets acquired and liabilities assumed, were recorded at fair value.

The following represents the consideration paid and purchase price allocation for the acquisition of Oncoceutics (in thousands, except for per share data):

Cash$23,836 
One-year closing anniversary payment14,000 
Shares common stock issued as consideration8,723,769 
Stock price per share on effective date4.98 
Value of estimated common stock consideration43,445 
Total consideration$81,281 
Net assets acquired$(1,310)
IPR&D assets expensed82,591 
Total purchase price allocated$81,281 
Transaction costs expensed to IPR&D(1)
$299 
Total IPR&D expensed$82,890 

(1) As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired. The primary asset acquired, the IPR&D asset, was expensed and the transaction related costs were included with and expensed with this asset. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses. Additionally, there were $0.6 million of expenses related to this acquisition recorded in the fourth quarter of 2020 to general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss.

Note 8. Subsequent Events

The Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of September 30, 2021, and events which occurred subsequently but were not recognized in the financial statements.

18


In accordance with the terms of the merger agreement between Chimerix and Oncoceutics, Inc., the achievement of the 20% overall response rate (ORR) via Blinded Independent Central Review (BICR) will result in a success milestone payment of $20 million to the former Oncoceutics, Inc. shareholders to be paid prior to year-end.

19


ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2020 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (SEC) on February 25, 2021. Past operating results are not necessarily indicative of results that may occur in future periods.
 
Forward-Looking Statements
The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item IA, “Risk Factors” in this Quarterly Report on Form 10-Q and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.
 
OVERVIEW

Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Our two most advanced clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in Phase 3 development as a potential first-line therapy in acute myeloid leukemia (AML).

Recent Developments

TEMBEXA (brincidofovir, BCV)

On June 4, 2021, the FDA granted TEMBEXA approval for the treatment of smallpox. TEMBEXA is available in tablets and oral suspension. It is approved for adult and pediatric patients, including neonates. TEMBEXA was developed as a medical countermeasure for the treatment of smallpox under an ongoing collaboration with Biomedical Advanced Research and Development Authority (BARDA). On July 19, 2021, the FDA confirmed that, following the recent approval, TEMBEXA is entitled to seven years’ orphan exclusivity for the treatment of smallpox beginning with the June 4, 2021 marketing approval. In addition to orphan exclusivity, TEMBEXA patent coverage is expected to extend to 2034.

TEMBEXA potentially fills an important role as a treatment countermeasure to smallpox; it has a differentiated mechanism of action, a relatively high barrier to resistance and available evidence suggests it can be used in patients who have received the other FDA approved smallpox antiviral treatment. In September, an article was published in the peer review journal, Antiviral Research, providing a thorough assessment of TEMBEXA as a medical counter measure for smallpox.

By year-end, we expect to complete initial TEMBEXA drug product manufacturing in order to execute first shipments to the strategic national stockpile in response to a potential procurement contract to support national preparedness in the United States.

Imipridones - ONC201, ONC206 and ONC212

Imipridones are a potential new class of selective cancer therapies. Clinical trials of ONC201 in glioma patients with the H3 K27M-mutation are underway at several locations in the U.S. Based on discussions with the FDA, we plan to integrate data from the ongoing ONC201 clinical studies into a registration cohort, along with a natural history study and other supporting clinical pharmacological data and CMC with the potential for New Drug Application (NDA) submission seeking accelerated approval.
20




ONC201 - Results from 50 Patient Cohort of ONC201 in Recurrent H3 K27M-mutant Glioma

On November 4, 2021, we reported top-line results from the blinded independent central review (BICR) efficacy analysis. The efficacy analysis by BICR of the 50 patient cohort determined the overall response rate (ORR) to be 20.0% (95% Confidence Interval (CI): 10.0-33.7%) as determined by Response Assessment in Neuro-Oncology Criteria for High Grade Gliomas (RANO-HGG). The median duration of response (mDOR) was 11.2 months (95% CI: 3.8 - not reached) and the median time to response (mTTR) was 8.3 months.

The cohort for a potential registration of ONC201 was comprised of the first 50 patients enrolled across five ONC201 clinical studies that met certain criteria. These patients were two years of age or older, had measurable diffuse midline glioma, harbored the H3 K27M mutation and had evidence of progression following prior therapy with at least radiation completed at least 90 days prior to enrollment, among certain other criteria.

One serious adverse event identified by an investigator was possibly related to ONC201. Full safety data collection and analysis for this cohort is ongoing. Prior safety review of ONC201 identified the most commonly reported adverse events (AEs) as nausea/vomiting, fatigue and decreased lymphocyte counts.

This data along with other supportive clinical data from the ONC201 clinical studies, a natural history evaluation, other supporting clinical pharmacology data and chemistry, manufacturing and controls (CMC) support will be compiled for review with the U.S. FDA in 2022.

In accordance with the terms of the merger agreement between Chimerix and Oncoceutics, Inc., the achievement of the 20% ORR via BICR will result in a success milestone payment of $20 million to the former Oncoceutics, Inc. shareholders to be paid prior to year-end.

ONC206 and ONC212

Phase 1 clinical trials for ONC206, our second imipridone product candidate, and IND-enabling work for our third imipridone candidate, ONC212, remain ongoing.

Dociparstat for First-Line Acute Myeloid Leukemia (AML)

During 2020, we conducted an end of Phase 2 meeting with the FDA related to our development of DSTAT in AML, which informed the design of the Phase 3 trial. We are currently enrolling in our 570-subject Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of DSTAT in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients. Chimerix expects to unblind data following enrollment of the first 80 evaluable patients in this study to assess complete response rates and minimal residual disease rates between the study arm and the control arm. To date, enrollment of this study has proceeded more slowly than expected due to hospital staffing shortages related to COVID-19. We expect to complete enrollment of the first 80 evaluable patients in the second half of 2022.

Business Development Review

In addition to our transactions with Cantex Pharmaceuticals, Inc. (Cantex), SymBio Pharmaceuticals Limited (SymBio) and Oncoceutics, Inc. (Oncoceutics), management is continuing to conduct a review and assessment of potential transaction opportunities with the goal of building our product candidate pipeline, including, but not limited to, licensing, merger or acquisition transactions, issuing or transferring shares of common stock, or the license, purchase or sale of specific assets, in addition to other potential actions aimed at maximizing stockholder value. There can be no assurance that this review will result in the identification or consummation of any additional transaction.

FINANCIAL OVERVIEW

Revenues

To date, we have not generated any revenue from product sales. All of our revenue to date has been derived from government grants and a contract and the receipt of up-front proceeds under our collaboration and license agreements.
21



In February 2011, we entered into a contract with BARDA, a U.S. governmental agency that supports the advanced research and development, manufacturing, acquisition, and stockpiling of medical countermeasures. The contract originally consisted of an initial performance period, referred to as the base performance segment, which ended on May 31, 2013, plus up to four extension periods, referred to as option segments, which have all been exercised. The contract was a cost-plus fixed fee development contract. Under the contract we received $72.5 million in expense reimbursement and $4.6 million in fees. The fourth and final option segment ended on September 1, 2021 and the contract expired in accordance with its terms. Under the BARDA contract, we recognized revenue of $0.1 million and $1.6 million during the three months ended September 30, 2021 and 2020, respectively, and we recognized revenue of $1.6 million and $4.2 million during the nine months ended September 30, 2021 and 2020, respectively.

In September 2019, we entered into a license agreement with SymBio for worldwide rights to develop, manufacture and commercialize TEMBEXA in all human indications, excluding the use for treatment of orthopoxviruses, including smallpox. Under the contract, we received a $5.0 million upfront payment in October 2019 and could receive up to an additional $180.0 million in potential regulatory and commercial milestones. Since the license agreement was entered into in September 2019, we have recognized all of the $5.0 million of revenue related to the upfront payment. The revenue from regulatory and commercial milestones and royalties from net sales will be recognized upon occurrence of the triggering events.
 
In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of any product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.
 
Research and Development Expenses

Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our product candidates. We recognize research and development expenses as they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors. We cannot determine with certainty the duration and completion costs of the current or future clinical studies of any product candidates. Our research and development expenses consist primarily of:
 
•fees paid to consultants and contract research organizations (CROs), including in connection with preclinical and clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis;
•salaries and related overhead expenses, which include stock option, restricted stock units and employee stock purchase program compensation and benefits, for personnel in research and development functions;
•payments to third-party manufacturers, which produce, test and package drug substance and drug product (including continued testing of process validation and stability);
•costs related to legal and compliance with regulatory requirements; and
•license fees for and milestone payments related to licensed products and technologies.
 
22


The table below summarizes our research and development expenses for the periods indicated (in thousands). Our direct research and development expenses consist primarily of external costs, such as fees paid to investigators, consultants, central laboratories and CROs, in connection with our clinical trials, preclinical development, and payments to third-party manufacturers of drug substance and drug product. We typically use our employee and infrastructure resources across multiple research and development programs.
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Direct research and development expenses$7,296 $5,943 $19,169 $15,151 
Research and development personnel costs - excluding stock-based compensation4,081 2,770 13,171 8,286 
Research and development personnel costs - stock-based compensation1,853 625 4,995 2,090 
Indirect research and development expenses590 680 2,145 2,018 
Total research and development expenses$13,820 $10,018 $39,480 $27,545 
 
The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the development of any product candidates or the period, if any, in which material net cash inflows from any product candidates may commence. This is due to the numerous risks and uncertainties associated with our business, as detailed in Part II, Item IA, “Risk Factors” in this Quarterly Report on Form 10-Q and in our other filings with the SEC.

TEMBEXA (Brincidofovir, BCV)

We developed TEMBEXA for the treatment of smallpox. FDA marketing approval for TEMBEXA was received on June 4, 2021. Under our cost-plus-fixed fee BARDA contract, we incurred expenses in connection with the development of orthopoxvirus animal models, the demonstration of efficacy and pharmacokinetics of TEMBEXA in the animal models, the conduct of clinical studies for subjects with DNA viral infections, the manufacture and process validation of bulk drug substance and TEMBEXA 100 mg tablets and TEMBEXA 10 mg/mL oral suspension, and submission of the NDAs to the FDA. In addition, we have incurred additional supportive costs for the development of TEMBEXA for smallpox that we did not seek reimbursement for from BARDA. We have incurred costs related to the manufacturing of TEMBEXA for a possible procurement contract. These costs were expensed as incurred until the June approval. Following the June approval, costs related to the manufacturing of TEMBEXA are recorded and shown as inventory on the Consolidated Balance Sheets.

Imipridones program

In January 2021, we acquired Oncoceutics. In connection with the transaction, we recorded $82.9 million of acquired in-process research and development expenses for the three months ended March 31, 2021, which included $25.0 million for an upfront payment to Oncoceutics, $43.4 million related to the fair value of 8,723,769 shares common stock issued to Oncoceutics, a $14.0 million promissory note due on the one-year anniversary of the acquisition, and $0.3 million related to transaction costs consisting primarily of legal and professional fees. As we continue to develop and prepare Oncoceutics’ lead compound, ONC201, for a U.S. regulatory approval, we expect to incur significant research and development expense. We also plan to incur development expenses in connection with the continued development of other Oncoceutics' compounds, including ONC206 and ONC212.

Dociparstat sodium (DSTAT)

As we continue to focus on the development of DSTAT for treatment of AML patients, we expect research and development expense to increase with the ongoing and planned clinical trials. We are currently enrolling our Phase 3 DASH AML trial.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance, marketing, investor relations, information technology, legal, human resources and administrative support functions, including share-based compensation expenses and benefits. Other significant general and administrative expenses include costs related to accounting and legal services, costs of various consultants, director and officer liability insurance, occupancy costs and information systems.
23


 
Interest Income and Other, Net

Interest income and other, net consists primarily of interest earned on our cash, cash equivalents and short-term and long-term investments.
 
Share-based Compensation  

The Financial Accounting Standards Board authoritative guidance requires that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. Total consolidated share-based compensation expense of $3.4 million and $1.3 million was recognized in the three months ended September 30, 2021 and 2020, respectively, and $9.1 million and $4.0 million was recognized in the nine months ended September 30, 2021 and 2020, respectively. The share-based compensation expense recognized included expense for stock options, RSUs and employee stock purchase plan purchase rights.
 
We estimate the fair value of our share-based awards to employees and directors using the Black-Scholes pricing model. This estimate is affected by our stock price as well as assumptions including the expected volatility, expected term, risk-free interest rate, expected dividend yield, expected rate of forfeiture and the fair value of the underlying common stock on the date of grant. 

For performance-based RSUs, we begin to recognize the expense when it is deemed probable that the performance-based goal will be achieved. We evaluate the probability of achieving performance-based goals on a quarterly basis.
 
CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
 
Our management’s discussion and analysis of financial condition and results of operations is based on our unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. In addition, our reported financial condition and results of operations could vary if new accounting standards are enacted that are applicable to our business.

We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity in Note 1 to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 25, 2021. There have been no material changes during the nine months ended September 30, 2021 to our critical accounting policies, significant judgments and estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.

24


RESULTS OF OPERATIONS 

Comparison of the Three Months Ended September 30, 2021 and September 30, 2020

The following table summarizes our results of operations for the three months ended September 30, 2021 and September 30, 2020, together with the changes in those items (in thousands, except percentages): 
 
 Three Months Ended September 30,Dollar Change% Change
 20212020Increase/(Decrease)
Revenues:
Contract and grant revenue$105 $1,591 $(1,486)(93.4)%
Licensing revenue2 18 (16)(88.9)
Total revenues107 1,609 (1,502)(93.3)%
Operating expenses:    
Research and development13,820 10,018 3,802 38.0 %
General and administrative4,887 3,151 1,736 55.1 %
Total operating expenses18,707 13,169 5,538 42.1 %
Loss from operations(18,600)(11,560)(7,040)60.9 %
Other income:
Interest income and other, net40 149 (109)(73.2)%
Net loss$(18,560)$(11,411)$(7,149)62.7 %

Contract and Licensing Revenue

For the three months ended September 30, 2021, total contract and licensing revenue decreased to $0.1 million compared to $1.6 million for the three months ended September 30, 2020. The decrease of $1.5 million, or 93.3%, is primarily attributable to a decrease in reimbursable expenses under our contract with BARDA.

Research and Development Expenses

For the three months ended September 30, 2021, our research and development expenses increased to $13.8 million compared to $10.0 million for the three months ended September 30, 2020. The increase of $3.8 million, or 38.0%, is primarily related to the following:

•an increase of $4.8 million in research and development expenses related to our ongoing clinical trials in patients, preparation of data for the efficacy analysis by Blinded Independent Central Review of ONC201 in recurrent H3 K27M-mutant glioma patients, and the development and manufacture of ONC201 and ONC206 drug substance and drug product; and
•an increase of $2.5 million in compensation expenses, of which $1.2 million is related to non-cash stock compensation, to support development of our current pipeline; offset by
•a decrease of $2.4 million in brincidofovir development expenses with the approval of TEMBEXA in June 2021;
•a decrease of $1.1 million in DSTAT development costs primarily related to curtailment of the Phase 2 trial to assess DSTAT for acute lung injury in COVID-19 patients.

General and Administrative Expenses

For the three months ended September 30, 2021, our general and administrative expenses increased to $4.9 million compared to $3.2 million for the three months ended September 30, 2020. The increase of $1.7 million, or 55.1%, is primarily related to the following:

•an increase of $1.2 million in compensation expenses, of which $0.9 million is related to non-cash stock compensation expense; and
•an increase of $0.5 million in consulting, legal and operational expenses with the growth of the company’s infrastructure.

25


Interest Income and Other, Net

For the three months ended September 30, 2021, our interest income and other, net decreased to $40,000 compared to $0.1 million for the three months ended September 30, 2020. This decrease is attributable to amortization of our investment premium balances offsetting interest earned.

Comparison of the Nine Months Ended September 30, 2021 and September 30, 2020

The following table summarizes our results of operations for the nine months ended September 30, 2021 and September 30, 2020, together with the changes in those items (in thousands except percentages): 
 
 Nine Months Ended September 30,Dollar Change% Change
 20212020Increase/(Decrease)
Revenues:
Contract and grant revenue$1,928 $4,158 $(2,230)(53.6)%
Licensing revenue5 94 (89)(94.7)%
Total revenues$1,933 $4,252 (2,319)(54.5)%
Operating expenses:  
Research and development$39,480 $27,545 11,935 43.3 %
General and administrative13,431 9,466 3,965 41.9 %
Acquired in-process research and development$82,890 $— $82,890 *
Total operating expenses135,801 37,011 98,790 266.9 %
Loss from operations(133,868)(32,759)(101,109)308.6 %
Other income:
Interest income and other, net130 912 (782)(85.7)%
Net loss$(133,738)$(31,847)$(101,891)319.9 %
* Not meaningful or not calculable

Contract and Licensing Revenue

For the nine months ended September 30, 2021, total contract and licensing revenue decreased to $1.9 million compared to $4.3 million for the nine months ended September 30, 2020. The decrease of $2.3 million, or 54.5%, is primarily related to a decrease in reimbursable expenses under our contract with BARDA.

Research and Development Expenses

For the nine months ended September 30, 2021, our research and development expenses increased to $39.5 million compared to $27.5 million for the nine months ended September 30, 2020. The increase of $11.9 million, or 43.3%, is primarily related to the following:

•an increase of $8.8 million related to research and development expenses of our ongoing clinical trials in patients, preparation of data for the efficacy analysis by Blinded Independent Central Review ONC201 in recurrent H3 K27M-mutant glioma, toxicology studies and development and the manufacture of ONC201 and ONC206 drug substance and drug product; and
•an increase of $7.7 million in compensation expenses, of which $2.9 million relates to non-cash compensation to support development of our current pipeline; offset by
•a decrease of $3.3 million in brincidofovir development expenses with the approval of TEMBEXA in June 2021; and
•a decrease of $1.5 million in DSTAT development costs related to curtailment of the Phase 2 trial to assess DSTAT for acute lung injury in COVID-19 patients.
26



General and Administrative Expenses

For the nine months ended September 30, 2021, our general and administrative expenses increased to $13.4 million compared to $9.5 million for the nine months ended September 30, 2020. The increase of $4.0 million, or 41.9%, is primarily related to the following:

•an increase of $2.8 million in compensation, of which $2.2 million relates to non-cash stock compensation; and
•an increase of $1.1 million in consulting, legal other operational expense with the growth of the company’s infrastructure.

Acquired In-process Research and Development Expenses

In connection with our acquisition of Oncoceutics in January 2021, we recorded a total of $82.9 million of acquired in-process research and development expenses for the nine months ended September 30, 2021, which included $25.0 million for an upfront payment to Oncoceutics, $43.4 million related to the fair value of the 8,723,769 shares of common stock issued to Oncoceutics, a $14.0 million promissory note due on the one-year anniversary of the acquisition and $0.3 million related to transaction costs consisting primarily of legal and professional fees.

Interest Income and Other, Net

For the nine months ended September 30, 2021, our interest income and other, net decreased to $0.1 million compared to $0.9 million for the nine months ended September 30, 2020. This decrease is attributable to amortization of our investment premium balances offsetting interest earned.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2021, we had capital available to fund operations of approximately $124.6 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. We have incurred losses since our inception in 2000 and as of September 30, 2021, we had an accumulated deficit of $846.1 million. We may continue to incur losses for the foreseeable future. The size of our losses will depend, in part, on the rate of future expenditures and our ability to generate revenues.

On August 10, 2020, we entered into an Open Market Sale AgreementSM (the Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, up to $75 million of shares of our common stock. Sales of our common stock made pursuant to the Jefferies Sales Agreement, if any, will be made under our shelf registration statement on Form S-3 (File No. 333-244146), which was declared effective by the SEC on August 17, 2020. As of September 30, 2021, we have not sold any shares of our common stock under the Jefferies Sales Agreement.

On January 20, 2021, we entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 11,765,000 shares (the Shares) of our common stock. The price to the public in this offering was $8.50 per share, and the Underwriters agreed to purchase the Shares from us pursuant to the Underwriting Agreement at a price of $7.99 per share. Under the terms of the Underwriting Agreement, we granted the Underwriters a 30-day option to purchase up to 1,764,750 additional shares of our common stock at the public offering price. The net proceeds to us from this offering were approximately $107.8 million, as the Underwriters’ option to purchase additional shares was exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on January 25, 2021.

On May 6, 2021, we filed an automatic shelf registration statement on Form S-3 with the SEC, which became effective upon filing, pursuant to which we registered for sale an unlimited amount of any combination of our common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a “well-known seasoned issuer” under SEC rules, This registration statement will remain in effect for up to three years from the date it became effective. As of September 30, 2021, no sales have been made under the automatic shelf registration statement.

We cannot assure that adequate funding will be available on terms acceptable to us, if at all. Any additional equity financings will be dilutive to our stockholders and any additional debt may involve operating covenants that may restrict our business. If adequate funds are not available through these means, we may be required to curtail significantly one or more of our research or development programs, and any launch and other commercialization expenses for any of our products that may receive
27


marketing approval. We cannot assure you that we will successfully develop or commercialize our products under development or that our products, if successfully developed, will generate revenues sufficient to enable us to earn a profit.

We believe that our existing cash, cash equivalents, and investments will enable us to fund our current operating expenses and capital requirements for at least the next 12 months. However, changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate.

Cash Flows

The following table sets forth the significant sources and uses of cash (in thousands): 
 Nine Months Ended September 30,
 20212020
Cash sources and uses:  
Net cash used in operating activities$(65,907)$(26,993)
Net cash (used in) provided by investing activities(67,285)47,155 
Net cash provided by financing activities112,377 1,067 
Net (decrease) increase in cash and cash equivalents$(20,815)$21,229 

The table above sets forth the net decrease or increase in cash and cash equivalents alone and not the change in our total capital available to fund operations, which also includes short-term and long-term investments. Cash and cash equivalents includes cash on hand and securities with original maturities of 90 days or less.
 
Operating Activities

Net cash used in operating activities of $65.9 million for the nine months ended September 30, 2021 was primarily the result of our $133.7 million net loss, partially offset by the change in operating assets and liabilities and the add-back of non-cash expenses. The change in operating assets and liabilities includes an increase of $3.5 million in accounts payable and accrued liabilities and a decrease in accounts receivable of $0.3 million, partially offset by an increase in prepaid expenses and other assets of $2.0 million and an increase in inventories of $1.6 million. Non-cash expenses included add-backs of $43.4 million for the fair value of common stock issued in relation to the Oncoceutics acquisition, $14.0 million for the note payable due on the one-year anniversary of the Oncoceutics acquisition, $9.1 million for share-based compensation, $0.1 million of depreciation of property and equipment and $0.6 million of amortization of discount/premium on investments. Net cash used in operating activities of $27.0 million for the nine months ended September 30, 2020 was primarily the result of our $31.8 million net loss offset by the change in operating assets and liabilities and the add-back of non-cash expenses. The change in operating assets and liabilities includes a decrease in prepaid expenses and other assets of $1.3 million and a decrease in accounts receivable of $0.9 million related to work on the BARDA contract, partially offset by a decrease of $1.3 million in accounts payable and accrued liabilities. Non-cash expenses included add-backs of $4.0 million for share-based compensation and $0.3 million of depreciation of property and equipment, offset by $0.3 million of amortization of discount/premium on investments.

Investing Activities

Net cash used in investing activities of $67.3 million for the nine months ended September 30, 2021 was primarily the result of the purchase of $105.4 million in short-term investments and the purchase of $9.6 million in long-term investments, partially offset by the maturity of $45.9 million in short-term investments and the sale of $2.0 million in short-term investments. Net cash provided by investing activities of $47.2 million for the nine months ended September 30, 2020 was primarily the result of the maturity of $104.6 million in short-term investments and the sale of $1.5 million in short-term investments, partially offset by the purchase of $58.9 million in short-term investments.

Financing Activities

Net cash provided by financing activities of $112.4 million for the nine months ended September 30, 2021 was primarily the result of $107.8 million in proceeds from the issuance of common stock and $4.5 million in proceeds from the exercise of stock options and stock purchases through our ESPP. Net cash provided by financing activities of $1.1 million for the nine months ended September 30, 2020 was primarily the result of $1.1 million in proceeds from the exercise of stock options and stock purchases through our ESPP.

28


CONTRACTUAL OBLIGATIONS AND COMMITMENTS
 
There have been no material changes to our contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations and Commitments” as contained in our Annual Report on Form 10-K for the year ended December 31, 2020 filed by us with the SEC on February 25, 2021.
 
Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.
29


ITEM 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.
 
We do not believe that our cash, cash equivalents and available-for-sale investments have significant risk of default or illiquidity. While we believe our cash and cash equivalents and certificates of deposit do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain certain amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.
 
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations for the three and nine months ended September 30, 2021 or September 30, 2020.
 
ITEM 4.     CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of September 30, 2021, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
 
Changes in Internal Control Over Financial Reporting

We routinely review our internal control over financial reporting and from time to time make changes intended to enhance the effectiveness of our internal control over financial reporting. We will continue to evaluate the effectiveness of our disclosure controls and procedures and internal control over financial reporting on an ongoing basis and will take action as appropriate. There have been no changes to our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the third quarter of 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
30


PART II - OTHER INFORMATION
 
ITEM 1.     LEGAL PROCEEDINGS
 
None.
 
ITEM 1A.        RISK FACTORS

Summary of Risk Factors

Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading “Risk Factors” below.

•We have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.
•We have only obtained regulatory approval for TEMBEXA, and all of our other product candidates are still under clinical development and may not obtain regulatory approval or be successfully commercialized. We may be unable to obtain, or may be delayed in obtaining, regulatory approval for other most advanced clinical candidates: ONC201 and DSTAT.
•Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates.
•Even though we have obtained regulatory approval for TEMBEXA, or if we obtain regulatory approval for any of our product candidates, including ONC201 and DSTAT, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.
•We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product candidates. We rely on limited sources of supply for the drug components for each of our product candidates including, TEMBEXA, ONC201 and DSTAT, and any disruption in the chain of supply for either of these product candidates may cause delays in their development and commercialization.
•We are evaluating external assets to build our pipeline of product candidates and there can be no assurance that we will be successful in identifying or completing a transaction for a candidate, that any such transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business. For example, we may experience difficulties in integrating the operations of Oncoceutics into our business and in realizing the expected benefits of the merger with Oncoceutics.
•If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our market.
•If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, delays in the development of our product candidates, penalties and a loss of business.
•We face risks related to the coronavirus (COVID-19) outbreak, which could significantly disrupt our preclinical studies and clinical trials

An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information contained elsewhere in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. We have marked with an asterisk (*) those risk factors that reflect changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on February 25, 2021.

Risks Related To Our Financial Condition and Need For Additional Capital

We have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.*

We are a biopharmaceutical company focused primarily on developing and commercializing TEMBEXA for the treatment of smallpox, ONC201 for the treatment of recurrent H3 K27M-mutant glioma and dociparstat (DSTAT) for the treatment of acute myeloid leukemia (AML). We have incurred significant net losses in each year since our inception, including net losses of
31


$133.7 million and $31.8 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, we had an accumulated deficit of approximately $846.1 million.

To date, we have financed our operations primarily through the sale of equity securities and, to a lesser extent, through government funding, licensing fees and debt. We have devoted most of our financial resources to research and development, including our preclinical development activities and clinical trials. We may continue to incur losses and negative cash flows for the foreseeable future. The size of any loss will depend, in part, on the rate of future expenditures and our ability to generate revenues. In particular, we expect to incur substantial expenses as we seek to:

•continue development and manufacturing activities related to imipridones, including ONC201 for the treatment of recurrent H3 K27M-mutant glioma, and other potential indications;
•continue development and manufacturing activities related to DSTAT for the treatment of AML and other potential indications;
•Enter into an agreement with BARDA to sell TEMBEXA into the US Strategic National Stockpile as a medical countermeasure for the treatment of smallpox;
•obtain regulatory approvals for ONC201 and DSTAT;
•scale-up manufacturing capabilities to commercialize TEMBEXA and in the event we receive regulatory approval, ONC201 and DSTAT;
•identify and in-license additional product candidates to expand our research and development pipeline;
•maintain, expand and protect our intellectual property portfolio; and
•continue our internal research and development efforts and seek to discover additional product candidates.

To become and remain profitable, we must succeed in developing and eventually commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including acquiring or discovering product candidates, completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We are only in the preliminary stages of some of these activities.

To date, we have only obtained regulatory approval for TEMBEXA, and none of our product candidates have been commercialized. We may not succeed in developing additional product candidates or commercializing any product candidate. If we do not successfully develop or commercialize any product candidate, or if revenues from any products that do receive regulatory approvals are insufficient, we will not achieve profitability and our business may fail. In addition to these risks in the United States, assuming regulatory approval in other geographies, our revenues are also dependent upon the size of markets outside of the United States, as well as our ability to obtain market approval and achieve commercial success outside of the United States.

Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.

Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates.*

Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We may not generate revenues from product sales for the foreseeable future. Our ability to generate future revenues from product sales depends heavily on our success in:

•reaching agreement with the US Federal government for the procurement of TEMBEXA in a dollar amount consistent with management's expectations, or at all;
•obtaining favorable results for and advancing development of imipridones, including ONC201 for the treatment of recurrent H3 K27M-mutant glioma, and other potential indications;
•obtaining favorable results for and advancing the development of DSTAT for the treatment of AML, and for a BARDA procurement agreement for TEMBEXA for the treatment of smallpox;
•obtaining United States regulatory approval(s) for ONC201 and DSTAT;
•obtaining foreign regulatory approval(s) for TEMBEXA, ONC201 and DSTAT;
•generating, licensing or otherwise acquiring a pipeline of product candidates which progress to clinical development, regulatory approval, and commercialization.
32



Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data required to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely increase if we do not obtain favorable results or if development of any product candidate is delayed. In particular, we would likely incur higher costs than we currently anticipate if development of any product candidate is delayed because we are required by the FDA or foreign regulatory authorities to perform studies or trials in addition to those that we currently anticipate, or we decide to conduct additional studies or trials for strategic reasons.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict with certainty the timing or amount of any increase in our anticipated development costs that will result should any additional trials be necessary.

In addition, TEMBEXA, or any product candidate if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that may not be commercially available for a number of years, if at all. For any approved product candidate, we anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved product candidate, or that we will achieve or maintain profitability even if we do generate sales.

If we fail to obtain additional financing, we could be forced to delay, reduce or eliminate our product development programs, seek corporate partners for the development of our product development programs or relinquish or license on unfavorable terms, our rights to technologies or product candidates.*

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete. We believe that our existing capital available to fund operations will enable us to fund our current operating expenses and capital requirements for at least the next twelve months. Changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate, and our clinical trials may encounter technical, enrollment or other difficulties that could increase our development costs more than we expected, or because the FDA or foreign regulatory authorities require us to perform studies or trials in addition to those that we currently anticipate.

In July 2019, we entered into a License and Development Agreement with Cantex in which we acquired an exclusive worldwide license to develop and commercialize DSTAT. We are currently enrolling a Phase 3 trial in AML.

In January 2021, we acquired Oncoceutics, Inc. (Oncoceutics), a privately-held, clinical-stage biotechnology company developing imipridones, a novel potential class of compounds. Oncoceutics’ lead product candidate, ONC201, selectively induced cell death in multiple cancer types in clinical trials. ONC201 is currently being evaluated in multiple clinical studies including in a registrational program for recurrent H3 K27M-mutant glioma.

We are also pursuing additional external opportunities to build our pipeline of product candidates, and we may need to raise additional funds if we identify additional product candidates, which we may obtain through one or more equity offerings, debt financings, government or other third-party funding, strategic alliances and licensing or collaboration arrangements.

Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our most advanced clinical compounds, or any other product candidate. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:

•significantly delay, scale back or discontinue the development or commercialization of TEMBEXA, ONC201, DSTAT, or any other product candidate;
•seek corporate partners for TEMBEXA, ONC201, DSTAT, or any other product candidate at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or
•relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.

If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.

33


We are evaluating external assets to build our pipeline of product candidates and there can be no assurance that we will be successful in identifying or completing a transaction for a candidate, that any such transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business.

In early 2019, we initiated a review of external assets that could be added to our pipeline of product candidates. In July 2019, in connection with this process, we entered into a License and Development Agreement with Cantex Pharmaceuticals, Inc. (Cantex) pursuant to which we acquired exclusive worldwide rights to develop and commercialize DSTAT for any and all uses. In January 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, including ONC201. In connection with these transactions, we are responsible for, and bear the future costs of, development and commercialization of the acquired compounds. These costs will be substantial, and we may require additional capital in order to pursue the development and commercialization of these compounds as planned. Moreover, the anticipated benefits of these transactions may never be realized due to the various risks and uncertainties associated with drug development detailed elsewhere in the risk factors.

In addition to our current assets, we may in-license or acquire additional assets, engage in a merger or acquisition transaction, issue additional shares of our common stock, or engage in other potential actions designed to maximize stockholder value. Our continuing review of external assets may not result in the identification or consummation of any transaction. The process of reviewing external opportunities may be time consuming and disruptive to our business operations and, if we are unable to effectively manage the process, our business, financial condition and results of operations could be adversely affected. We could incur substantial expenses associated with identifying, evaluating, negotiating, and consummating potential transactions. There can be no assurance that any potential additional transaction, if consummated, will provide greater value to our stockholders than that reflected in the current price of our common stock. In addition, once any potential additional transaction is consummated, we are likely to incur substantial costs associated with future development and testing of any new product candidate, which may require us to raise additional capital.

 Risks Related to Clinical Development and Regulatory Approval

We face risks related to the coronavirus (COVID-19) outbreak, which could significantly disrupt our preclinical studies and clinical trials.

The duration and the geographic impact of the business disruption and related financial impact resulting from the coronavirus cannot be reasonably estimated at this time and our business could be adversely impacted by the effects. We are currently conducting clinical trials of our product candidates in the United States. We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our non-clinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs. Similarly, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. We also rely on third party suppliers and contract manufacturers to produce the drug product we utilize in our clinical trials, and the outbreak may cause delays in delivery and increases in the cost of active pharmaceutical ingredients (APIs) and drug product.  As a result, the expected timeline for data readouts of our non-clinical studies and clinical trials and certain regulatory filings may be negatively impacted, and our APIs and drug product may become more expensive to obtain. The COVID-19 pandemic is also causing disruption of global financial markets which, if sustained or recurrent, could make it more difficult for us to access capital. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change, and may adversely affect our business, healthcare systems and the global economy as a whole.

We have only received regulatory approval for TEMBEXA, and all our other product candidates are still under clinical development and may not obtain regulatory approval or be successfully commercialized.*

We have not marketed, distributed or sold any products. Our product candidates are ONC201, which we are developing for the treatment of recurrent H3 K27M-mutant glioma, as well as DSTAT, which we are developing for the treatment of AML and other potential indications. We are in late-stage clinical development for both ONC201 and DSTAT.

There is no guarantee that our current or future clinical trials will be approved by regulators, and no guarantee that they will be completed or, if completed, will be successful, or if successful, will result in an approval for the sale of any of our product candidates. The success of each of DSTAT, ONC201 and TEMBEXA will depend on several factors, including the following:

•generating positive safety and efficacy data from our clinical trials of DSTAT and ONC201;
•receipt of marketing approvals from the FDA and corresponding regulatory authorities outside the United States;
•establishing manufacturing capabilities necessary for a registration trial and commercialization of DSTAT;
34


•establishing commercial manufacturing capabilities for TEMBEXA;
•acceptance of the product, if approved for marketing;
•effectively competing with other therapies;
•a continued acceptable safety profile of the product following approval; and
•obtaining, maintaining, enforcing and defending intellectual property rights and claims.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize TEMBEXA, ONC201, and DSTAT, which would materially harm our business.

We may be unable to obtain, or may be delayed in obtaining, regulatory approval for our most advanced clinical candidates: ONC201 and DSTAT.*

In July 2019, we entered into a license agreement with Cantex where we acquired an exclusive license to global development and commercialization rights to DSTAT. We are currently enrolling our 570-subject Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML.

In January 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, a novel potential class of compounds. Oncoceutics’ lead product candidate, ONC201, is currently being evaluated in multiple clinical studies including in a registrational program for recurrent H3 K27M-mutant glioma.

We have not yet reached agreement with the FDA or foreign regulators regarding the adequacy of these planned studies, for any of our most advanced clinical candidates, with respect to a potential approval for marketing. We may be required to conduct additional clinical, nonclinical or manufacturing validation studies and submit those data before reconsideration of our application occurs. Depending on the extent of these or any other required studies, approval of any NDA or application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA and/or foreign health authorities to approve our NDA or foreign application.

In particular, based on discussions with the FDA, we plan to integrate data from ongoing ONC201 trials into a registration cohort with the potential for an NDA submission seeking accelerated approval of ONC201 in the United States. Recently, the FDA has announced that the agency’s Oncology Center of Excellence reassessed the marketing authorizations for several oncology medicines that received accelerated approvals where their confirmatory clinical trials did not demonstrate clinical benefit. It is possible that the occurrence or outcome of such reassessment may make it more difficult for us to apply for or obtain accelerated approval based on data from ongoing trials of our clinical candidates ONC201 and DSTAT. It is also possible that confirmatory clinical trials may not demonstrate clinical benefit.

Any delay in obtaining, or an inability to obtain, regulatory approvals could prevent us from generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for ONC201 and/or DSTAT, which would have a material adverse effect on our business and could potentially cause us to cease operations.

We depend on the successful completion of clinical trials for our product candidates, including ONC201 and DSTAT. The positive clinical results obtained for our product candidates in prior clinical studies may not be repeated in future clinical studies.

Before obtaining regulatory approval for the sale of our product candidates, including ONC201 and DSTAT, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

We may experience a number of unforeseen events during, or as a result of, clinical trials for our product candidates, that could adversely affect the completion of our clinical trials, including:

•regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
35


•clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
•we might be required to change one of our clinical research organizations (CROs) during ongoing clinical programs;
•the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, or subjects may drop out of these clinical trials at a higher rate than we anticipate;
•our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
•we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks, or other factors such as the impact of the ongoing COVID-19 pandemic;
•regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory or quality requirements;
•the cost of clinical trials of our product candidates may be greater than we anticipate;
•we may encounter agency or judicial enforcement actions which impact our clinical trials;
•the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or
•our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials.

We do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our most advanced product candidates, including ONC201 and DSTAT. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for any of our product candidates may be adversely impacted.

Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.

Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all.

Events which may result in a delay or unsuccessful completion of clinical trials, including our currently planned or future clinical trials for either ONC201 or DSTAT, include:

•inability to raise funding necessary to initiate or continue a trial;
•delays in obtaining, or failure to obtain, regulatory approval of Investigational New Drug applications or to commence a trial;
•delays in reaching agreement with the FDA and foreign health authorities on final trial design;
•imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;
•delays caused by disagreements with existing CROs and/or clinical trial sites;
•delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
•delays in obtaining, or failure to obtain, required IRB or ethics committee (EC) approvals covering each site;
•delays in recruiting suitable patients to participate in a trial;
•delays in having subjects complete participation in a trial or return for post-treatment follow-up;
•delays caused by subjects dropping out of a trial due to side effects or otherwise;
•clinical sites declining to participate or dropping out of a trial to the detriment of enrollment;
•agency or judicial enforcement actions against us;
•changes in standard of care in specific diseases;
•time required to add new clinical sites; and
•delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.

Many of the above factors may be caused or exacerbated by the impact of the ongoing COVID-19 pandemic. If initiation or completion of any of our clinical trials for our product candidates, are delayed for any of the above reasons, our development costs may increase, our approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may have more time to bring products to market
36


before we do. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our business.

Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.

Adverse events (AEs) caused by our product candidates could cause us, other reviewing entities, clinical study sites or regulatory authorities to interrupt, delay or halt clinical studies and could result in the denial of regulatory approval. For example, subjects enrolled in clinical trials for DSTAT have experienced febrile neutropenia and liver enzyme elevations. If an unacceptable frequency and/or severity of AEs are reported in our clinical trials for our product candidates, our ability to obtain regulatory approval for product candidates may be negatively impacted.

If any of our approved products cause serious or unexpected side effects prior to or after receiving market approval, a number of potentially significant negative consequences could result, including:

•regulatory authorities may approve the product only with a risk evaluation and mitigation strategy (REMS), potentially with restrictions on distribution and other elements to assure safe use (ETASU);
•regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a modified REMS;
•regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;
•we may be required to change the way the product is administered or to conduct additional clinical studies;
•we could be sued and held liable for harm caused to patients; and
•our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates.

After the completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize any of our product candidates and we cannot, therefore, predict the timing of any future revenue from ONC201 or DSTAT.*

We cannot commercialize our product candidates, including ONC201 and DSTAT, until the appropriate regulatory authorities have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for any of our product candidates. Delays may occur because we may not be able to obtain accelerated approval for our product candidates and large confirmatory studies may be needed. For ONC201, a diagnostic test may be needed to identify patients with H3 K27M-mutant glioma before approval. Additional delays in the United States may result if any of our product candidates is brought before an FDA advisory committee, which could recommend restrictions on approval or recommend non-approval of the product candidate. In the EU context, an Oral Explanation during MAA review could extend approval timelines and result in a Negative Opinion. A re-examination procedure is available in the EU whereby a Negative Opinion could be over-turned and become a Positive Opinion. New rapporteurs would be selected for the product. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. As a result, we cannot predict when, if at all, we will receive any future revenue from commercialization of any of our product candidates.

The FDA may determine that ONC201 or any of our other product candidates, if approved, do not meet the eligibility criteria for a priority review voucher.*

Upon regulatory approval of a product candidate for a rare pediatric disease, neglected tropical disease, or medical countermeasure, the FDA may award to the sponsor of the treatment a transferable voucher that enables the bearer to priority review of another product candidate.

The FDA has granted rare pediatric disease designation to ONC201 for treatment of H3 K27M-mutant glioma. Designation of a drug for a rare pediatric disease does not guarantee that an NDA for such drug will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act (FDCA), we will need to request a rare pediatric disease priority review voucher in our original NDA for ONC201. The
37


FDA may determine that an NDA for ONC201, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:

•treatment of H3 K27M-mutant glioma no longer meets the definition of a rare pediatric disease;
•the NDA contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in an NDA;
•the NDA is not deemed eligible for priority review;
•the NDA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population (that is, if the NDA does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or
•the NDA is approved for a different adult indication than the rare pediatric disease for which ONC201 is designated.

The authority for the FDA to award rare pediatric disease priority review vouchers for drugs that have received rare pediatric disease designation prior to September 30, 2024 currently expires on September 30, 2026, although it is possible the FDA’s authority to award rare pediatric disease priority review vouchers will be further extended through federal lawmaking. Absent any such extension, if the NDA for ONC201 is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease priority review voucher, it will not be eligible for a priority review voucher.

Similar risks apply to any of our other product candidates that may be eligible for a priority review voucher.

Following regulatory approval for TEMBEXA, or should any of our product candidates be approved, including ONC201 and DSTAT, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.*

Even if we obtain regulatory approval, the granting authority may still impose significant restrictions on the indicated uses, distribution or marketing of our product candidates, including ONC201, DSTAT and TEMBEXA, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the labeling ultimately approved for our product candidates, will likely include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data obtained in those evaluations. In addition, the distribution of ONC201, DSTAT or TEMBEXA may be tightly controlled through a REMS with ETASU, which are required medical interventions or other actions healthcare professionals need to execute prior to prescribing or dispensing the drug to the patient. For ONC201, a diagnostic test may be needed to identify the patients with H3 K27M-mutant glioma after approval.

With respect to the FDA’s approval of TEMBEXA for the treatment of smallpox, we received approval according to the Animal Rule and are subject to certain post-approval requirements. For example, we will need to conduct a large confirmatory clinical trial during a smallpox outbreak, which may be expensive and time-consuming and may not confirm the benefit making the marketing approval for TEMBEXA subject to withdrawal by the FDA, which could significantly harm our business. This study may be difficult to enroll due to the size and/or location of the smallpox outbreak. These outbreak studies are highly specialized in their design and conduct and are associated with considerable expenses, and based on the outcome, could result in further labeling restrictions that could impair or restrict the way in which we are able to market TEMBEXA, or negatively impact its overall clinical profile. In addition, we will need to conduct in vitro resistance testing to address post-marketing commitments which could negatively impact the labeling.

Our product candidates will also be subject to additional ongoing regulatory requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. In the United States, the holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. If a REMS is required, the NDA holder may be required to monitor and evaluate those in the healthcare system who are responsible for implementing ETASU measures. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Moreover, EU and member countries impose strict restrictions on the promotion and marketing of drug products. The off-label promotion of medicinal products is prohibited in the U.S., EU and in other territories. Physicians, on the other hand, may prescribe products for off-label uses in the U.S. Although the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. The promotion of medicinal products that are not subject to a marketing authorization is also prohibited in the EU. Violations of the rules
38


governing the promotion of medicinal products in the EU and in other territories could be penalized by administrative measures, fines and imprisonment.

In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by regulatory authorities for compliance with Current Good Manufacturing Practices (cGMP), and adherence to commitments made in the application. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

If we fail to comply with applicable regulatory requirements following approval of any product candidates, a regulatory agency may:

•issue an untitled or warning letter asserting that we are in violation of the law;
•seek an injunction or impose civil or criminal penalties or monetary fines;
•suspend or withdraw regulatory approval;
•suspend any ongoing clinical trials;
•refuse to approve a pending application or supplements to an application submitted by us;
•recall and/or seize product; or
•refuse to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and inhibit our ability to generate revenues.

Having obtained FDA approval for TEMBEXA in the United States does not mean we will ever obtain approval for or commercialize TEMBEXA, ONC201, DSTAT, or any other products outside of the United States, nor does approval of any of our products outside the United States mean we will ever obtain approval for or commercialize any other products inside the United States, all of which could limit our ability to realize their full market potential.

In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in any markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.

Conversely, approval by regulatory authorities outside the United States, such as the European Commission, does not ensure approval by the FDA. Moreover, clinical trials conducted outside the United States may not be accepted by the FDA.

Coverage and adequate reimbursement may not be available for ONC201, DSTAT or any of our other current or future product candidates, which could make it difficult for us to sell profitably, if approved.*

Market acceptance and sales of ONC201, DSTAT, or any other product candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement will be available from third-party payers, including government health administration authorities, managed care organizations and private health insurers. Third-party payers decide which therapies they will pay for and establish reimbursement levels. Third-party payers in the United States often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payer-by-payer basis. One payer’s determination to provide coverage for a drug does not assure that other payers will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payer’s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Third-party payers are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products,
39


therapies and services, in addition to questioning their safety and efficacy. Even if favorable coverage and reimbursement status is attained for our products candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

Our relationships with investigators, health care professionals, consultants, third-party payers, and customers may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Healthcare providers and others play a primary role in the recommendation and prescribing of any products for which we obtain marketing approval. Our current business operations and future arrangements with investigators, healthcare professionals, consultants, third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:

•the federal healthcare anti-kickback statute which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;
•the federal civil and criminal false claims laws, including the Federal Civil False Claims Act (False Claims Act) which permit private individuals to bring a civil action on behalf of the federal government to enforce certain of these laws thought civil whistleblower or qui tam actions and the Federal Civil Monetary Penalties Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;
•the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private) and knowingly or willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their implementing regulations impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, and their business associates as well as their covered subcontractors;
•the General Data Protection Regulation (GDPR), which impose obligations on companies in relation to the handling of personal data of individuals within the EU, along with related national legislation;
•mandated physician payments reporting laws and/or requirements throughout global jurisdictions, including EU member states, in which we conduct research and development and/or other business activities;
•the FDCA which prohibits, among other things, the adulteration or misbranding of drugs and devices;
•the federal transparency law, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies to report to the Centers for Medicare & Medicaid Services (CMS) information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and
•analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by state governmental and non-governmental third-party payers, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by
40


the federal government; state and local laws that require the registration of pharmaceutical sales representatives; state laws and regulations that require manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.

Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these or any other health regulatory laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and/or divert our management’s attention from the operation of our business. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they also may be subject to significant criminal, civil or administrative sanctions, including, but not limited to, exclusions from government funded healthcare programs, which could also materially affect our business.

Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.

For example, in March 2010, the ACA was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA revises the definition of “average manufacturer price” for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposes a significant annual fee on companies that manufacture or import branded prescription drug products. New provisions affecting compliance have also been enacted, which may affect our business practices with health care practitioners. However, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018 (the BBA), among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, and also increased in the percentage that a drug manufacturer must discount the cost of prescription drugs from 50 percent to 70 percent. Additionally, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and other litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.

Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government
41


program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration’s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services (DHHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, in August 2021, CMS published a proposed rule that seeks to rescind the MFN model interim final rule. In July 2021, the Biden administration released an executive order with multiple provisions aimed at prescription drugs. In response to this executive order, in September 2021, DHHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions DHHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Such reform efforts are likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.

Healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, lower reimbursement, and additional downward pressure on the price that we receive for any future approved product. It is possible that additional governmental action may be taken in response to the COVID-19 pandemic. We cannot predict what healthcare reform initiatives may be adopted in the future.

Risks Related to Our Reliance on Third Parties

We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product candidates, including TEMBEXA.*

We do not own or operate, and we do not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing with respect to TEMBEXA or our other product candidates, including ONC201 and DSTAT. In the past, we have relied on third-party manufacturers for supply of our preclinical and clinical drug supplies. We expect that in the future we will continue to rely on such manufacturers for drug supply that will be used in clinical trials and for commercialization of any of our product candidates that receive regulatory approval.

In July 2019, we were assigned Cantex’s rights under a supply agreement with Scientific Protein Laboratories LLC (SPL) pursuant to which SPL will exclusively produce DSTAT for us through October 2040. We have agreed that SPL will be our exclusive provider of DSTAT bulk drug substance during the term of the agreement.

Our reliance on third-party manufacturers entails risks, including:

•inability to meet our product specifications and quality requirements consistently;
•delay or inability to procure or expand sufficient manufacturing capacity;
•manufacturing and product quality issues related to scale-up of manufacturing;
•costs and validation of new equipment and facilities required for scale-up;
•failure to comply with cGMP and similar foreign standards;
•inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
•termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;
42


•reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms;
•lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;
•operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, or other factors such as the impact of the ongoing COVID-19 pandemic;
•carrier disruptions or increased costs that are beyond our control; and
•failure to deliver our products under specified storage conditions and in a timely manner.

Any of these events could lead to clinical study delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our products. Some of these events could be the basis for FDA or equivalent foreign regulator action, including injunction, recall, seizure, or total or partial suspension of production. The severity of the coronavirus (COVID-19) pandemic could make access to our existing supply chain difficult or impossible and could materially impact our business.

We rely on limited sources of supply for the drug components for TEMBEXA as well as each of our product candidates including ONC201 and DSTAT, and any disruption in the chain of supply for any of these product candidates may cause delays in their development and commercialization.*

Manufacturing of drug components is subject to certain FDA and comparable foreign qualifications with respect to manufacturing standards. Our manufacturing of TEMBEXA is comprised of separate processes for each of bulk drug substance, tablets, and suspension. In addition, each of these forms can be manufactured at either small or large scale. For each form and scale of manufacturing, the process must be validated in order to supply TEMBEXA commercially. We have validated the TEMBEXA drug substance manufacturing process at our selected contractor that will produce drug substance at large scale. We have selected our TEMBEXA tablet and suspension manufacturers that will produce at both small and large scale. We have scaled up the tablet manufacturing process and plan to scale up the suspension manufacturing process to meet forecasted demand. There can be no assurance that manufacturing the suspension at large scale will be successful or will be completed in a timely fashion in order to meet large scale demands. If we are unable to successfully scale up to meet forecasted demands our business could be materially harmed.

In connection with the approval of TEMBEXA, we have only one supplier of drug substance and one separate supplier of drug product qualified as vendors with the FDA. We plan to validate the DSTAT and ONC201 drug substance and drug product processes prior to regulatory approval. It is our expectation that only one supplier of drug substance and one supplier of drug product will be qualified as vendors with the FDA for each of DSTAT and ONC201. If supply from an approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new drug substance or drug product supplier is relied upon for commercial production.

These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of DSTAT, ONC201 or TEMBEXA, and cause us to incur additional costs. As an example, we source a significant number of materials used in the manufacture of our products from China; the impact of the recent coronavirus outbreak could make access to our existing supply chain difficult or impossible and could materially harm our business. If our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredient on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials for DSTAT, ONC201 and TEMBEXA may be delayed, which could inhibit our ability to generate revenues.

Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization of TEMBEXA, ONC201 and DSTAT.*

We have validated processes for drug substance and drug product production for TEMBEXA.

We plan to validate DSTAT and ONC201 drug substance and drug product processes prior to approval at our selected vendors. It is our expectation that only one supplier of drug substance and one supplier of drug product will be qualified as vendors for each of DSTAT and ONC201 with the FDA.

As more batch data is generated post-validation for both the drug substance and drug products, and as additional stability data is collected, issues may arise in our processes and stability programs which could require resolution in order to proceed with our planned clinical trials and obtain regulatory approval for the commercial marketing of our products and product candidates. In
43


the future, we may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical program and regulatory approval for our products and product candidates, increases in our operating expenses, or failure to obtain or maintain approval for each of DSTAT, ONC201 or in the case of TEMBEXA, maintain approval.

We depend on SymBio for developing and commercializing TEMBEXA for human diseases other than orthopoxviruses, including smallpox.

In 2019, we entered into a licensing arrangement with SymBio, whereby SymBio is responsible for the future development and commercialization of TEMBEXA. Under this arrangement, SymBio is responsible for conducting preclinical studies and clinical trials, obtaining required regulatory approvals for TEMBEXA in non-orthopox indications (e.g. smallpox), and manufacturing and commercializing TEMBEXA in those indications. Our right to receive milestone payments under the licensing agreement depends on the achievement of certain development, regulatory and commercial milestones by SymBio and our ability to receive royalties under the agreement depends on SymBio's successful commercialization of TEMBEXA in the licensed indications.

The development and commercialization of the non-orthopox uses of TEMBEXA in humans and our ability to receive potential milestones and royalty payments under the license agreement with SymBio, would be adversely affected if SymBio:

•lacks or does not devote sufficient time and resource to the development and commercialization of TEMBEXA;
•lacks or does not devote sufficient capital to fund the development and commercialization of TEMBEXA;
•develops, either alone or with others, products that compete with TEMBEXA;
•fails to gain the requisite regulatory approvals for TEMBEXA;
•does not successfully commercialize TEMBEXA;
•does not conduct its activities in a timely manner;
•terminates its license with us;
•does not effectively pursue and enforce intellectual property rights relating to TEMBEXA; or
•merges with a third-party that wants to terminate the collaboration.

We have limited or no control over the occurrence of any of the foregoing. Furthermore, disagreements with SymBio could lead to litigation or arbitration, which could be time-consuming and expensive. If any of these issues arise, it may delay the development and commercialization milestones and royalties based on further development and sales of TEMBEXA.

We rely on third parties to conduct, supervise and monitor our clinical studies and related data, and if those third parties perform in an unsatisfactory manner, it may harm our business.

We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CROs to monitor and manage data for our ongoing clinical programs for our product candidates, as well as the execution of nonclinical studies. We control only certain aspects of our CROs’ activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on CROs does not relieve us of our regulatory responsibilities.

We and our CROs are required to comply with the FDA’s guidance for clinical trials conducted within the jurisdiction of the United States (or the foreign regulatory authority equivalent for clinical trials conducted outside the jurisdiction of the United States), which follows the International Council for Harmonization Good Clinical Practice (ICH GCP), which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces the ICH GCP through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with the ICH GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications.

Our CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.

If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or
44


regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize ONC201, DSTAT, TEMBEXA or any other product candidates. Disagreements with our CROs over contractual issues, including performance, compliance or compensation could lead to termination of CRO agreements and/or delays in our clinical program and risks to the accuracy and usability of clinical data. As a result, our financial results and the commercial prospects for our product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.

Risks Related to Commercialization of Our Product Candidates

The commercial success of TEMBEXA, ONC201, DSTAT and any other product candidates will depend upon the acceptance of these products by the medical community, including physicians, patients, pharmacists, health care payers or government procurement agencies (e.g. BARDA).*

Following receipt of marketing approval, a product or product candidate may not gain sufficient market acceptance by physicians, patients, healthcare payers and others in the medical community. If these products do not achieve an adequate level of market acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:

•demonstration of clinical safety and efficacy in our clinical trials;
•relative convenience, ease of administration and acceptance by physicians, patients, pharmacists and health care payers;
•prevalence and severity of any AEs;
•limitations or warnings contained in the FDA-approved labeling from Regulatory Authorities such as the FDA and EMA for the relevant product candidate;
•availability, efficacy and safety of alternative treatments;
•price and cost-effectiveness;
•effectiveness of our or any future collaborators’ or competitor’s sales and marketing strategies;
•ability to obtain hospital formulary approval;
•ability to ensure availability for product through appropriate channels;
•ability to maintain adequate inventory; and
•ability to obtain and maintain sufficient third-party coverage and adequate reimbursement, which may vary from country to country.

Even if we obtain regulatory approval, the granting authority may still impose significant restrictions on the indicated uses, distribution or marketing of TEMBEXA or our other product candidates, including ONC201 and DSTAT, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the labeling ultimately approved for our product candidates, will likely include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data obtained in those evaluations. In addition, the distribution of ONC201 or DSTAT may be tightly controlled through a REMS with ETASU, which are required medical interventions or other actions healthcare professionals need to execute prior to prescribing or dispensing the drug to the patient. Some actions may also be required in order for the patient to continue on treatment. For example, the label for TEMBEXA includes a boxed warning, or “black box,” regarding the mortality disadvantage with extended dosing observed in the SUPPRESS trial.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.

We currently do not have an organization for the sales and distribution of pharmaceutical products. The cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved we must establish our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We may enter into strategic partnerships with third parties to commercialize our product candidates.

Our strategy for each of ONC201 and DSTAT, is to establish a specialty sales force and/or collaborate with third parties to promote the product to healthcare professionals and third-party payers in the United States and elsewhere. We may elect to launch with a contract sales organization and utilize accompanying commercial support services provided by a contract sales organization. Our future collaboration partners, if any, may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the distribution and sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that are not covered by our own marketing and sales force, or if our potential
45


future collaboration partners do not successfully commercialize our product candidates, our ability to generate revenues from product sales, including sales of ONC201 and DSTAT, will be adversely affected.

Establishing an internal or contract sales force involves many challenges, including:

•recruiting and retaining talented people;
•training employees that we recruit;
•establishing compliance standards;
•setting the appropriate system of incentives;
•managing additional headcount;
•ensuring that appropriate support functions are in place to support sales force organizational needs; and
•integrating a new business unit into an existing corporate architecture.

If we are unable to establish our own sales force or negotiate a strategic partnership for the commercialization of our product candidates in any markets, we may be forced to delay the potential commercialization of our product candidates in those markets, reduce the scope of our sales or marketing activities for our product candidates in those markets or undertake the commercialization activities for in those markets at our own expense. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market or generate product revenue. Limited or lack of funding will impede our ability to achieve successful commercialization.

If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

In addition, there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales, marketing and market access personnel.

If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.

If our product candidates are approved for commercialization, we may enter into agreements with third parties to market those product candidates outside the United States. We expect that we will be subject to additional risks related to entering into international business relationships, including:

•different regulatory requirements for drug approvals in the EU and other foreign countries;
•reduced protection for intellectual property rights;
•unexpected changes in tariffs, trade barriers and regulatory and labor requirements;
•economic weakness, including inflation, or political instability in particular foreign economies and markets;
•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
•foreign taxes, including withholding of payroll taxes;
•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
•differing payer reimbursement regimes, governmental payers or patient self-pay systems and price controls;
•workforce uncertainty in countries where labor unrest is more common than in the United States;
•production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
•regulatory risks associated with cross-border transportation of animal-sourced material;
•business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and other events outside our control including epidemics, pandemics, earthquakes, typhoons, floods and fires; and
•regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti‑bribery provisions, or similar anti‑bribery or anti‑corruption laws and regulations.
46



We have limited experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the EU and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products outside the United States to be very challenging.

We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.

Many of our competitors have substantially greater financial, technical, commercial and other resources, such as larger research and development staff, stronger intellectual property portfolios and experienced marketing and manufacturing organizations and established sales forces. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors.

Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drug products that are more effective or less costly than TEMBEXA, or any of our drug candidates that we are currently developing or that we may develop including ONC201 and DSTAT.

We will face competition from other drugs currently approved or that will be approved in the future for the same indications. Therefore, our ability to compete successfully will depend largely on our ability to:

•discover and develop medicines that are superior to other products in the market;
•demonstrate through our clinical trials that our product candidates, including ONC201 and DSTAT, are differentiated from existing and future therapies;
•attract qualified scientific, product development and commercial personnel;
•obtain and successfully defend and enforce patent and/or other proprietary protection for our medicines and technologies;
•obtain required regulatory approvals;
•successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines;
•deliver a competitive value proposition compared to established competition and/or competitors who will enter the market before or after any of our product candidates, including TEMBEXA, ONC201 and DSTAT; and
•negotiate competitive pricing and reimbursement with third-party payers.

The availability of our competitors’ products could affect the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential.

47


Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

•our research methodology or that of our collaboration partners may be unsuccessful in identifying potential product candidates;
•our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; and
•our collaboration partners may change their development profiles for potential product candidates or abandon a therapeutic area.

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our research efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.

If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights.

Risks Related to Our Intellectual Property

If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our market.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover the products in the United States or in other countries. If this were to occur, early generic competition could be expected against any product candidates we may develop. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability, scope or ownership, which may result in such patents, or our rights to such patents, being narrowed or invalidated.

Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold or license with respect to any of our product candidates fails to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found not invalid and not unenforceable, will go unthreatened by third parties or will adequately protect our products and product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market DSTAT and TEMBEXA under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to any of our product candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be provoked by a third party or instituted by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license it from the prevailing party, which may not be possible. In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that such agreements provide adequate protection and will not be breached, that our trade secrets and other confidential proprietary information will not otherwise be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.
48



Further, the laws of some foreign countries do not protect patents and other proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property abroad. We may also fail to pursue or obtain patents and other intellectual property protection relating to our products and product candidates in all foreign countries.

Finally, certain of our activities and our licensors’ activities have been funded, and may in the future be funded, by the U.S. federal government. When new technologies are developed with U.S. federal government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise “march-in” rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government, U.S. government funding must be disclosed in any resulting patent applications, and our rights in such inventions may be subject to certain requirements to manufacture products in the United States.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts or otherwise affect our business.

Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party reexamination proceedings before the United States Patent and Trademark Office (U.S. PTO) and its foreign counterparts. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of ONC201, DSTAT, TEMBEXA and/or any other product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any
49


assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.

We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors and licensees or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.

Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counterclaims against us.

We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in a litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.

While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and patent applications covering our product candidates, we may lose our rights and our competitors might be able to enter the market, which would have a material adverse effect on our business.

Risks Related to Our United States Government Contracts and Grants

There can be no assurances that we will be able to enter into a contract with BARDA to act as the sole supplier for the procurement of TEMBEXA for the treatment of smallpox.*

In April 2015, BARDA posted a notice of intent to use other than full and open competition to award a sole source contract to us for the procurement of TEMBEXA for the treatment of smallpox. In May 2015, BARDA posted an approved justification for the use of other than full and open competition for the contract. In July 2015, BARDA issued a Request for Proposal (RFP) entitled “2015 Procurement of a Second Smallpox Antiviral Drug for the Strategic National Stockpile.” In August 2015, we submitted a response to the RFP and we subsequently engaged in discussions with BARDA regarding our response. The issuance of that RFP did not culminate with agreement for the sole source supply of TEMBEXA for the Strategic National Stockpile (SNS).

We remain in discussions with BARDA regarding the potential to supply TEMBEXA to the SNS, and on March 24, 2021, BARDA issued a Small Business Sources Sought Notice (SSN) seeking information on availabilities and capabilities for
50


procuring, stockpiling, and investing in the development of FDA-approved smallpox antiviral(s) with alternative mechanism(s) of action to TPOXX. We responded to the SSN with information on our relevant capabilities, experience and interest; however, there can be no assurances that a future RFP for TEMBEXA procurement will be issued.

Furthermore, in the event that BARDA issues an RFP for procurement of a smallpox antiviral therapeutic, there can be no assurance that we would reach agreement with BARDA on terms related to the manufacture and delivery of TEMBEXA to the SNS. Among the material terms to be negotiated and agreed to are: price, volume, and payment and delivery schedules, as we currently do not have TEMBEXA finished goods inventory that would be available for immediate delivery.

Unfavorable provisions in government contracts, including our contract with BARDA, may harm our business, financial condition and operating results.

United States government contracts typically contain unfavorable provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. For example, under our contract with BARDA, the U.S. government has the power to unilaterally:

•audit and object to any BARDA contract-related costs and fees on grounds that they are not allowable under the FAR, and require us to reimburse all such costs and fees;
•suspend or prevent us for a set period of time from receiving new contracts or extending our existing contract based on violations or suspected violations of laws or regulations;
•claim nonexclusive, nontransferable rights to product manufactured and intellectual property developed under the BARDA contract and may, under certain circumstances, such as circumstances involving public health and safety, license such inventions to third parties without our consent;
•cancel, terminate or suspend our BARDA contract based on violations or suspected violations of laws or regulations;
•terminate our BARDA contract in whole or in part for the convenience of the government for any reason or no reason, including if funds become unavailable to the applicable governmental agency;
•reduce the scope and value of our BARDA contract;
•decline to exercise an option to continue the BARDA contract;
•direct the course of a development program in a manner not chosen by the government contractor;
•require us to perform the option segments even if doing so may cause us to forego or delay the pursuit of other opportunities with greater commercial potential;
•take actions that result in a longer development timeline than expected; and
•change certain terms and conditions in our BARDA contract.

The U.S. government also has the right to terminate the BARDA contract if termination is in the government’s interest, or if we default by failing to perform in accordance with the milestones set forth in the contract. Termination-for-convenience provisions generally enable us to recover only our costs incurred or committed (plus a portion of the agreed fee) and settlement expenses on the work completed prior to termination. Except for the amount of services received by the government, termination-for-default provisions do not permit recovery of fees.

In addition, we must comply with numerous laws and regulations that affect how we conduct business with the United States government. Among the most significant government contracting regulations that affect our business are:

•FAR, and agency-specific regulations supplements to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts and implement federal procurement policy in numerous areas, such as employment practices, protection of the environment, accuracy and retention periods of records, recording and charging of costs, treatment of laboratory animals and human subject research;
•business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act and the Foreign Corrupt Practices Act;
•export and import control laws and regulations; and
•laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.

Furthermore, we may be required to enter into agreements and subcontracts with third parties, including suppliers, consultants and other third-party contractors, in order to satisfy our contractual obligations pursuant to our agreements with the U.S. government. Negotiating and entering into such arrangements can be time-consuming and we may not be able to reach agreement with such third parties. Any such agreement must also be compliant with the terms of our government contract. Any
51


delay or inability to enter into such arrangements or entering into such arrangements in a manner that is non-compliant with the terms of our contract, may result in violations of our contract.

As a result of these unfavorable provisions, we must undertake significant compliance activities. The diversion of resources from commercial programs to these compliance activities, as well as the exercise by the U.S. government of any rights under these provisions, could materially harm our business.

Our business is subject to audit by the U.S. government, including under our contract with BARDA, and a negative audit could adversely affect our business.

United States government agencies, such as the DHHS, routinely audit and investigate government contractors and recipients of federal grants, including our contract with BARDA. These agencies review a contractor’s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.

The DHHS can also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:

•termination of contracts;
•forfeiture of profits;
•suspension of payments;
•fines; and
•suspension or prohibition from conducting business with the U.S. government.

In addition, we could suffer serious reputational harm if allegations of impropriety were made against us by the U.S. government, which could adversely affect our business.

Agreements with government agencies may lead to claims against us under the Federal False Claims Act, and these claims could result in substantial fines and other penalties.

The biopharmaceutical industry is, and in recent years has been, under heightened scrutiny as the subject of government investigations and enforcement actions. Our BARDA contract is subject to substantial financial penalties under the Federal Civil Monetary Penalties Act and the False Claims Act. The False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false record or statement material to a false or fraudulent claim paid or approved by the government. Under the False Claims Act’s “whistleblower” provisions, private enforcement of fraud claims against businesses on behalf of the U.S. government has increased due in part to amendments to the False Claims Act that encourage private individuals to sue on behalf of the government. These whistleblower suits, known as qui tam actions, may be filed by private individuals, including present and former employees. The False Claims Act provides for treble damages and significant civil monetary penalties per false claim. If our operations are found to be in violation of any of these laws, or any other governmental regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations. Any penalties, damages, fines, exclusions, curtailment, or restructuring of our operations could adversely affect our ability to operate our business and our financial results.

Risks Related to Our Business Operations and Industry

Increasing demand for compassionate use of our unapproved therapies could result in losses.

Recent media attention to individual patients' expanded access requests has resulted in the introduction of legislation at the local and national level referred to as "Right to Try" laws, such as the Right to Try Act, which are intended to give patients access to unapproved therapies. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future. In addition, during 2014, we were the target of an active and disruptive social media campaign related to a request for access to TEMBEXA. If we experience similar social media campaigns in the future, we may experience significant disruption to our business which could result in losses.

A possible consequence of both activism and legislation in this area is the need for us to initiate an unanticipated expanded access program or to make ONC201, DSTAT or TEMBEXA more widely available sooner than anticipated. We are a small
52


company with limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals.

In addition, patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high which could have a negative impact on the safety profile of our product candidates, which could cause significant delays or an inability to successfully commercialize them, which could materially harm our business. We may also need to restructure or pause ongoing compassionate use and/or expanded access programs in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of our product candidates, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs.

If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, delays in the development of our product candidates, penalties and a loss of business.

Our activities, and the activities of our collaborators, partners and third-party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare companies. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the Foreign Corrupt Practices Act, or violations related to environmental matters. Violations of governmental regulation may be punishable by criminal, civil and administrative sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to penalties for violation of laws and regulations, we could be required to delay or terminate the development of our product candidates, or we could be required to repay amounts we received from government payers, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.*

We are highly dependent on the principal members of our executive team. While we have entered into employment agreements or offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. To help attract, retain, and motivate qualified employees, we use share-based incentive awards such as employee stock options and restricted stock units. If our share-based compensation ceases to be viewed as a valuable benefit, our ability to attract, retain, and motivate employees could be weakened, which could harm our results of operations.

We do not maintain “key person” insurance for any of our executives or other employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of appropriately skilled executives in our industry, which is likely to continue. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, failure of any of our clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee may adversely affect the progress of our research, development and commercialization objectives.

In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives.

Potential product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.

The use of our product candidates, including ONC201 and DSTAT, in clinical studies and the sale of any products for which we obtain marketing approval, including TEMBEXA, exposes us to the risk of product liability claims. Product liability claims
53


might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

•impairment of our business reputation and significant negative media attention;
•withdrawal of participants from our clinical studies;
•significant costs to defend the related litigation;
•distraction of management’s attention from our primary business;
•substantial monetary awards to patients or other claimants;
•inability to commercialize TEMBEXA or our product candidates, including ONC201 and DSTAT; and
•decreased demand for our product candidates, if approved for commercial sale.

We currently carry $15 million in product liability insurance covering our clinical trials, but not yet extending coverage to commercial sales. Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

The COVID-19 pandemic, which began in late 2019 and has spread worldwide, may affect our ability to initiate or continue our planned, ongoing and future clinical trials, disrupt regulatory activities, disrupt our ability to maintain a commercial infrastructure for our products or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business and operations.

The COVID-19 pandemic, which began in December 2019, has spread worldwide, causing many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened border scrutiny, and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the pandemic and its effects on our business and operations are uncertain.

In the event of a continuation of shelter-in-place orders and/or other mandated local travel restrictions, our employees conducting research and development activities may not be able to access our research space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. In light of the pandemic, we may choose to pause certain research programs, delay the start of certain longer-term clinical studies and limit hiring.

We may face difficulties recruiting or retaining patients in our ongoing clinical trials because of the pandemic. For example, patients for our recently initiated trial of DSTAT as a treatment for AML may be unable or unwilling to visit clinical trial sites which may impact the collection of important clinical trial data or such a delay may alter DSTAT's potential time to market which could reduce its commercial attractiveness in a competitive AML marketplace. In addition, limitations in the ability to visit sites may adversely affect, our enrollment timelines for our clinical trials, and may adversely affect the timing of completion of our clinical trials or our ability to complete clinical trials in a fully compliant manner. Additionally, the potential suspension of clinical trial activity at clinical trial sites may have an adverse impact on our clinical trial plans and timelines.

We may face disruptions that may affect our ability to initiate and complete clinical trials including disruptions in procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates and laboratory supplies for planned and ongoing clinical trials, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring, data collection, data integrity and data analysis may be paused or delayed or negatively impacted due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. We may face manufacturing disruptions or disruptions related to the ability to obtain necessary institutional review board (IRB) or other necessary site approvals, as well as other delays at clinical trial sites.

54


The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.

The COVID-19 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds through public offerings and may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.

We may experience difficulties in integrating the operations of Oncoceutics into our business and in realizing the expected benefits of the merger with Oncoceutics.

The success of our merger with Oncoceutics (the Merger) will depend in part on our ability to realize the anticipated benefits from combining the operations of Oncoceutics with our business in an efficient and effective manner. The integration process could take longer than anticipated and could result in the loss of key employees, the disruption of each company’s ongoing businesses, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to achieve the anticipated benefits of the Merger, and could harm our financial performance and impair stockholder value. If we are unable to successfully or timely integrate the operations of Oncoceutics with our business, we may incur unanticipated liabilities and be unable to realize the revenue growth, synergies and other anticipated benefits resulting from the Merger, and our business, results of operations and financial condition could be materially and adversely affected. We have incurred significant costs in connection with the Merger. The substantial majority of these costs are non-recurring expenses related to the Merger. We may incur additional costs in the integration of Oncoceutics, and may not achieve cost synergies and other benefits sufficient to offset the incremental costs of the Merger.

Risks Related To Our Common Stock

The market price of our common stock is likely to be volatile, and you may not be able to resell your shares at or above your purchase price.

The trading price of our common stock has been volatile, and is likely to continue to be volatile for the foreseeable future. Our stock price is subject to wide fluctuations in response to a variety of factors, including the following:

•results of clinical trials of our product candidates or those of our competitors;
•any delay in filing an application for any of our product candidates and any adverse development or perceived adverse development with respect to regulatory review of that application;
•failure to successfully develop and commercialize TEMBEXA or our product candidates, including ONC201 and DSTAT;
•termination of any of our license or collaboration agreements;
•any agency or judicial enforcement actions against us;
•inability to obtain additional funding;
•regulatory or legal developments in the United States and other countries applicable to our product candidates;
•adverse regulatory decisions;
•changes in the structure of healthcare payment systems;
•inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;
•introduction of new products, services or technologies by our competitors;
•failure to meet or exceed financial projections we provide to the public;
•failure to meet or exceed the estimates and projections of the investment community;
•changes in the market valuations of similar companies;
•market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts’ reports or recommendations;
•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;
•significant lawsuits (including patent or stockholder litigation), and disputes or other developments relating to proprietary rights (including patents, litigation matters and our ability to obtain patent protection for our technologies);
•additions or departures of key scientific or management personnel;
55


•sales of our common stock by us or our stockholders in the future;
•trading volume of our common stock;
•general economic, industry and market conditions, including the impact of the ongoing COVID-19 pandemic; and
•the other factors described in this “Risk Factors” section.

In addition, the stock market in general, and The Nasdaq Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Based upon shares of common stock outstanding as of September 30, 2021, our then executive officers, directors, 5% stockholders (known to us through available information) and their affiliates beneficially owned approximately 7.7% of our voting stock. Therefore, these stockholders have the ability to substantially influence us through this ownership position. For example, these stockholders, if they choose to act together, may be able to influence the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.

Failure to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.

As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations of the Securities and Exchange Commission, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.

Our compliance with Section 404 of the Sarbanes-Oxley Act has required and will continue to require that we incur substantial accounting expense and expend significant management efforts. In this or future years, our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls that we would be required to remediate in a timely manner so as to be able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act each year. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner each year, we could be subject to sanctions or investigations by the Securities and Exchange Commission, The Nasdaq Stock Market or other regulatory authorities which would require additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

In July 2019, we entered into a license agreement with Cantex where we acquired an exclusive license to global development and commercialization rights to DSTAT. As partial consideration for our rights under the license agreement, we issued to Cantex 10,000,000 shares of our common stock. We are continuing to review additional potential transactions to add to our pipeline of product candidates, and these transactions could involve the issuance of additional shares of common stock or other equity securities. On January 7, 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, including ONC201. As part of the consideration for the acquisition, we paid an upfront cash payment of approximately $25.0 million and issued an aggregate of 8,723,769 shares of our common stock.
56



Pursuant to our 2013 Equity Incentive Plan (the 2013 Plan), our management is authorized to grant stock options to our employees, directors and consultants. The number of shares available for future grant under our 2013 Plan will automatically increase on January 1st each year, through January 1, 2023, by an amount equal to 4.0% of all shares of our capital stock outstanding as of December 31st of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of such increase in any given year. In addition, our board of directors may grant or provide for the grant of rights to purchase shares of our common stock pursuant to the terms of our 2013 Employee Stock Purchase Plan (ESPP). The number of shares of our common stock reserved for issuance under our ESPP will automatically increase on January 1st each year, through January 1, 2023, by an amount equal to the lesser of 422,535 shares or one percent of all shares of our capital stock outstanding as of December 31st of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of such increase in any given year. Unless our board of directors elects not to increase the number of shares underlying our 2013 Plan and ESPP each year, our stockholders may experience additional dilution, which could cause our stock price to fall.

We have broad discretion in the use of the net proceeds from our financing transactions and may not use them effectively.

Our management has broad discretion in the application of the net proceeds from our financing transactions. Because of the number and variability of factors that will determine our use of the net proceeds from our financing transactions, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we have invested the net proceeds from our financing transactions in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.

Volatility in our stock price could subject us to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.*

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act (Tax Act) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.

Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the Tax Act, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.

57


Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Our U.S. net operating loss (NOL) carryforwards generated in tax years ending on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, our federal NOLs generated in tax years ending after December 31, 2017, may be carried forward indefinitely. The CARES Act revised the NOL limitations such that the of federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change U.S. tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have determined that a Section 382 ownership change occurred in 2002 and 2007 resulting in limitations of at least $64,000 and $762,000, respectively, of losses incurred prior to the respective ownership change dates. In addition, we have determined that another Section 382 ownership change occurred in 2013 with our IPO, our most recent private placement and other transactions that have occurred since 2007, resulting in a limitation of at least $6.7 million of losses incurred prior to the ownership change date. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, our pre-2018 NOL carryforwards may expire prior to being used, and our NOL carryforwards generated in 2018 and thereafter will be subject to a percentage limitation.  In addition, it is possible that we have in the past undergone, and in the future may undergo, additional ownership changes that could limit our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock would be your sole source of gain on an investment in our common stock for the foreseeable future.

Provisions in our corporate charter documents and under Delaware law could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:

•authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors;
•allowing the authorized number of our directors to be changed only by resolution of our board of directors;
•limiting the removal of directors;
•creating a staggered board of directors;
•requiring that stockholder actions must be effected at a duly called stockholder meeting and prohibiting stockholder actions by written consent;
•eliminating the ability of stockholders to call a special meeting of stockholders; and
•establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at duly called stockholder meetings.

The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require the affirmative vote of the holders of at least 66 2/3 percent of the voting power of all of our then outstanding common stock.

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the
58


members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

Risks Related to Information Technology

Significant disruptions of information technology systems or breaches of data security could adversely affect our business.

Our business is increasingly dependent on critical, complex, and interdependent information technology (IT) systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in the impairment of our ability to operate our business effectively.

In addition, our systems are potentially vulnerable to data security breaches-whether by employees or others-which may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, business partners and others.

Any such disruption or security breach could result in legal proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disruptions to our operations and collaborations, and damage to our reputation, which could harm our business and results of operations.

Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.

We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable laws and regulations. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.

ITEM 2.     UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
None.
 
ITEM 3.     DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4.     MINE SAFETY DISCLOSURES
 
Not applicable.
 
ITEM 5.     OTHER INFORMATION
 
Not applicable.
59


ITEM 6.     EXHIBITS
 
The following exhibits are filed as part of this report: 
Number Description
3.1(1) 
   
3.2(1) 
   
4.1(2) 
   
10.1
10.2+
31.1 
   
31.2 
   
32.1 
   
32.2 
101.INSInline XBRL Instance Document - - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
 
*Schedules and exhibits to the Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.

+ Certain portions of this exhibit are omitted because they are not material and would likely cause competitive harm to the Company if publicly disclosed.

(1)Incorporated by reference to the corresponding exhibit in Chimerix, Inc.’s Current Report on Form 8-K (No. 001-35867), filed with the SEC on April 16, 2013.

(2)Incorporated by reference to the corresponding exhibit in Chimerix, Inc.’s Registration Statement on Form S-1 (No. 333-187145), as amended.



60


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 CHIMERIX, INC.
   
November 4, 2021By:/s/ Michael A. Sherman
  Michael A. Sherman
  President and Chief Executive Officer
(Principal Executive Officer)
   
November 4, 2021By:/s/ Michael T. Andriole
  Michael T. Andriole
  Chief Business and Financial Officer
(Principal Financial Officer)
 
61

 EX-10.1 2 a20210930cmrxex-101.htm EX-10.1 Document
Exhibit 10.1
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT1. CONTRACT ID CODEPAGE OF PAGES
12
2. AMENDMENT/MODIFICATION NO

P00066
3. EFFECTIVE DATE

See Block 16C
4. REQUISITION/PURCHASE REQ NO

N/A.
5. PROJECT NO (if applicable)
6. ISSUED BY    CODEASPR-BARDA
7. ADMINISTERED BY (if other than line item 6)    CODE
ASPR-BARDA02
ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201
ASPR-BARDA
330 Independence Ave., SW, Rm G640
Washington DC 20201
8. NAME AND ADDRESS OF CONTRACTOR (No, street, county, State and ZIP Code)
(x)9A AMENDMENT OF SOLICITATION NO.
CHIMERIX, INC. 1377270
CHIMERIX, INC.    2505 MERIDIAN P
2505 MERIDIAN PKWY STE 340
DURHAM NC 277135246
9B DATED (SEE ITEM 11)


X
10A MODIFICATION OF CONTRACT/ORDER NO
HHSO100201100013C

10B DATED (SEE ITEM 13)
 02/16/2011
CODE 1377270
FACILITY CODE
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified of receipt of Offers     is extended. is not extended
Offers must acknowledge receipt of this amendment prior to the hour end dale specified in the solicitation or as amended, by one or the following methods: (a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
12. ACCOUNTING AND APPROPRIATION DATA (if required)
N/A.
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
CHECK ONE
A.    THIS CHANGE ORDER IS ISSUED PURSUANT TO (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO IN ITEM 10A
X
B.    THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
C.    THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF

D.    OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not. is required to sign this document and return 0 copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)
Tax ID Number: 33-0903395
DUNS Number: 121785997
A. The purpose of this no cost bilateral modification is to incorporate the following changes into the contract:
1. The Contracting Officer's Representative (COR) is hereby changed from Carol J. Diaz-Diaz to Ramya Natarajan.
2. The period of performance of CLIN 0005 under the contract hereby remains unchanged from 17 June 2020 through 1 September 2021.
Continued ...
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A. NAME AND TITLE OF SIGNER (Type or print)
 
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
ETHAN J. MUELLER
15B. CONTRACTOR/OFFEROR
                                                       
(Signature of person authorized to sign)
15C. DATE SIGNED

16B. UNITED STATES OF AMERICA
  /s/ Ethan J. Mueller     
(Signature of person authorized to sign)
16C. DATE SIGNED

5/24/21
NSN 7540-152-8070    STANDARD FORM 30 (REV 10-83)
Previous edition unusable    Prescribed by GSA
    FAR (48 CFR) 53.243




CONTINUATION SHEET
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100013C/P00066    
PAGE OF
22
NAME OF OFFEROR OR CONTRACTOR
CHIMERIX, INC. 1377270
ITEM NO.
(A)
SUPPLIES/SERVICES
(B)
QUANTITY
(C)
UNIT
(D)
UNIT PRICE
(E)
AMOUNT
(F)
3. The total amount, scope and period of performance of all other CLINs that are currently being performed under the contract remain unchanged. This modification does not exercise any unexercised Option CLINs under the contract and does not authorize any performance of efforts under any unexercised Option CLINs under the contract. In addition, the total amount, scope and period of performance of all unexercised Option CLINs under the contract remain unchanged. This modification also confirms that all activities under the base period of performance CLIN 0001 were completed as of 31 May 2013 and confirms that all activities under the Option 1/CLIN 0002 period of performance were completed as of 30 April 2015 and confirms that all activities under the Option 2/CLIN 0003 and CLIN 0004 periods of performance were completed as of 20 August 2020.
B. This is a no cost bilateral modification. The total amount, scope and all other terms and conditions of Contract Number HHSO100201100013C remain unchanged.
Period of Performance: 02/16/2011 to 09/01/2021
NSN 7540-152-8067    STANDARD FORM 336 (4-86)
    Sponsored by GSA
    FAR (48 CFR) 53.110

 EX-10.2 3 a20210930cmrxex-102.htm EX-10.2 Document
Exhibit 10.2
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT1. CONTRACT ID CODEPAGE OF PAGES
14
2. AMENDMENT/MODIFICATION NO

P00067
3. EFFECTIVE DATE

See Block 16C
4. REQUISITION/PURCHASE REQ NO

N/A.
5. PROJECT NO (if applicable)
6. ISSUED BY    CODEASPR-BARDA
7. ADMINISTERED BY (if other than line item 6)    CODE
ASPR-BARDA02
ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201
ASPR-BARDA
330 Independence Ave., SW, Rm G640
Washington DC 20201
8. NAME AND ADDRESS OF CONTRACTOR (No, street, county, State and ZIP Code)
(x)9A AMENDMENT OF SOLICITATION NO.
CHIMERIX, INC. 1377270
CHIMERIX, INC.    2505 MERIDIAN P
2505 MERIDIAN PKWY STE 340
DURHAM NC 277135246
9B DATED (SEE ITEM 11)


X
10A MODIFICATION OF CONTRACT/ORDER NO
HHSO100201100013C

10B DATED (SEE ITEM 13)
 02/16/2011
CODE 1377270
FACILITY CODE
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified of receipt of Offers     is extended. is not extended
Offers must acknowledge receipt of this amendment prior to the hour end dale specified in the solicitation or as amended, by one or the following methods: (a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
12. ACCOUNTING AND APPROPRIATION DATA (if required)
N/A.
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
CHECK ONE
A.    THIS CHANGE ORDER IS ISSUED PURSUANT TO (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO IN ITEM 10A
B.    THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
C.    THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF

X
D.    OTHER (Specify type of modification and authority)
Bilateral: Mutual Agreement of the Parties.
E. IMPORTANT: Contractor is not. is required to sign this document and return 0 copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)
Tax ID Number: 33-0903395
DUNS Number: 121785997
A. The purpose of this modification is to deobligate unused funding under the completed CLIN 0001 (Completed as of 31 May 2013), Option 2/CLIN 0003 (Completed as of 20 August 2020) and CLIN 0004 (Completed as of 20 August 2020) in the amount of $[*].
1. The deobligation of this amount from the base CLIN 0001 under Contract Number HHSO100201100013C results in Contract Line Item Number (CLIN) 0001 being changed as follows:

Total Estimated Cost of CLIN 0001: From $[*] By $[*] To $[*]

Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A. NAME AND TITLE OF SIGNER (Type or print)
 Michael Alrutz SVP & General Counsel
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
ETHAN J. MUELLER
15B. CONTRACTOR/OFFEROR
 /s/ Michael Alrutz    
(Signature of person authorized to sign)
15C. DATE SIGNED
9/8/21
16B. UNITED STATES OF AMERICA
  /s/ Ethan J. Mueller     
(Signature of person authorized to sign)
16C. DATE SIGNED
9/20/21
NSN 7540-152-8070    STANDARD FORM 30 (REV 10-83)
Previous edition unusable    Prescribed by GSA
    FAR (48 CFR) 53.243

1


CONTINUATION SHEET
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100013C/P00067    
PAGE OF
24
NAME OF OFFEROR OR CONTRACTOR
CHIMERIX, INC. 1377270
ITEM NO.
(A)
SUPPLIES/SERVICES
(B)
QUANTITY
(C)
UNIT
(D)
UNIT PRICE
(E)
AMOUNT
(F)
No changed to the Total Fixed Fee Amount of CLIN 0001 of $[*]
Total Estimated Cost Plus Fixed Fee of CLIN 0001: From $[*] by $[*] To $[*]

2. The deobligation of this amount from Option 2/CLIN 0003 under Contract Number HHSO100201100013C results in Option 2/CLIN 0003 being changed as follows:
Total Estimated Cost of Option 2/CLIN 0003: From $[*] By $[*] To $[*]
No change to the Total Fixed Fee Amount of Option 2/CLIN 0003 of $[*]
Total Estimated Cost Plus Fixed Fee of Option 2/CLIN 0003: From $[*] By $[*] to $[*].
3. The deobligation of this amount from CLIN 0004 under Contract Number HHSO100201100013C results in CLIN 0004 being changed as follows:

Total Estimated Cost of CLIN 0004: From $[*] By $[*] To $[*]
No change to the Total Fixed Fee Amount of CLIN 0004 of $[*]
Total Estimated Cost Plus Fixed Fee of CLIN 0004: From $[*] By $[*] to $[*].
4. This modification also results a change in the total amount of the contract from $[*] by $[*] to $[*] as well as the following:
Total Estimated Cost of the Contract: From $[*] By $[*] To $[*]

No change to the Total Fixed Fee Amount of $[*].

Total Estimated Cost Plus Fixed Fee of the Contract: From $[*] By $[*] To $[*]

5. This modification hereby results in a decrease in the total amount of the contract from $[*] by $[*] to $[*].

6. Block 15G of the SF 26, the amount of $[*] shall be changed to $[*].
7. In signing this bilateral modification, the Contractor hereby certifies that they have received as of the executed date of this modification full payment under CLIN 0001, CLIN 0002, CLIN 0003 and CLIN 0004 (Including Any Supplemental Amounts) for all direct expenses and all indirect expenses (both forward billing indirect expenses and retroactive billing indirect expenses). In signing this bilateral modification, the Contractor hereby acknowledges that full payment under CLIN 0001,
Continued ...


NSN 7540-152-8067    STANDARD FORM 336 (4-86)
    Sponsored by GSA
    FAR (48 CFR) 53.110


CONTINUATION SHEET
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100013C/P00067    
PAGE OF
34
NAME OF OFFEROR OR CONTRACTOR
CHIMERIX, INC. 1377270
ITEM NO.
(A)
SUPPLIES/SERVICES
(B)
QUANTITY
(C)
UNIT
(D)
UNIT PRICE
(E)
AMOUNT
(F)
CLIN 0002, CLIN 0003 and CLIN 0004 (Including Any Supplemental Amounts) for all direct expenses and all indirect expenses (both forward billing and retroactive billing indirect expenses) does not guarantee final allowability of these expenses. In signing this bilateral modification, the Contract hereby agrees that the total amount of any sustained audit exceptions for CLIN 0001, CLIN 0002, CLIN 0003 and CLIN 0004 (Including Any Supplemental Amounts) will be refunded to the Department of Health and Human Services.
8. The total amount, scope and period of performance of all other CLINs that are currently being performed under the contract remain unchanged. This modification does not exercise any unexercised Option CLINs under the contract and does not authorize any performance of efforts under any unexercised Option CLINs under the contract. In addition, the total amount, scope and period of performance of all unexercised Option CLINs under the contract remain unchanged. This modification also confirms that all activities under the base period of performance CLIN 0001 were completed as of 31 May 2013 and confirms that all activities under the Option 1/CLIN 0002 period of performance were completed as of 30 April 2015 and confirms that all activities under the Option 2/CLIN 0003 and CLIN 0004 period of performance were completed as of 20 August 2020.

B. This is a bilateral modification. The scope and all other terms and conditions of Contract Number HHSO100201100013C remain unchanged.
Period of Performance: 02/16/2011 to 09/01/2021

Change Item 1 to read as follows (amount shown is the obligated amount):

[*]. [*]

Reports and Other Data Deliverables.

Accounting Info:
2011.1992002.25329 Appr. Yr.: 2011 CAN: 1992002 Object Class: 25329
Funded: $[*]

2012.1992002.25329 Appr. Yr.: 2012 CAN: 1992002 Object Class: 25329
Funded: $[*]

2013.1992002.25329 Appr. Yr.: 2013 CAN: 1992002 Object Class: 25329
Funded: $[*]


Change Item 3 to read as follows (amount shown is the obligated amount):

Continued ...

                                                                                                                                                                       




















NSN 7540-152-8067    STANDARD FORM 336 (4-86)
    Sponsored by GSA
    FAR (48 CFR) 53.110


CONTINUATION SHEET
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100013C/P00067    
PAGE OF
44
NAME OF OFFEROR OR CONTRACTOR
CHIMERIX, INC. 1377270
ITEM NO.
(A)
SUPPLIES/SERVICES
(B)
QUANTITY
(C)
UNIT
(D)
UNIT PRICE
(E)
AMOUNT
(F)
[*]. [*]
Reports and Other Data Deliverables.


Accounting Info:
2014.1992003.25106 Appr. Yr.: 2014 CAN: 1992003 Object Class: 25106
Funded: $[*]

Accounting Info:
2016.1992016.25103 Appr. Yr.: 2016 CAN: 1992016 Object Class: 25103
Funded: $[*]

Accounting Info:
2018.1992018.25106 Appr. Yr.: 2018 CAN: 1992018 Object Class: 25106
Funded: $[*]

Accounting Info:
2019.1992019.25106 Appr. Yr.: 2019 CAN: 1992019 Object Class: 25106
Funded: $[*]

Change Item 4 to read as follows (amount shown is the obligated amount):

[*] $[*]

Reports and Other Data Deliverables

Accounting Info:
2015.1992015.25103 Appr. Yr.: 2015 CAN: 1992015 Object Class: 25103
Funded: $[*]

Accounting Info:
2018.1992018.25106 Appr. Yr.: 2018 CAN: 1992018 Object Class: 25106
Funded: $[*]






















 EX-31.1 4 a20210930cmrxex-311.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Michael A. Sherman, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2021 of Chimerix, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:November 4, 2021/s/ Michael A. Sherman
 Michael A. Sherman
 President & Chief Executive Officer
(Principal Executive Officer)

 

 EX-31.2 5 a20210930cmrxex-312.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Michael T. Andriole, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2021 of Chimerix, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 4, 2021/s/ Michael T. Andriole
 Michael T. Andriole
 Chief Business and Financial Officer
(Principal Financial Officer)

 

 EX-32.1 6 a20210930cmrxex-321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 
In connection with the Quarterly Report on Form 10-Q of Chimerix, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael A. Sherman, as Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:November 4, 2021/s/ Michael A. Sherman
 Michael A. Sherman
 President & Chief Executive Officer
(Principal Executive Officer)
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 
 

 EX-32.2 7 a20210930cmrxex-322.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Chimerix, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael T. Andriole, as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:November 4, 2021/s/ Michael T. Andriole
Michael T. Andriole
 Chief Business and Financial Officer
(Principal Financial Officer)
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


 EX-101.SCH 8 cmrx-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - The Business and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2108102 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Investments - Summary of Available-for-Sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Investments - Schedule of Investment Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2113103 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2118104 - Disclosure - Equity Transactions and Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Equity Transactions and Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2122105 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - Significant Agreements link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Significant Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2126107 - Disclosure - Oncoceutics Acquisition link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Oncoceutics Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Oncoceutics Acquisition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cmrx-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 cmrx-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 cmrx-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounts and notes receivable net Accounts and Financing Receivable, after Allowance for Credit Loss Asset Acquisition [Axis] Asset Acquisition [Axis] Lease-related obligations Operating lease long-term liabilities (recorded within Lease-related obligations) Operating Lease, Liability, Noncurrent Total purchase price allocated Asset Acquisition, Assets Acquired and Liabilities Assumed, Net and Research and Development in Progress Asset Acquisition, Assets Acquired and Liabilities Assumed, Net and Research and Development in Progress Measurement Frequency [Domain] Measurement Frequency [Domain] Number of shares reserved for issuance, annual increase (in shares) Increase (Decrease) In Number of Shares Authorized Increase (decrease) in number of shares authorized. Inventory, work in process Inventory, Work in Process, Gross Basic and Diluted Net Loss Per Share of Common Stock Earnings Per Share, Policy [Policy Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Fair value of common stock issued related to asset acquisition Issuance of Stock and Warrants for Services or Claims Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Number of extension periods Number Of Extension Periods The number of extension periods. Short-term investments, available-for-sale Debt Securities, Available-for-sale, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding City Area Code City Area Code Income Statement Location [Axis] Income Statement Location [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Rent abatement term Lessee, Operating Lease, Rent Abatement Term Lessee, Operating Lease, Rent Abatement Term Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Employee stock purchase plan purchases (in shares) Shares issued pursuant to employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Segments Segment Reporting, Policy [Policy Text Block] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Royalty percentage to be paid (at least) License Agreement, Royalty Percentage To Be Paid License Agreement, Royalty Percentage To Be Paid Discounted purchase price from market price, purchase date Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date U.S. treasury securities US Treasury Securities [Member] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Entity Filer Category Entity Filer Category Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Other long-term assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Number of shares reserved for future issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant The Business and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Shares issued for restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Federal or state income taxes Income Tax Expense (Benefit) Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Summary of short-term and long-term investments Debt Securities, Available-for-sale [Table Text Block] Total current assets Assets, Current Document Fiscal Year Focus Document Fiscal Year Focus Sale of Stock [Domain] Sale of Stock [Domain] Total future minimum rental payments Lessee, Operating Lease, Liability, to be Paid Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Asset Acquisition [Table] Asset Acquisition [Table] Inventories Inventory, Net Subsequent Event Type [Domain] Subsequent Event Type [Domain] Transaction costs expensed to IPR&D Research and Development in Progress, Including Transaction Costs Research and Development in Progress, Including Transaction Costs Oncoceutics Acquisition Asset Acquisition [Text Block] Entity File Number Entity File Number SymBio Pharmaceuticals SymBio Pharmaceuticals [Member] SymBio Pharmaceuticals [Member] Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding as of September 30, 2021 and December 31, 2020 Preferred Stock, Value, Outstanding Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Termination notice period License Agreement, Termination Notice Term License Agreement, Termination Notice Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Transaction costs expensed to IPR&D Research and Development in Progress, Transaction Costs Research and Development in Progress, Transaction Costs Research and development expense Research and Development Expense [Member] Product and Service [Axis] Product and Service [Axis] Transaction expenses Asset Acquisition, Consideration Transferred, Transaction Cost Sale of Stock [Axis] Sale of Stock [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Subsequent Events [Abstract] Subsequent Events [Abstract] Total number of base segments Revenue, Performance Obligation, Total Number Of Base Segments Revenue, Performance Obligation, Total Number Of Base Segments Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Combination and Asset Acquisition [Abstract] Evergreen option provision, equity increase Share-Based Compensation, Evergreen Option Provision, Equity Increase Share-Based Compensation, Evergreen Option Provision, Equity Increase Equity Component [Domain] Equity Component [Domain] RSU stock issuance (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Year one Lessee, Operating Lease, Liability, to be Paid, Year One ASSETS Assets Assets [Abstract] Accrued compensation Accrued Salaries Statement [Line Items] Statement [Line Items] Schedule of Investments Schedule of Investments [Line Items] Private Foundations Private Foundations [Member] Private Foundations Issuance of common stock related to asset acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Summary of the scheduled maturity of company investments Investments Classified by Contractual Maturity Date [Table Text Block] The 2013 Plan The 2013 Plan [Member] The 2013 Plan [Member] Fair Value, Separate Account Investment [Table] Fair Value, Separate Account Investment [Table] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Long-term investments Debt Securities, Available-for-sale, Noncurrent Value of estimated common stock consideration Asset Acquisition, Consideration Transferred, Equity Interests Issued and Issuable Asset Acquisition, Consideration Transferred, Equity Interests Issued and Issuable Ohara Pharmaceutical Co., Ltd. Ohara Pharmaceutical Co., Ltd. [Member] Ohara Pharmaceutical Co., Ltd. Revenue Recognition [Abstract] Revenue Recognition [Abstract] Entity Address, City or Town Entity Address, City or Town Schedule of employee and non-employee share-based compensation expense recognized related to stock options, the ESPP and RSUs Share-based Payment Arrangement, Cost by Plan [Table Text Block] Estimated Fair Value Total debt investments Debt Securities, Available-for-sale Accumulated Deficit Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Year four Lessee, Operating Lease, Liability, to be Paid, Year Four Entity Address, State or Province Entity Address, State or Province Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Fair value, total Debt Securities, Available-for-sale, Unrealized Loss Position Entity [Domain] Entity [Domain] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Accounts receivable Increase (Decrease) in Accounts Receivable Purchases of short-term investments Payments to Acquire Short-term Investments Use of Estimates Use of Estimates, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Percentage of pay that employee can contribute, maximum Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Local Phone Number Local Phone Number Scenario, Forecast Forecast [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Interactive Data Current Entity Interactive Data Current Proceeds from issuance of common stock, net of commissions Proceeds from Issuance of Common Stock Total assets Assets Gain on sale of investments Realized Investment Gains (Losses) Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of segments Number of Operating Segments Cash payment for acquisition Payments to Acquire Productive Assets, Gross Payments to Acquire Productive Assets, Gross Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Net loss, basic (in dollars per share) Earnings Per Share, Basic Rent expense under non-cancelable operating leases Operating Lease, Expense Proceeds from employee stock purchase plan Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Year three Lessee, Operating Lease, Liability, to be Paid, Year Three Cantex Pharmaceuticals Inc. Cantex Pharmaceuticals [Member] Cantex Pharmaceuticals [Member] Sublease income Sublease Income Milestone payments for ORR Asset Acquisition, Contingent Consideration, Milestone Payments ORR Asset Acquisition, Contingent Consideration, Milestone Payments ORR Product and Service [Domain] Product and Service [Domain] Document Type Document Type Contract and grant revenue Contract and Grant [Member] Contract and Grant Lease extension term Lessee, Operating Lease, Renewal Term Contingent consideration for acquisition Asset Acquisition, Consideration Transferred, Contingent Consideration Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Lease-related amortization Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent Entity Current Reporting Status Entity Current Reporting Status Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Acquired in-process research and development IPR&D assets expensed Research and Development in Process Schedule of Investments [Table] Schedule of Investments [Table] Commercial paper Commercial Paper [Member] Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized to be granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Lease payments Operating Lease, Payments Corporate bonds Corporate bonds Corporate Bond Securities [Member] Subsequent Event Subsequent Event [Line Items] Research and Development Prepaids and Accruals Research and Development Expense, Policy [Policy Text Block] Weighted-average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss, diluted (in dollars per share) Earnings Per Share, Diluted Price of shares sold (in dollars per share) Sale of Stock, Price Per Share Accrued research and development expenses Accrued Development Liabilities Accrued development liabilities. Subsequent Events Subsequent Events [Text Block] Stock price per share on effective date (in USD per share) Asset Acquisition, Share Price Asset Acquisition, Share Price The 2013 Employee Stock Purchase Plan The 2013 Employee Stock Purchase Plan [Member] The 2013 Employee Stock Purchase Plan Member. Plan Name [Axis] Plan Name [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Payments to be made for regulatory milestones (up to) License Agreement, Amount To Be Paid Upon Receipt Of Product Approvals License Agreement, Amount To Be Paid Upon Receipt Of Product Approvals Provision for refundable amounts Contract with Customer, Liability Total assets Assets, Fair Value Disclosure Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Lessee, Operating Lease, Liability, Payment, Due Lessee, Operating Lease, Liability, Payment, Due [Abstract] Total liabilities and stockholders’ equity Liabilities and Equity Other accrued liabilities Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] License agreement cost License Agreement Cost License Agreement Cost Scenario [Axis] Scenario [Axis] Year five Lessee, Operating Lease, Liability, to be Paid, Year Five Accounts payable Accounts Payable, Current Additional paid-in capital Additional Paid in Capital Fair Value, Separate Account Investment Fair Value, Separate Account Investment [Line Items] Number of grants Number of Grants Acquired Number of Grants Acquired Schedule of certain assets measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Purchase interval Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Deferred revenue Contract with Customer, Asset, after Allowance for Credit Loss Income Tax Contingency [Table] Income Tax Contingency [Table] Operating lease right-of-use assets and liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Operating expenses: Operating Expenses [Abstract] Federal Goverment Federal Goverment [Member] Federal Goverment Payments to be made upon achievement of specified net sales levels (up to) License Agreement, Amount To Be Paid Upon Achievement Of Specified Sales Levels License Agreement, Amount To Be Paid Upon Achievement Of Specified Sales Levels Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Public Stock Offering Public Stock Offering [Member] Public Stock Offering Number of securities with unrealized losses, less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Unrealized gain (loss) on debt investments, net Unrealized loss on investments, net OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Year two Lessee, Operating Lease, Liability, to be Paid, Year Two Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Unrecognized tax benefits Unrecognized Tax Benefits Income Statement Location [Domain] Income Statement Location [Domain] Stockholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Long-term Purchase Commitment Long-term Purchase Commitment [Line Items] Additional shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Fair value, greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Trading Symbol(s) Trading Symbol Property and equipment, net of accumulated depreciation Property, Plant and Equipment, Net Total operating expenses Operating Expenses Issuance of common stock related to asset acquisition Stock Issued During Period, Value, Acquisitions Current liabilities: Liabilities, Current [Abstract] Issuance of common stock, net of issuance costs of $7.2 million Stock Issued During Period, Value, New Issues Maturing after one year through two years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two General and administrative General and Administrative Expense Purchase option term Sale of Stock, Purchase Option Term Sale of Stock, Purchase Option Term Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Per share information: Earnings Per Share [Abstract] Note payable related to asset acquisition Increase (Decrease) in Notes Payable, Current Discounted purchase price from market price, offering date Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date Equity Transactions and Share-based Compensation Share-based Payment Arrangement [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Document Quarterly Report Document Quarterly Report Unrealized loss, total Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Issuance costs Payments of Stock Issuance Costs Issuance of common stock, net of issuance costs $7.2 million (in shares) Stock Issued During Period, Shares, New Issues Number of product candidates Number Of Product Candidates Number Of Product Candidates Liabilities Operating Lease, Liability [Abstract] Accrued legal expenses Accrued Professional Fees, Current Inventory, finished goods Inventory, Finished Goods, Gross Debt issued for acquisition One-year closing anniversary payment Asset Acquisition, Consideration Transferred, Liabilities Incurred Asset Acquisition, Consideration Transferred, Liabilities Incurred Total present value of lease payments Operating Lease, Liability Total consideration Asset Acquisition, Consideration Transferred Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation of Revenue Disaggregation of Revenue [Line Items] Number of securities with unrealized losses, total Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Asset Acquisition [Domain] Asset Acquisition [Domain] Subsequent Event [Table] Subsequent Event [Table] License agreement, nonrefundable regulatory milestone payment to be received License Agreement, Nonrefundable Regulatory Milestone Payment to be Received License Agreement, Nonrefundable Regulatory Milestone Payment to be Received Total share-based compensation expense Share-based Payment Arrangement, Expense Accumulated other comprehensive loss, net Accumulated Other Comprehensive Income (Loss), Net of Tax Remainder of fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Document Fiscal Period Focus Document Fiscal Period Focus Asset Acquisition Asset Acquisition [Line Items] Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Significant Agreements Research and Development Arrangement, Contract to Perform for Others [Table Text Block] Estimated annual effective tax rate Effective Income Tax Rate Reconciliation, Percent Number of shares issued for acquisition Shares common stock issued as consideration (in shares) Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number of Shares Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number of Shares Amortization of discount/premium on investments Accretion (Amortization) of Discounts and Premiums, Investments Counterparty Name [Axis] Counterparty Name [Axis] Document Period End Date Document Period End Date Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Area of sublease space (in sq ft) Lessee, Operating Sublease, Area Of Sublease Property Lessee, Operating Sublease, Area Of Sublease Property Gain on sale of equipment Gain (Loss) on Disposition of Property Plant Equipment Cash and cash equivalents Beginning of period End of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total number of option segments Revenue, Performance Obligation, Total Number Of Option Segments Revenue, Performance Obligation, Total Number Of Option Segments Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Entity Registrant Name Entity Registrant Name Summary of investments with unrealized losses, aggregated by investment type and the length of time Schedule of Unrealized Loss on Investments [Table Text Block] Interest income and other, net Interest Income (Expense), Net Current assets: Assets, Current [Abstract] Less amount of lease payments representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Tax Contingency Income Tax Contingency [Line Items] Net assets acquired Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Other income: Other Nonrecurring (Income) Expense [Abstract] Entity Central Index Key Entity Central Index Key Proceeds from shares sold Sale of Stock, Consideration Received on Transaction Name of each exchange on which registered Security Exchange Name Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash Payments to Acquire Productive Assets BARDA BARDA BARDA [Member] BARDA [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Exercise of stock options (in shares) Shares issued pursuant to the exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current CR Sanjui Sanjiu Medical & Pharmaceutical Co., Ltd. [Member] Sanjiu Medical & Pharmaceutical Co., Ltd. Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Weighted-average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Financial Instrument [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Participation term Share-based Compensation Arrangement by Share-based Payment Award, Participation Term Share-based Compensation Arrangement by Share-based Payment Award, Participation Term Fair value, measurements, recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Underwriter's Option Over-Allotment Option [Member] Liability for closing payment adjustments Asset Acquisition, Closing Payment Adjustment Liability Asset Acquisition, Closing Payment Adjustment Liability Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Proceeds from sales of short-term investments Proceeds from Sale of Short-term Investments Fair value, less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common Stock Common Stock [Member] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Employee stock purchase plan purchases Stock Issued During Period, Value, Employee Stock Purchase Plan Loss from operations Operating Income (Loss) Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative expense General and Administrative Expense [Member] Purchases of long-term investments Payments to Acquire Long-term Investments Operating lease short-term liabilities (recorded within Accrued liabilities) Operating Lease, Liability, Current Debt Securities, Available-for-sale Debt Securities, Available-for-sale [Line Items] Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Total current liabilities Liabilities, Current Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Share-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-in Capital Additional Paid-in Capital [Member] Depreciation of property and equipment Depreciation Money market funds Money Market Funds [Member] Cash and cash equivalents: Cash and Cash Equivalents [Abstract] Total revenues Revenue from Contract with Customer, Including Assessed Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Operating lease, liability, current, statement of financial position [extensible list] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Title of each class Title of 12(b) Security Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Impact of Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Number of securities with unrealized losses, greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Fees Fees [Member] Fees Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Subsequent Event Subsequent Event [Member] Legal Entity [Axis] Legal Entity [Axis] Proceeds from maturities of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-term Investments Cover [Abstract] Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Operating lease maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent All remaining years Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Expense reimbursement Expense Reimbursement [Member] Expense Reimbursement [Member] Payment to be received upon achievement of milestones License Agreement, Payment To Be Received Upon Milestones Achieved License Agreement, Payment To Be Received Upon Milestones Achieved Unrealized loss, less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Common stock, shares issued (in shares) Common Stock, Shares, Issued Licensing revenue License [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Inventories Inventory, Policy [Policy Text Block] Scenario [Domain] Scenario [Domain] Grant Grant [Member] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2021 and December 31, 2020; 86,848,426 and 62,816,039 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Outstanding Maturing in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Asset acquisition Asset Acquisition [Table Text Block] Oncoceutics, Inc. Oncoceutics, Inc. [Member] Oncoceutics, Inc. Unrealized loss, greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Total number of separate contracts Revenue, Performance Obligation, Total Number Of Contracts Revenue, Performance Obligation, Total Number Of Contracts Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Note payable Notes Payable, Current Refundable Agreements Refundable Agreements [Member] Refundable Agreements [Member] EX-101.PRE 12 cmrx-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 cmrx-20210930_htm.xml IDEA: XBRL DOCUMENT 0001117480 2021-01-01 2021-09-30 0001117480 2021-10-31 0001117480 2021-09-30 0001117480 2020-12-31 0001117480 cmrx:ContractAndGrantMember 2021-07-01 2021-09-30 0001117480 cmrx:ContractAndGrantMember 2020-07-01 2020-09-30 0001117480 cmrx:ContractAndGrantMember 2021-01-01 2021-09-30 0001117480 cmrx:ContractAndGrantMember 2020-01-01 2020-09-30 0001117480 us-gaap:LicenseMember 2021-07-01 2021-09-30 0001117480 us-gaap:LicenseMember 2020-07-01 2020-09-30 0001117480 us-gaap:LicenseMember 2021-01-01 2021-09-30 0001117480 us-gaap:LicenseMember 2020-01-01 2020-09-30 0001117480 2021-07-01 2021-09-30 0001117480 2020-07-01 2020-09-30 0001117480 2020-01-01 2020-09-30 0001117480 us-gaap:CommonStockMember 2020-12-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001117480 us-gaap:RetainedEarningsMember 2020-12-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001117480 2021-01-01 2021-03-31 0001117480 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001117480 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001117480 us-gaap:CommonStockMember 2021-03-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001117480 us-gaap:RetainedEarningsMember 2021-03-31 0001117480 2021-03-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001117480 2021-04-01 2021-06-30 0001117480 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001117480 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001117480 us-gaap:CommonStockMember 2021-06-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001117480 us-gaap:RetainedEarningsMember 2021-06-30 0001117480 2021-06-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001117480 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001117480 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001117480 us-gaap:CommonStockMember 2021-09-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001117480 us-gaap:RetainedEarningsMember 2021-09-30 0001117480 us-gaap:CommonStockMember 2019-12-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001117480 us-gaap:RetainedEarningsMember 2019-12-31 0001117480 2019-12-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001117480 2020-01-01 2020-03-31 0001117480 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001117480 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001117480 us-gaap:CommonStockMember 2020-03-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001117480 us-gaap:RetainedEarningsMember 2020-03-31 0001117480 2020-03-31 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001117480 2020-04-01 2020-06-30 0001117480 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001117480 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001117480 us-gaap:CommonStockMember 2020-06-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001117480 us-gaap:RetainedEarningsMember 2020-06-30 0001117480 2020-06-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001117480 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001117480 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001117480 us-gaap:CommonStockMember 2020-09-30 0001117480 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001117480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001117480 us-gaap:RetainedEarningsMember 2020-09-30 0001117480 2020-09-30 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001117480 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001117480 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001117480 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001117480 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001117480 cmrx:BARDAMember cmrx:ExpenseReimbursementMember 2011-02-01 2021-09-01 0001117480 cmrx:BARDAMember cmrx:FeesMember 2011-02-01 2021-09-01 0001117480 cmrx:BARDAMember 2011-02-01 2021-09-01 0001117480 cmrx:FederalGovermentMember cmrx:OncoceuticsIncMember 2021-09-30 0001117480 cmrx:PrivateFoundationsMember cmrx:OncoceuticsIncMember 2021-09-30 0001117480 us-gaap:GrantMember cmrx:OncoceuticsIncMember 2021-09-30 0001117480 us-gaap:GrantMember cmrx:OncoceuticsIncMember 2021-07-01 2021-09-30 0001117480 us-gaap:GrantMember cmrx:OncoceuticsIncMember 2021-01-01 2021-09-30 0001117480 cmrx:SymBioPharmaceuticalsMember 2019-10-01 2019-10-31 0001117480 cmrx:SymBioPharmaceuticalsMember 2019-09-30 0001117480 cmrx:SymBioPharmaceuticalsMember 2019-10-01 2019-10-31 0001117480 us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001117480 us-gaap:USTreasurySecuritiesMember 2021-09-30 0001117480 us-gaap:CommercialPaperMember 2021-09-30 0001117480 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001117480 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001117480 cmrx:BARDAMember cmrx:RefundableAgreementsMember 2021-09-30 0001117480 cmrx:BARDAMember cmrx:RefundableAgreementsMember 2020-12-31 0001117480 cmrx:PublicStockOfferingMember 2021-01-20 2021-01-20 0001117480 2021-01-20 0001117480 cmrx:PublicStockOfferingMember 2021-01-20 0001117480 us-gaap:OverAllotmentOptionMember 2021-01-20 0001117480 us-gaap:OverAllotmentOptionMember 2021-01-20 2021-01-20 0001117480 cmrx:The2013PlanMember 2021-01-01 2021-09-30 0001117480 cmrx:The2013PlanMember 2021-01-01 2021-01-01 0001117480 cmrx:The2013PlanMember 2021-09-30 0001117480 cmrx:The2013PlanMember 2021-07-01 2021-09-30 0001117480 cmrx:The2013PlanMember 2020-07-01 2020-09-30 0001117480 cmrx:The2013PlanMember 2020-01-01 2020-09-30 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2021-09-30 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2021-01-01 2021-01-01 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2021-07-01 2021-09-30 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2020-07-01 2020-09-30 0001117480 cmrx:The2013EmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001117480 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001117480 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001117480 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001117480 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001117480 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001117480 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001117480 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001117480 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001117480 srt:ScenarioForecastMember 2021-01-01 2021-12-31 0001117480 cmrx:BARDAMember 2011-02-01 2011-02-28 0001117480 cmrx:BARDAMember 2021-07-01 2021-09-30 0001117480 cmrx:BARDAMember 2020-07-01 2020-09-30 0001117480 cmrx:BARDAMember 2021-01-01 2021-09-30 0001117480 cmrx:BARDAMember 2020-01-01 2020-09-30 0001117480 cmrx:CantexPharmaceuticalsMember 2019-07-26 0001117480 cmrx:SymBioPharmaceuticalsMember 2019-09-01 2019-09-30 0001117480 cmrx:OharaPharmaceuticalCoLtdMember 2019-12-31 0001117480 cmrx:SanjiuMedicalPharmaceuticalCoLtdMember cmrx:OncoceuticsIncMember 2020-12-01 2020-12-31 0001117480 cmrx:OncoceuticsIncMember 2021-01-07 2021-01-07 0001117480 cmrx:OncoceuticsIncMember 2021-09-30 0001117480 cmrx:OncoceuticsIncMember 2021-01-07 0001117480 cmrx:OncoceuticsIncMember 2020-10-01 2020-12-31 0001117480 srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2021-10-01 2021-12-31 shares iso4217:USD iso4217:USD shares cmrx:product cmrx:segment cmrx:contract cmrx:grant cmrx:security pure utr:sqft cmrx:extension false 2021 Q3 0001117480 --12-31 http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent 10-Q true 2021-09-30 false 001-35867 CHIMERIX, INC. DE 33-0903395 2505 Meridian Parkway Suite 100 Durham NC 27713 919 806-1074 Common Stock, par value $0.001 per share CMRX NASDAQ Yes Yes Non-accelerated Filer true false false 86862426 26174000 46989000 96384000 31973000 53000 340000 1595000 0 4327000 2356000 128533000 81658000 2035000 0 264000 214000 2509000 2825000 60000 26000 133401000 84723000 1792000 1283000 10498000 7250000 14000000 0 26290000 8533000 2525000 2814000 28815000 11347000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 86848426 86848426 62816039 62816039 87000 63000 950597000 785673000 0 0 -846098000 -712360000 104586000 73376000 133401000 84723000 105000 1591000 1928000 4158000 2000 18000 5000 94000 107000 1609000 1933000 4252000 13820000 10018000 39480000 27545000 4887000 3151000 13431000 9466000 0 0 82890000 0 18707000 13169000 135801000 37011000 -18600000 -11560000 -133868000 -32759000 40000 149000 130000 912000 -18560000 -11411000 -133738000 -31847000 11000 -97000 0 -2000 -18549000 -11508000 -133738000 -31849000 -0.21 -0.21 -0.18 -0.18 -1.59 -1.59 -0.51 -0.51 86335357 86335357 62242456 62242456 84277555 84277555 62009941 62009941 62816039 63000 785673000 0 -712360000 73376000 2584000 2584000 710132 1000 3529000 3530000 259837 330000 330000 168752 8723769 9000 43436000 43445000 7200000 13529750 13000 107829000 107842000 -43000 -43000 -97415000 -97415000 -97458000 86208279 86000 943381000 -43000 -809775000 133649000 3112000 3112000 41465 119000 119000 32000 32000 -17763000 -17763000 -17731000 86249744 86000 946612000 -11000 -827538000 119149000 3431000 3431000 74588 130000 130000 283094 1000 424000 425000 241000 11000 11000 -18560000 -18560000 -18549000 86848426 87000 950597000 0 -846098000 104586000 61590013 62000 778693000 35000 -668838000 109952000 1326000 1326000 177193 229000 229000 163133 -46000 -46000 -10420000 -10420000 -10466000 61930339 62000 780248000 -11000 -679258000 101041000 1391000 1391000 242079 578000 578000 141000 141000 -10016000 -10016000 -9875000 62172418 62000 782217000 130000 -689274000 93135000 1282000 1282000 20592 1000 62000 63000 159879 197000 197000 276833 -97000 -97000 -11411000 -11411000 -11508000 62629722 63000 783758000 33000 -700685000 83169000 -133738000 -31847000 143000 309000 -648000 268000 9127000 4000000 43445000 0 14000000 2000 1000 0 10000 314000 -47000 -288000 -855000 1595000 0 2005000 -1284000 3468000 -1268000 -65907000 -26993000 193000 60000 0 10000 105355000 58895000 9594000 0 2007000 1498000 45850000 104602000 -67285000 47155000 3780000 641000 754000 426000 107843000 0 112377000 1067000 -20815000 21229000 46989000 16901000 26174000 38130000 The Business and Summary of Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Our two most advanced clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in Phase 3 development as a potential first-line therapy in acute myeloid leukemia (AML).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of the Company’s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020, the Company had cash equivalents including money market funds, whose value is based on quoted market prices. At September 30, 2021 and December 31, 2020, the Company had short-term investments, including U.S. Treasury securities, whose value is based on quoted market prices. At September 30, 2021, the Company had long-term investments including U.S. Treasury securities, whose value is based on quoted market prices. Accordingly, these securities are classified as Level 1. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had short-term investments, including commercial paper, and corporate bonds, and on December 31, 2020, the Company had short-term investments including corporate bonds. As quoted prices are not available for these securities, they are valued using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security’s credit rating, prepayment assumptions and other factors such as credit loss assumptions. Accordingly, these securities are classified as Level 2.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company's investments, please refer to Note 2, "Investments."</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,734 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,476 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company’s inventory is related to TEMBEXA, which is being manufactured for the treatment of smallpox and potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The Company's inventories at September 30, 2021 consisted of $1.6 million of work-in-process and no finished goods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assessment of market value requires the use of estimates regarding the net realizable value of its inventory balances, including an assessment of excess or obsolete inventory. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. The Company determines excess or obsolete inventory based on multiple factors, including an estimate of the future demand for its products, product expiration dates and current sales levels. The Company’s assumptions of future demand for its products are inherently uncertain and if the Company were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that the Company reports in a particular period. In addition, the Company's inventory may experience expiration of its shelf-life stability. During the nine months ended September 30, 2021, the Company did not record a reserve for inventory as the Company assumes TEMBEXA will be sold to the US government under a procurement contract with Biomedical Advanced Research and Development Authority (BARDA) or could be sold to other governmental agencies. Should no procurement contract be secured in the future, the Company may reserve part or all of our inventory balance, which would be included in cost of sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues generally consist of (i) contract and grant revenue - revenue generated under federal and private foundation grants and contracts, and (ii) collaboration and licensing revenue - revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biomedical Advanced Research and Development Authority (BARDA) </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees over the performance of one base segment and four option segments. Exercise of each option segment was solely at the discretion of BARDA. The Company assessed the services in accordance with the authoritative guidance and concluded that there was a potential of five separate contracts (one base segment and four option segments) within this agreement, each of which had a single performance obligation. All option segments (one through four) were exercised, as well as the base segment. The transaction price for each segment, based on the transaction price as defined in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each segment contract, was allocated to the single performance obligation for each contract. The transaction price was recognized over time by measuring the progress toward complete satisfaction of the performance obligation. For reimbursable expenses, this occurred as qualifying research activities were conducted based on invoices from company vendors. For the fixed fee, the progress toward complete satisfaction was estimated based on the costs incurred to date relative to the total estimated costs per the terms of each contract. The Company typically invoiced BARDA monthly as costs were incurred. Any amounts received in advance of performance were recorded as deferred revenue until earned. The base segment and first option segment were completed prior to adoption of ASC 606. The second and third option segments were completed on August 20, 2020. The fourth option segment was completed on September 1, 2021 and the contract has expired in accordance with its terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. As a result of its acquisition of Oncoceutics, Inc. (Oncoceutics), the Company became the beneficiary of two federal grant programs and two grant programs with private foundations, of which the federal grant programs ended in the third quarter of 2021. At September 30, 2021, the Company has a deferred revenue balance of $0.2 million related to these grants. Additionally, for the three and nine months ended September 30, 2021, the Company recognized $18,000 and $0.4 million of grant revenue related to these grants, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SymBio Pharmaceuticals </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, the Company entered into a license agreement with SymBio Pharmaceuticals Limited (SymBio) under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. The Company assessed the agreement in accordance with the authoritative guidance and concluded that the SymBio contract includes multiple performance obligations. The SymBio contract has one fixed transaction amount of a $5.0 million upfront payment received in October 2019 and several variable transaction amounts, up to $180 million, due to the Company at certain regulatory and commercial milestones, along with low double-digit percent royalties based on net sales of TEMBEXA. All variable transaction amounts are fully constrained, therefore the allocated transaction price is $5.0 million. The majority of the transaction price of the contract has been allocated to the combined performance obligation of the granting of the license to TEMBEXA and associated technology transfer which was recognized when the technology transfer was completed in the fourth quarter of 2019. The revenue from regulatory and commercial milestones and royalties from net sales will be recognized upon the occurrence of the triggering events or when those transaction amounts are no longer fully constrained. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net loss per share of common stock is computed by dividing net loss by </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three and nine months ended September 30, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in only one segment, pharmaceuticals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of Recently Issued Accounting Standards</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements. 2 Basis of PresentationThe accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of the Company’s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020, the Company had cash equivalents including money market funds, whose value is based on quoted market prices. At September 30, 2021 and December 31, 2020, the Company had short-term investments, including U.S. Treasury securities, whose value is based on quoted market prices. At September 30, 2021, the Company had long-term investments including U.S. Treasury securities, whose value is based on quoted market prices. Accordingly, these securities are classified as Level 1. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had short-term investments, including commercial paper, and corporate bonds, and on December 31, 2020, the Company had short-term investments including corporate bonds. As quoted prices are not available for these securities, they are valued using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security’s credit rating, prepayment assumptions and other factors such as credit loss assumptions. Accordingly, these securities are classified as Level 2.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company's investments, please refer to Note 2, "Investments."</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,734 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,476 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,734 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">               Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,476 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20165000 20165000 0 0 20165000 20165000 0 0 7534000 7534000 0 0 51277000 0 51277000 0 37573000 0 37573000 0 96384000 7534000 88850000 0 2035000 2035000 0 0 2035000 2035000 0 0 118584000 29734000 88850000 0 1503000 1503000 0 0 1503000 1503000 0 0 28715000 28715000 0 0 3258000 0 3258000 0 31973000 28715000 3258000 0 33476000 30218000 3258000 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company’s inventory is related to TEMBEXA, which is being manufactured for the treatment of smallpox and potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The Company's inventories at September 30, 2021 consisted of $1.6 million of work-in-process and no finished goods. </span></div>The Company’s assessment of market value requires the use of estimates regarding the net realizable value of its inventory balances, including an assessment of excess or obsolete inventory. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. The Company determines excess or obsolete inventory based on multiple factors, including an estimate of the future demand for its products, product expiration dates and current sales levels. The Company’s assumptions of future demand for its products are inherently uncertain and if the Company were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that the Company reports in a particular period. In addition, the Company's inventory may experience expiration of its shelf-life stability. During the nine months ended September 30, 2021, the Company did not record a reserve for inventory as the Company assumes TEMBEXA will be sold to the US government under a procurement contract with Biomedical Advanced Research and Development Authority (BARDA) or could be sold to other governmental agencies. Should no procurement contract be secured in the future, the Company may reserve part or all of our inventory balance, which would be included in cost of sales. 1600000 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3276000 1375000 4502000 4473000 213000 651000 2507000 751000 10498000 7250000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policy</span></div>The Company’s revenues generally consist of (i) contract and grant revenue - revenue generated under federal and private foundation grants and contracts, and (ii) collaboration and licensing revenue - revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation. 72500000 4600000 1 4 5 1 4 2 2 200000 18000 400000 5000000 180000000 5000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net loss per share of common stock is computed by dividing net loss by </span></div>the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three and nine months ended September 30, 2021 and 2020. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div> SegmentsThe Company operates in only one segment, pharmaceuticals. 1 Impact of Recently Issued Accounting Standards<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements. Impact of Recently Issued Accounting Standards<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements. Investments<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's debt investments (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews available-for-sale debt investments for other-than-temporary declines in fair value below the cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company’s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. At September 30, 2021, the Company did not intend to sell, and was not more likely than not to be required to sell, the available-for-sale debt investments in an unrealized loss position before recovery of the cost basis of the securities, which may be at maturity. There were no such declines in value for the three and nine months ended September 30, 2021 and 2020. Unrealized gains and losses on debt investments are recorded to unrealized (loss) gain on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company's debt investments at September 30, 2021 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's debt investments (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 37579000 1000 7000 37573000 9568000 2000 1000 9569000 51272000 7000 2000 51277000 98419000 10000 10000 98419000 3256000 2000 0 3258000 28717000 1000 3000 28715000 31973000 3000 3000 31973000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27554000 7000 0 0 27554000 7000 10491000 2000 0 0 10491000 2000 7034000 1000 0 0 7034000 1000 45079000 10000 0 0 45079000 10000 16 0 16 16598000 3000 0 0 16598000 3000 16598000 3000 0 0 16598000 3000 6 0 6 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company's debt investments at September 30, 2021 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,419 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 96384000 2035000 98419000 Commitments and Contingencies<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company's sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company's discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company's operating leases as of September 30, 2021 was 4.84 years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to leases is recorded on a straight-line basis over the lease term. Lease expense under operating leases, including common area maintenance fees, totaled approximately $0.2 million and $0.2 million, respectively, for the three months ended September 30, 2021 and 2020 and approximately $0.5 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate implicit within the Company's leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of September 30, 2021, the operating lease liabilities reflect a weighted-average discount rate of 7.89%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the operating lease right-of-use assets and liabilities as of September 30, 2021 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI3YzFlYTJhNzNlOTRjNzBiMmE5MDgyYWNkMTA0ZjI5L3NlYzpiN2MxZWEyYTczZTk0YzcwYjJhOTA4MmFjZDEwNGYyOV8zNy9mcmFnOjJkYWM5MzJkNGRjNzRlNWJhOGVjMGIxYjZiNGJlMDZhL3RhYmxlOjExZmU5Y2UyZmE3OTQ5ZjdiMWE0NGFjZjA5ZGM3Y2EwL3RhYmxlcmFuZ2U6MTFmZTljZTJmYTc5NDlmN2IxYTQ0YWNmMDlkYzdjYTBfNC0wLTEtMS0xOTgzNw_1a793252-cebf-4358-872c-4a1524412483"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI3YzFlYTJhNzNlOTRjNzBiMmE5MDgyYWNkMTA0ZjI5L3NlYzpiN2MxZWEyYTczZTk0YzcwYjJhOTA4MmFjZDEwNGYyOV8zNy9mcmFnOjJkYWM5MzJkNGRjNzRlNWJhOGVjMGIxYjZiNGJlMDZhL3RhYmxlOjExZmU5Y2UyZmE3OTQ5ZjdiMWE0NGFjZjA5ZGM3Y2EwL3RhYmxlcmFuZ2U6MTFmZTljZTJmYTc5NDlmN2IxYTQ0YWNmMDlkYzdjYTBfNC0wLTEtMS0xOTgzNw_dfd2f8e1-cfd0-4ba1-a163-e62761e33805">Operating lease short-term liabilities (recorded within Accrued liabilities)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease long-term liabilities (recorded within Lease-related obligations)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments over the remainder of the lease terms are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All remaining years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company entered into the Ninth Amendment of its lease for the Company's headquarters in Durham, North Carolina, which extended the term of the lease by 65 months to July 31, 2026. As part of the amendment, the Company is entitled to receive a rent abatement of the first five months of the new lease term which began on March 1, 2021. Additionally, the Ninth Amendment grants the Company a refurbishment allowance, which the Company expects to receive in 2021 after the refurbishment has been completed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, operating lease payments over the remainder of the lease terms were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021 and 2020, the Company made lease payments of approximately $122,000 and $181,000, respectively, and for the nine months ended September 30, 2021 and 2020, the Company made lease payments of approximately $292,000 and $538,000, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleased 3,537 square feet of its office space under a non-cancelable operating lease that expired in February 2021. For the three and nine months ended September 30, 2021, the Company recognized $0 and approximately $12,000 of income, respectively, and for the three and nine months ended September 30, 2020, the Company recognized approximately $18,000 and $53,000 of income, respectively, in Interest income and other, net on the Consolidated Statement of Operations and Comprehensive Loss. As this lease has terminated, there are no future minimum rentals payments to be received.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significance of Revenue Source</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the recipient of federal research contract funds from BARDA, the primary source of the Company's contract and grant revenue. Periodic audits are required under the Company’s BARDA agreement and certain costs may be questioned as appropriate under the BARDA agreement. At September 30, 2021 and December 31, 2020, the Company had recorded a provision for potential refundable amounts of $52,000 and $38,000, respectively.</span></div> P4Y10M2D 200000 200000 500000 600000 0.0789 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the operating lease right-of-use assets and liabilities as of September 30, 2021 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI3YzFlYTJhNzNlOTRjNzBiMmE5MDgyYWNkMTA0ZjI5L3NlYzpiN2MxZWEyYTczZTk0YzcwYjJhOTA4MmFjZDEwNGYyOV8zNy9mcmFnOjJkYWM5MzJkNGRjNzRlNWJhOGVjMGIxYjZiNGJlMDZhL3RhYmxlOjExZmU5Y2UyZmE3OTQ5ZjdiMWE0NGFjZjA5ZGM3Y2EwL3RhYmxlcmFuZ2U6MTFmZTljZTJmYTc5NDlmN2IxYTQ0YWNmMDlkYzdjYTBfNC0wLTEtMS0xOTgzNw_1a793252-cebf-4358-872c-4a1524412483"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI3YzFlYTJhNzNlOTRjNzBiMmE5MDgyYWNkMTA0ZjI5L3NlYzpiN2MxZWEyYTczZTk0YzcwYjJhOTA4MmFjZDEwNGYyOV8zNy9mcmFnOjJkYWM5MzJkNGRjNzRlNWJhOGVjMGIxYjZiNGJlMDZhL3RhYmxlOjExZmU5Y2UyZmE3OTQ5ZjdiMWE0NGFjZjA5ZGM3Y2EwL3RhYmxlcmFuZ2U6MTFmZTljZTJmYTc5NDlmN2IxYTQ0YWNmMDlkYzdjYTBfNC0wLTEtMS0xOTgzNw_dfd2f8e1-cfd0-4ba1-a163-e62761e33805">Operating lease short-term liabilities (recorded within Accrued liabilities)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease long-term liabilities (recorded within Lease-related obligations)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2509000 416000 2525000 2941000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments over the remainder of the lease terms are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All remaining years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company entered into the Ninth Amendment of its lease for the Company's headquarters in Durham, North Carolina, which extended the term of the lease by 65 months to July 31, 2026. As part of the amendment, the Company is entitled to receive a rent abatement of the first five months of the new lease term which began on March 1, 2021. Additionally, the Ninth Amendment grants the Company a refurbishment allowance, which the Company expects to receive in 2021 after the refurbishment has been completed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, operating lease payments over the remainder of the lease terms were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 97000 715000 736000 759000 781000 467000 3555000 614000 2941000 P65M P5M 260000 715000 736000 759000 781000 467000 3718000 792000 2926000 122000 181000 292000 538000 3537 0 12000 18000 53000 52000 38000 Equity Transactions and Share-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 11,765,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share (the Common Stock). The price to the public in this offering was $8.50 per share, and the Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $7.99 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,764,750 additional shares of Common Stock at the public offering price. The net proceeds to the Company from this offering were approximately $107.8 million, as the Underwriters’ option to purchase additional shares was exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on January 25, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increases on January 1 of each calendar year by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. On January 1, 2021, the common stock reserved for issuance under the 2013 Plan was automatically increased by 2.5 million shares. As of September 30, 2021, there was a total of 2.2 million shares reserved for future issuance under the 2013 Plan. The Company issued approximately 75,000 and 826,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2021, respectively. The Company issued 21,000 and 263,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of its designated affiliates. The Company has reserved a total of 3.9 million shares of common stock to be purchased under the ESPP, of which 2.3 million shares remained available for purchase as of September 30, 2021. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, by the lesser of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 422,535 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b). On January 1, 2021, the common stock reserved for issuance under the ESPP was automatically increased by an additional 422,535 shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides for an automatic reset feature to start participants on a new twenty-four month participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the twenty-four month offering period. Eligible employees may authorize an amount up to 15% of their salary to purchase common stock at the lower of a 15% discount to the beginning price of their offering period or a 15% discount to the ending price of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each six-month purchase interval. The Company issued approximately 283,000 and 160,000 shares of common stock pursuant to the ESPP during the three months ended September 30, 2021 and 2020, respectively. The Company issued approximately 543,000 and 337,000 shares of common stock pursuant to the ESPP during the nine months ended September 30, 2021 and 2020, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the “look-back” option and were determined using a Black-Scholes option pricing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company's common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company's common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued 241,000 shares and approximately 410,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2021, respectively. The Company issued 277,000 shares and approximately 440,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11765000 0.001 8.50 7.99 P30D 1764750 107800000 0.04 2500000 2200000 75000 826000 21000 263000 3900000 2300000 0.01 422535 422535 P24M P24M 0.15 0.15 0.15 P6M 283000 160000 543000 337000 241000 410000 277000 440000 Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1853000 625000 4995000 2090000 1578000 657000 4132000 1910000 3431000 1282000 9127000 4000000 Income Taxes <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the nine month period ended September 30, 2021, and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had no unrecognized tax benefits that would reduce the Company’s effective tax rate if recognized.</span></div> 0 0 0 Significant Agreements <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biomedical Advanced Research and Development Authority (BARDA)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, BARDA agreed to reimburse the Company, plus pay a fixed fee, for the research and development of TEMBEXA as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections. The contract consists of an initial performance period, referred to as the base performance segment, plus up to four extension periods, referred to as option segments, of which all have been exercised. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fourth option segment ended on September 1, 2021 and the contract has expired in accordance with its terms. For the three months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $0.1 million and $1.6 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, respectively, and for the nine months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $1.6 million and $4.2 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cantex Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a License and Development Agreement with Cantex Pharmaceuticals, Inc. (Cantex) pursuant to which the Company acquired exclusive worldwide rights to develop and commercialize, for any and all uses, a glycosaminoglycan compound known as DSTAT, which is currently being studied for the treatment of acute myeloid leukemia. Under the terms of the license agreement, the Company is responsible for, and bears the future costs of, worldwide development and commercialization of DSTAT. In connection with the transaction, Cantex assigned to the Company all of its rights under its DSTAT supply agreements, including its bulk API agreement with Scientific Protein Laboratories LLC (SPL), including subsequent amendments, pursuant to which SPL will exclusively produce DSTAT for the Company through December 2040.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement obligates the Company to pay Cantex regulatory milestone payments of up to $202.5 million upon receipt of product approvals in the United States, the European Union and Japan, and sales milestone payments of up to $385.0 million upon achievement of specified net sales levels. The Company also agreed to pay Cantex tiered royalties based on percentages of net sales beginning at 10% and not to exceed the high-teens.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SymBio Pharmaceuticals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, the Company entered into a license agreement with SymBio under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. Under the terms of the license agreement, SymBio will be responsible for, and bear the future costs of, worldwide development and commercialization of TEMBEXA in the licensed indications. Either party may terminate the license agreement upon the occurrence of a material breach by the other party (subject to standard cure periods). SymBio may also terminate the license agreement without cause on a country-by-country basis upon ninety days' prior notice.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the license to SymBio under the Company's TEMBEXA rights, the Company received an upfront payment of $5.0 million in October 2019. In addition, the Company is eligible to receive up to $180.0 million in clinical, regulatory and commercial milestones worldwide, as well as low double-digit percent royalties based on net sales of TEMBEXA. Since entering into the license agreement in September 2019, the Company has recognized all of the $5.0 million upfront payment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CR Sanjiu Agreement</span></div>In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in China. 4 72500000 4600000 100000 1600000 1600000 4200000 202500000 385000000 0.10 P90D 5000000 180000000 5000000 2500000 5000000 Oncoceutics AcquisitionOn January 7, 2021, the Company, Ocean Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (Merger Sub), Oncoceutics and Fortis Advisors, LLC solely in its capacity as representative of the securityholders of Oncoceutics (the Securityholders’ Representative), entered into an Agreement and Plan of Merger (the Merger Agreement). Concurrently with the execution of the Merger Agreement, Merger Sub merged with and into Oncoceutics (the Merger) whereupon the separate corporate existence of Merger Sub ceased, with Oncoceutics continuing as the surviving corporation of the Merger as a wholly-owned subsidiary of the Company.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As consideration for the Merger, the Company (a) paid an upfront cash payment of approximately $25.0 million, subject to certain customary adjustments, (b) issued an aggregate of 8,723,769 shares of the Company's common stock, (c) issued a promissory note to the Securityholders' Representative in the principal amount of $14.0 million (the Seller Note), to be paid in cash, subject to the terms and conditions of the Merger Agreement and the Seller Note, upon the one year anniversary of the closing of the Merger, and (d) agreed to make contingent payments up to an aggregate of $360.0 million based on the achievement of certain development, regulatory and commercialization events as set forth in the Merger Agreement, as well as additional tiered royalty payments based upon future net sales of ONC 201 and ONC 206 products, subject to certain reductions as set forth in the Merger Agreement, and a contingent payment in the event the Company receives any proceeds from the sale of a rare pediatric disease priority review voucher based on Oncoceutics' products. The closing payment may be adjusted after the closing, pursuant to procedures set forth in the Merger Agreement, in connection with the finalization of the cash, transaction expenses, debt and working capital amounts at closing. As of September 30, 2021, the Company has recorded an estimated liability of $0.2 million related to closing payment adjustments. Additionally, as of September 30, 2021, the Company has recorded an estimated receivable of $0.6 million related to the repayment of certain severance amounts due from the Oncoceutics' shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the Oncoceutics acquisition as an asset acquisition as the majority of the value of the assets acquired related to the ONC201 acquired in-process research and development (IPR&amp;D) asset. In accordance with Accounting Standards Codification (ASC) Subtopic 730-10-25, Accounting for Research and Development Costs, the up-front payments to acquire a new drug compound, as well as future milestone payments when paid or payable, are immediately expensed as acquired IPR&amp;D in transactions other than a business combination provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Therefore, the portion of the purchase price that was allocated to the IPR&amp;D assets acquired was immediately expensed. Other assets acquired and liabilities assumed, were recorded at fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the consideration paid and purchase price allocation for the acquisition of Oncoceutics (in thousands, except for per share data):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-year closing anniversary payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares common stock issued as consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price per share on effective date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of estimated common stock consideration</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,445 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D assets expensed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price allocated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs expensed to IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total IPR&amp;D expensed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired. The primary asset acquired, the IPR&amp;D asset, was expensed and the transaction related costs were included with and expensed with this asset. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses. Additionally, there were $0.6 million of expenses related to this acquisition recorded in the fourth quarter of 2020 to general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. 25000000 8723769 14000000 360000000 200000 600000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the consideration paid and purchase price allocation for the acquisition of Oncoceutics (in thousands, except for per share data):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-year closing anniversary payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares common stock issued as consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price per share on effective date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of estimated common stock consideration</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,445 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D assets expensed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price allocated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs expensed to IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total IPR&amp;D expensed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired. The primary asset acquired, the IPR&amp;D asset, was expensed and the transaction related costs were included with and expensed with this asset. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses. Additionally, there were $0.6 million of expenses related to this acquisition recorded in the fourth quarter of 2020 to general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. 23836000 14000000 8723769 4.98 43445000 81281000 -1310000 82591000 81281000 299000 82890000 600000 Subsequent EventsThe Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of September 30, 2021, and events which occurred subsequently but were not recognized in the financial statements.In accordance with the terms of the merger agreement between Chimerix and Oncoceutics, Inc., the achievement of the 20% overall response rate (ORR) via Blinded Independent Central Review (BICR) will result in a success milestone payment of $20 million to the former Oncoceutics, Inc. shareholders to be paid prior to year-end. 20000000 XML 14 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Oct. 31, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-35867  
Entity Registrant Name CHIMERIX, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 33-0903395  
Entity Address, Address Line One 2505 Meridian Parkway  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Durham  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 27713  
City Area Code 919  
Local Phone Number 806-1074  
Title of each class Common Stock, par value $0.001 per share  
Trading Symbol(s) CMRX  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   86,862,426
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001117480  
Current Fiscal Year End Date --12-31  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 26,174 $ 46,989
Short-term investments, available-for-sale 96,384 31,973
Accounts receivable 53 340
Inventories 1,595 0
Prepaid expenses and other current assets 4,327 2,356
Total current assets 128,533 81,658
Long-term investments 2,035 0
Property and equipment, net of accumulated depreciation 264 214
Operating lease right-of-use assets 2,509 2,825
Other long-term assets 60 26
Total assets 133,401 84,723
Current liabilities:    
Accounts payable 1,792 1,283
Accrued liabilities 10,498 7,250
Note payable 14,000 0
Total current liabilities 26,290 8,533
Lease-related obligations 2,525 2,814
Total liabilities 28,815 11,347
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding as of September 30, 2021 and December 31, 2020 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2021 and December 31, 2020; 86,848,426 and 62,816,039 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 87 63
Additional paid-in capital 950,597 785,673
Accumulated other comprehensive loss, net 0 0
Accumulated deficit (846,098) (712,360)
Total stockholders’ equity 104,586 73,376
Total liabilities and stockholders’ equity $ 133,401 $ 84,723
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 86,848,426 62,816,039
Common stock, shares outstanding (in shares) 86,848,426 62,816,039
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Total revenues $ 107 $ 1,609 $ 1,933 $ 4,252
Operating expenses:        
Research and development 13,820 10,018 39,480 27,545
General and administrative 4,887 3,151 13,431 9,466
Acquired in-process research and development 0 0 82,890 0
Total operating expenses 18,707 13,169 135,801 37,011
Loss from operations (18,600) (11,560) (133,868) (32,759)
Other income:        
Interest income and other, net 40 149 130 912
Net loss (18,560) (11,411) (133,738) (31,847)
Other comprehensive loss:        
Unrealized gain (loss) on debt investments, net 11 (97) 0 (2)
Comprehensive loss $ (18,549) $ (11,508) $ (133,738) $ (31,849)
Per share information:        
Net loss, basic (in dollars per share) $ (0.21) $ (0.18) $ (1.59) $ (0.51)
Net loss, diluted (in dollars per share) $ (0.21) $ (0.18) $ (1.59) $ (0.51)
Weighted-average shares outstanding, basic (in shares) 86,335,357 62,242,456 84,277,555 62,009,941
Weighted-average shares outstanding, diluted (in shares) 86,335,357 62,242,456 84,277,555 62,009,941
Contract and grant revenue        
Total revenues $ 105 $ 1,591 $ 1,928 $ 4,158
Licensing revenue        
Total revenues $ 2 $ 18 $ 5 $ 94
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   61,590,013      
Beginning balance at Dec. 31, 2019 $ 109,952 $ 62 $ 778,693 $ 35 $ (668,838)
Increase (Decrease) in Stockholders' Equity          
Share-based compensation 1,326   1,326    
Employee stock purchase plan purchases 229   229    
Employee stock purchase plan purchases (in shares)   177,193      
RSU stock issuance (in shares)   163,133      
Comprehensive loss:          
Unrealized loss on investments, net (46)     (46)  
Net loss (10,420)       (10,420)
Comprehensive loss (10,466)        
Ending balance at Mar. 31, 2020 101,041 $ 62 780,248 (11) (679,258)
Ending balance (in shares) at Mar. 31, 2020   61,930,339      
Beginning balance at Dec. 31, 2019 109,952 $ 62 778,693 35 (668,838)
Comprehensive loss:          
Unrealized loss on investments, net (2)        
Net loss (31,847)        
Comprehensive loss (31,849)        
Ending balance at Sep. 30, 2020 83,169 $ 63 783,758 33 (700,685)
Ending balance (in shares) at Sep. 30, 2020   62,629,722      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   61,930,339      
Beginning balance at Mar. 31, 2020 101,041 $ 62 780,248 (11) (679,258)
Increase (Decrease) in Stockholders' Equity          
Share-based compensation 1,391   1,391    
Exercise of stock options 578   578    
Exercise of stock options (in shares)   242,079      
Comprehensive loss:          
Unrealized loss on investments, net 141     141  
Net loss (10,016)       (10,016)
Comprehensive loss (9,875)        
Ending balance at Jun. 30, 2020 93,135 $ 62 782,217 130 (689,274)
Ending balance (in shares) at Jun. 30, 2020   62,172,418      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   62,172,418      
Share-based compensation 1,282   1,282    
Exercise of stock options 63 $ 1 62    
Exercise of stock options (in shares)   20,592      
Employee stock purchase plan purchases 197   197    
Employee stock purchase plan purchases (in shares)   159,879      
RSU stock issuance (in shares)   276,833      
Comprehensive loss:          
Unrealized loss on investments, net (97)     (97)  
Net loss (11,411)       (11,411)
Comprehensive loss (11,508)        
Ending balance at Sep. 30, 2020 83,169 $ 63 783,758 33 (700,685)
Ending balance (in shares) at Sep. 30, 2020   62,629,722      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   62,629,722      
Beginning balance (in shares)   62,816,039      
Beginning balance at Dec. 31, 2020 73,376 $ 63 785,673 0 (712,360)
Increase (Decrease) in Stockholders' Equity          
Share-based compensation 2,584   2,584    
Exercise of stock options 3,530 $ 1 3,529    
Exercise of stock options (in shares)   710,132      
Employee stock purchase plan purchases 330   330    
Employee stock purchase plan purchases (in shares)   259,837      
RSU stock issuance (in shares)   168,752      
Issuance of common stock related to asset acquisition 43,445 $ 9 43,436    
Issuance of common stock related to asset acquisition (in shares)   8,723,769      
Issuance of common stock, net of issuance costs of $7.2 million 107,842 $ 13 107,829    
Issuance of common stock, net of issuance costs $7.2 million (in shares)   13,529,750      
Comprehensive loss:          
Unrealized loss on investments, net (43)     (43)  
Net loss (97,415)       (97,415)
Comprehensive loss (97,458)        
Ending balance at Mar. 31, 2021 133,649 $ 86 943,381 (43) (809,775)
Ending balance (in shares) at Mar. 31, 2021   86,208,279      
Beginning balance at Dec. 31, 2020 73,376 $ 63 785,673 0 (712,360)
Comprehensive loss:          
Unrealized loss on investments, net 0        
Net loss (133,738)        
Comprehensive loss (133,738)        
Ending balance at Sep. 30, 2021 104,586 $ 87 950,597 0 (846,098)
Ending balance (in shares) at Sep. 30, 2021   86,848,426      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   86,208,279      
Beginning balance at Mar. 31, 2021 133,649 $ 86 943,381 (43) (809,775)
Increase (Decrease) in Stockholders' Equity          
Share-based compensation 3,112   3,112    
Exercise of stock options 119   119    
Exercise of stock options (in shares)   41,465      
Comprehensive loss:          
Unrealized loss on investments, net 32     32  
Net loss (17,763)       (17,763)
Comprehensive loss (17,731)        
Ending balance at Jun. 30, 2021 119,149 $ 86 946,612 (11) (827,538)
Ending balance (in shares) at Jun. 30, 2021   86,249,744      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   86,249,744      
Share-based compensation 3,431   3,431    
Exercise of stock options 130   130    
Exercise of stock options (in shares)   74,588      
Employee stock purchase plan purchases 425 $ 1 424    
Employee stock purchase plan purchases (in shares)   283,094      
RSU stock issuance (in shares)   241,000      
Comprehensive loss:          
Unrealized loss on investments, net 11     11  
Net loss (18,560)       (18,560)
Comprehensive loss (18,549)        
Ending balance at Sep. 30, 2021 $ 104,586 $ 87 $ 950,597 $ 0 $ (846,098)
Ending balance (in shares) at Sep. 30, 2021   86,848,426      
Increase (Decrease) in Stockholders' Equity          
Beginning balance (in shares)   86,848,426      
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)
$ in Millions
 3 Months Ended
Mar. 31, 2021
USD ($)
Statement of Stockholders' Equity [Abstract]  
Issuance costs $ 7.2
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (133,738) $ (31,847)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 143 309
Amortization of discount/premium on investments 648 (268)
Share-based compensation 9,127 4,000
Fair value of common stock issued related to asset acquisition 43,445 0
Note payable related to asset acquisition 14,000
Gain on sale of investments (2) (1)
Gain on sale of equipment 0 (10)
Lease-related amortization 314 (47)
Changes in operating assets and liabilities:    
Accounts receivable 288 855
Inventories (1,595) 0
Prepaid expenses and other assets (2,005) 1,284
Accounts payable and accrued liabilities 3,468 (1,268)
Net cash used in operating activities (65,907) (26,993)
Cash flows from investing activities:    
Purchases of property and equipment (193) (60)
Proceeds from sale of property and equipment 0 10
Purchases of short-term investments (105,355) (58,895)
Purchases of long-term investments (9,594) 0
Proceeds from sales of short-term investments 2,007 1,498
Proceeds from maturities of short-term investments 45,850 104,602
Net cash (used in) provided by investing activities (67,285) 47,155
Cash flows from financing activities:    
Proceeds from exercise of stock options 3,780 641
Proceeds from employee stock purchase plan 754 426
Proceeds from issuance of common stock, net of commissions 107,843 0
Net cash provided by financing activities 112,377 1,067
Net (decrease) increase in cash and cash equivalents (20,815) 21,229
Cash and cash equivalents:    
Beginning of period 46,989 16,901
End of period $ 26,174 $ 38,130
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
The Business and Summary of Significant Accounting Policies The Business and Summary of Significant Accounting Policies
 
Description of Business

Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Our two most advanced clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in Phase 3 development as a potential first-line therapy in acute myeloid leukemia (AML).

Basis of Presentation

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of the Company’s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year. 

Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.
 
For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.
 
The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:
 
•Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
•Level 2 — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.
•Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

At September 30, 2021 and December 31, 2020, the Company had cash equivalents including money market funds, whose value is based on quoted market prices. At September 30, 2021 and December 31, 2020, the Company had short-term investments, including U.S. Treasury securities, whose value is based on quoted market prices. At September 30, 2021, the Company had long-term investments including U.S. Treasury securities, whose value is based on quoted market prices. Accordingly, these securities are classified as Level 1.
 
At September 30, 2021, the Company had short-term investments, including commercial paper, and corporate bonds, and on December 31, 2020, the Company had short-term investments including corporate bonds. As quoted prices are not available for these securities, they are valued using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security’s credit rating, prepayment assumptions and other factors such as credit loss assumptions. Accordingly, these securities are classified as Level 2.
 
There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company's investments, please refer to Note 2, "Investments."
 
Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):
 
Fair Value Measurements
September 30, 2021
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$20,165 $20,165 $— $— 
          Total cash equivalents20,165 20,165 — — 
Short-term investments
     U.S. treasury securities7,534 7,534 — — 
     Commercial paper51,277 — 51,277 — 
     Corporate bonds37,573 — 37,573 — 
          Total short-term investments96,384 7,534 88,850 — 
Long-term investments
     U.S. treasury securities2,035 2,035 — — 
          Total long-term investments2,035 2,035 — — 
               Total assets$118,584 $29,734 $88,850 $— 
Fair Value Measurements
December 31, 2020
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$1,503 $1,503 $— $— 
          Total cash equivalents1,503 1,503 — — 
Short-term investments
     U.S. treasury securities28,715 28,715 — — 
     Corporate bonds3,258 — 3,258 — 
          Total short-term investments31,973 28,715 3,258 — 
               Total assets$33,476 $30,218 $3,258 $— 
  
Inventories

The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories.
At September 30, 2021, the Company’s inventory is related to TEMBEXA, which is being manufactured for the treatment of smallpox and potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.

The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The Company's inventories at September 30, 2021 consisted of $1.6 million of work-in-process and no finished goods.

The Company’s assessment of market value requires the use of estimates regarding the net realizable value of its inventory balances, including an assessment of excess or obsolete inventory. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. The Company determines excess or obsolete inventory based on multiple factors, including an estimate of the future demand for its products, product expiration dates and current sales levels. The Company’s assumptions of future demand for its products are inherently uncertain and if the Company were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that the Company reports in a particular period. In addition, the Company's inventory may experience expiration of its shelf-life stability. During the nine months ended September 30, 2021, the Company did not record a reserve for inventory as the Company assumes TEMBEXA will be sold to the US government under a procurement contract with Biomedical Advanced Research and Development Authority (BARDA) or could be sold to other governmental agencies. Should no procurement contract be secured in the future, the Company may reserve part or all of our inventory balance, which would be included in cost of sales.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):
September 30, 2021December 31, 2020
Accrued research and development expenses$3,276 $1,375 
Accrued compensation4,502 4,473 
Accrued legal expenses213 651 
Other accrued liabilities2,507 751 
Total accrued liabilities$10,498 $7,250 

Revenue Recognition

Policy

The Company’s revenues generally consist of (i) contract and grant revenue - revenue generated under federal and private foundation grants and contracts, and (ii) collaboration and licensing revenue - revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.

Biomedical Advanced Research and Development Authority (BARDA)

In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees over the performance of one base segment and four option segments. Exercise of each option segment was solely at the discretion of BARDA. The Company assessed the services in accordance with the authoritative guidance and concluded that there was a potential of five separate contracts (one base segment and four option segments) within this agreement, each of which had a single performance obligation. All option segments (one through four) were exercised, as well as the base segment. The transaction price for each segment, based on the transaction price as defined in
each segment contract, was allocated to the single performance obligation for each contract. The transaction price was recognized over time by measuring the progress toward complete satisfaction of the performance obligation. For reimbursable expenses, this occurred as qualifying research activities were conducted based on invoices from company vendors. For the fixed fee, the progress toward complete satisfaction was estimated based on the costs incurred to date relative to the total estimated costs per the terms of each contract. The Company typically invoiced BARDA monthly as costs were incurred. Any amounts received in advance of performance were recorded as deferred revenue until earned. The base segment and first option segment were completed prior to adoption of ASC 606. The second and third option segments were completed on August 20, 2020. The fourth option segment was completed on September 1, 2021 and the contract has expired in accordance with its terms.

Grant Revenue

Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. As a result of its acquisition of Oncoceutics, Inc. (Oncoceutics), the Company became the beneficiary of two federal grant programs and two grant programs with private foundations, of which the federal grant programs ended in the third quarter of 2021. At September 30, 2021, the Company has a deferred revenue balance of $0.2 million related to these grants. Additionally, for the three and nine months ended September 30, 2021, the Company recognized $18,000 and $0.4 million of grant revenue related to these grants, respectively.

SymBio Pharmaceuticals

On September 30, 2019, the Company entered into a license agreement with SymBio Pharmaceuticals Limited (SymBio) under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. The Company assessed the agreement in accordance with the authoritative guidance and concluded that the SymBio contract includes multiple performance obligations. The SymBio contract has one fixed transaction amount of a $5.0 million upfront payment received in October 2019 and several variable transaction amounts, up to $180 million, due to the Company at certain regulatory and commercial milestones, along with low double-digit percent royalties based on net sales of TEMBEXA. All variable transaction amounts are fully constrained, therefore the allocated transaction price is $5.0 million. The majority of the transaction price of the contract has been allocated to the combined performance obligation of the granting of the license to TEMBEXA and associated technology transfer which was recognized when the technology transfer was completed in the fourth quarter of 2019. The revenue from regulatory and commercial milestones and royalties from net sales will be recognized upon the occurrence of the triggering events or when those transaction amounts are no longer fully constrained.
 
Research and Development Prepaids and Accruals

As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.

The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
 
Basic and Diluted Net Loss Per Share of Common Stock 

Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net loss per share of common stock is computed by dividing net loss by
the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three and nine months ended September 30, 2021 and 2020.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Segments

The Company operates in only one segment, pharmaceuticals.

Impact of Recently Issued Accounting Standards
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Investments
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
 
The following tables summarize the Company's debt investments (in thousands):
 September 30, 2021
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$37,579 $1 $(7)$37,573 
U.S. treasury securities9,568 2 (1)9,569 
Commercial paper51,272 7 (2)51,277 
Total investments$98,419 $10 $(10)$98,419 
 December 31, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$3,256 $2 $— $3,258 
U.S. treasury securities28,717 1 (3)28,715 
Total investments$31,973 $3 $(3)$31,973 
 
The following tables summarize the Company's debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):

September 30, 2021
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
Corporate bonds$27,554 $(7)$— $— $27,554 $(7)
Commercial paper10,491 (2)— — 10,491 (2)
U.S. treasury securities7,034 (1)— — 7,034 (1)
Total$45,079 $(10)$— $— $45,079 $(10)
Number of securities with unrealized losses16 — 16 
December 31, 2020
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
U.S. treasury securities$16,598 $(3)$— $— $16,598 $(3)
Total$16,598 $(3)$— $— $16,598 $(3)
Number of securities with unrealized losses6 — 6 

The Company periodically reviews available-for-sale debt investments for other-than-temporary declines in fair value below the cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company’s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. At September 30, 2021, the Company did not intend to sell, and was not more likely than not to be required to sell, the available-for-sale debt investments in an unrealized loss position before recovery of the cost basis of the securities, which may be at maturity. There were no such declines in value for the three and nine months ended September 30, 2021 and 2020. Unrealized gains and losses on debt investments are recorded to unrealized (loss) gain on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.

The following table summarizes the scheduled maturity for the Company's debt investments at September 30, 2021 (in thousands):
Maturing in one year or less$96,384 
Maturing after one year through two years2,035 
     Total debt investments$98,419 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
 
Leases

The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company's sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company's discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company's operating leases as of September 30, 2021 was 4.84 years.
Expense related to leases is recorded on a straight-line basis over the lease term. Lease expense under operating leases, including common area maintenance fees, totaled approximately $0.2 million and $0.2 million, respectively, for the three months ended September 30, 2021 and 2020 and approximately $0.5 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.

The discount rate implicit within the Company's leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of September 30, 2021, the operating lease liabilities reflect a weighted-average discount rate of 7.89%.

The following table sets forth the operating lease right-of-use assets and liabilities as of September 30, 2021 (in thousands):
Assets
Operating lease right-of-use assets $2,509 
Liabilities
Operating lease short-term liabilities (recorded within Accrued liabilities)$416 
Operating lease long-term liabilities (recorded within Lease-related obligations)2,525 
     Total operating lease liabilities$2,941 

Operating lease payments over the remainder of the lease terms are as follows (in thousands):
Years Ending December 31,As of September 30, 2021
2021 (1)$97 
2022715 
2023736 
2024759 
2025781 
All remaining years467 
Total future minimum rental payments$3,555 
     Less amount of lease payments representing interest614 
Total present value of lease payments$2,941 

(1)The Company entered into the Ninth Amendment of its lease for the Company's headquarters in Durham, North Carolina, which extended the term of the lease by 65 months to July 31, 2026. As part of the amendment, the Company is entitled to receive a rent abatement of the first five months of the new lease term which began on March 1, 2021. Additionally, the Ninth Amendment grants the Company a refurbishment allowance, which the Company expects to receive in 2021 after the refurbishment has been completed.

As of December 31, 2020, operating lease payments over the remainder of the lease terms were as follows (in thousands):
Years Ending December 31,As of December 31, 2020
2021$260 
2022715 
2023736 
2024759 
2025781 
Thereafter467 
Total future minimum rental payments$3,718 
     Less amount of lease payments representing interest792 
Total present value of lease payments$2,926 

For the three months ended September 30, 2021 and 2020, the Company made lease payments of approximately $122,000 and $181,000, respectively, and for the nine months ended September 30, 2021 and 2020, the Company made lease payments of approximately $292,000 and $538,000, respectively.
Sublease

The Company subleased 3,537 square feet of its office space under a non-cancelable operating lease that expired in February 2021. For the three and nine months ended September 30, 2021, the Company recognized $0 and approximately $12,000 of income, respectively, and for the three and nine months ended September 30, 2020, the Company recognized approximately $18,000 and $53,000 of income, respectively, in Interest income and other, net on the Consolidated Statement of Operations and Comprehensive Loss. As this lease has terminated, there are no future minimum rentals payments to be received.

Significance of Revenue Source

The Company is the recipient of federal research contract funds from BARDA, the primary source of the Company's contract and grant revenue. Periodic audits are required under the Company’s BARDA agreement and certain costs may be questioned as appropriate under the BARDA agreement. At September 30, 2021 and December 31, 2020, the Company had recorded a provision for potential refundable amounts of $52,000 and $38,000, respectively.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions and Share-based Compensation
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Equity Transactions and Share-based Compensation Equity Transactions and Share-based Compensation
Common Stock

On January 20, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 11,765,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share (the Common Stock). The price to the public in this offering was $8.50 per share, and the Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $7.99 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,764,750 additional shares of Common Stock at the public offering price. The net proceeds to the Company from this offering were approximately $107.8 million, as the Underwriters’ option to purchase additional shares was exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on January 25, 2021.

Stock Options

The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increases on January 1 of each calendar year by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. On January 1, 2021, the common stock reserved for issuance under the 2013 Plan was automatically increased by 2.5 million shares. As of September 30, 2021, there was a total of 2.2 million shares reserved for future issuance under the 2013 Plan. The Company issued approximately 75,000 and 826,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2021, respectively. The Company issued 21,000 and 263,000 shares of common stock pursuant to the exercise of stock options during the three and nine months ended September 30, 2020, respectively.

Employee Stock Purchase Plan

The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of its designated affiliates. The Company has reserved a total of 3.9 million shares of common stock to be purchased under the ESPP, of which 2.3 million shares remained available for purchase as of September 30, 2021. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, by the lesser of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 422,535 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b). On January 1, 2021, the common stock reserved for issuance under the ESPP was automatically increased by an additional 422,535 shares.

The ESPP provides for an automatic reset feature to start participants on a new twenty-four month participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the twenty-four month offering period. Eligible employees may authorize an amount up to 15% of their salary to purchase common stock at the lower of a 15% discount to the beginning price of their offering period or a 15% discount to the ending price of
each six-month purchase interval. The Company issued approximately 283,000 and 160,000 shares of common stock pursuant to the ESPP during the three months ended September 30, 2021 and 2020, respectively. The Company issued approximately 543,000 and 337,000 shares of common stock pursuant to the ESPP during the nine months ended September 30, 2021 and 2020, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the “look-back” option and were determined using a Black-Scholes option pricing model.

Restricted Stock Units

The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company's common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company's common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued 241,000 shares and approximately 410,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2021, respectively. The Company issued 277,000 shares and approximately 440,000 shares of common stock pursuant to the vesting of RSUs during the three and nine months ended September 30, 2020, respectively.

Stock-based Compensation

For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Research and development expense$1,853 $625 $4,995 $2,090 
General and administrative expense1,578 657 4,132 1,910 
          Total share-based compensation expense$3,431 $1,282 $9,127 $4,000 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
 
The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the nine month period ended September 30, 2021, and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740.

Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable.
 
At September 30, 2021, the Company had no unrecognized tax benefits that would reduce the Company’s effective tax rate if recognized.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Agreements
 9 Months Ended
Sep. 30, 2021
Revenue Recognition [Abstract]  
Significant Agreements Significant Agreements
     
Biomedical Advanced Research and Development Authority (BARDA)

In February 2011, the Company entered into a contract with BARDA for the advanced development of TEMBEXA as a medical countermeasure in the event of a smallpox release. Under the contract, BARDA agreed to reimburse the Company, plus pay a fixed fee, for the research and development of TEMBEXA as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections. The contract consists of an initial performance period, referred to as the base performance segment, plus up to four extension periods, referred to as option segments, of which all have been exercised. Under the contract, the Company received $72.5 million in expense reimbursement and $4.6 million in fees.

The fourth option segment ended on September 1, 2021 and the contract has expired in accordance with its terms. For the three months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $0.1 million and $1.6
million, respectively, and for the nine months ended September 30, 2021 and 2020, the Company recognized revenue under this contract of $1.6 million and $4.2 million, respectively.

Cantex Pharmaceuticals, Inc.

In July 2019, the Company entered into a License and Development Agreement with Cantex Pharmaceuticals, Inc. (Cantex) pursuant to which the Company acquired exclusive worldwide rights to develop and commercialize, for any and all uses, a glycosaminoglycan compound known as DSTAT, which is currently being studied for the treatment of acute myeloid leukemia. Under the terms of the license agreement, the Company is responsible for, and bears the future costs of, worldwide development and commercialization of DSTAT. In connection with the transaction, Cantex assigned to the Company all of its rights under its DSTAT supply agreements, including its bulk API agreement with Scientific Protein Laboratories LLC (SPL), including subsequent amendments, pursuant to which SPL will exclusively produce DSTAT for the Company through December 2040.

The license agreement obligates the Company to pay Cantex regulatory milestone payments of up to $202.5 million upon receipt of product approvals in the United States, the European Union and Japan, and sales milestone payments of up to $385.0 million upon achievement of specified net sales levels. The Company also agreed to pay Cantex tiered royalties based on percentages of net sales beginning at 10% and not to exceed the high-teens.

SymBio Pharmaceuticals

On September 30, 2019, the Company entered into a license agreement with SymBio under which the Company granted SymBio exclusive worldwide rights to develop, manufacture and commercialize TEMBEXA for all human indications, excluding the prevention and treatment of orthopoxviruses, including smallpox. Under the terms of the license agreement, SymBio will be responsible for, and bear the future costs of, worldwide development and commercialization of TEMBEXA in the licensed indications. Either party may terminate the license agreement upon the occurrence of a material breach by the other party (subject to standard cure periods). SymBio may also terminate the license agreement without cause on a country-by-country basis upon ninety days' prior notice.

In exchange for the license to SymBio under the Company's TEMBEXA rights, the Company received an upfront payment of $5.0 million in October 2019. In addition, the Company is eligible to receive up to $180.0 million in clinical, regulatory and commercial milestones worldwide, as well as low double-digit percent royalties based on net sales of TEMBEXA. Since entering into the license agreement in September 2019, the Company has recognized all of the $5.0 million upfront payment.

Ohara Agreement

In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan.

CR Sanjiu Agreement
In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0 million in nonrefundable regulatory milestone payments. The Company is entitled to tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in China.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Oncoceutics Acquisition
 9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Oncoceutics Acquisition Oncoceutics AcquisitionOn January 7, 2021, the Company, Ocean Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (Merger Sub), Oncoceutics and Fortis Advisors, LLC solely in its capacity as representative of the securityholders of Oncoceutics (the Securityholders’ Representative), entered into an Agreement and Plan of Merger (the Merger Agreement). Concurrently with the execution of the Merger Agreement, Merger Sub merged with and into Oncoceutics (the Merger) whereupon the separate corporate existence of Merger Sub ceased, with Oncoceutics continuing as the surviving corporation of the Merger as a wholly-owned subsidiary of the Company.
As consideration for the Merger, the Company (a) paid an upfront cash payment of approximately $25.0 million, subject to certain customary adjustments, (b) issued an aggregate of 8,723,769 shares of the Company's common stock, (c) issued a promissory note to the Securityholders' Representative in the principal amount of $14.0 million (the Seller Note), to be paid in cash, subject to the terms and conditions of the Merger Agreement and the Seller Note, upon the one year anniversary of the closing of the Merger, and (d) agreed to make contingent payments up to an aggregate of $360.0 million based on the achievement of certain development, regulatory and commercialization events as set forth in the Merger Agreement, as well as additional tiered royalty payments based upon future net sales of ONC 201 and ONC 206 products, subject to certain reductions as set forth in the Merger Agreement, and a contingent payment in the event the Company receives any proceeds from the sale of a rare pediatric disease priority review voucher based on Oncoceutics' products. The closing payment may be adjusted after the closing, pursuant to procedures set forth in the Merger Agreement, in connection with the finalization of the cash, transaction expenses, debt and working capital amounts at closing. As of September 30, 2021, the Company has recorded an estimated liability of $0.2 million related to closing payment adjustments. Additionally, as of September 30, 2021, the Company has recorded an estimated receivable of $0.6 million related to the repayment of certain severance amounts due from the Oncoceutics' shareholders.

The Company accounted for the Oncoceutics acquisition as an asset acquisition as the majority of the value of the assets acquired related to the ONC201 acquired in-process research and development (IPR&D) asset. In accordance with Accounting Standards Codification (ASC) Subtopic 730-10-25, Accounting for Research and Development Costs, the up-front payments to acquire a new drug compound, as well as future milestone payments when paid or payable, are immediately expensed as acquired IPR&D in transactions other than a business combination provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Therefore, the portion of the purchase price that was allocated to the IPR&D assets acquired was immediately expensed. Other assets acquired and liabilities assumed, were recorded at fair value.

The following represents the consideration paid and purchase price allocation for the acquisition of Oncoceutics (in thousands, except for per share data):

Cash$23,836 
One-year closing anniversary payment14,000 
Shares common stock issued as consideration8,723,769 
Stock price per share on effective date4.98 
Value of estimated common stock consideration43,445 
Total consideration$81,281 
Net assets acquired$(1,310)
IPR&D assets expensed82,591 
Total purchase price allocated$81,281 
Transaction costs expensed to IPR&D(1)
$299 
Total IPR&D expensed$82,890 
(1) As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired. The primary asset acquired, the IPR&D asset, was expensed and the transaction related costs were included with and expensed with this asset. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses. Additionally, there were $0.6 million of expenses related to this acquisition recorded in the fourth quarter of 2020 to general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsThe Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of September 30, 2021, and events which occurred subsequently but were not recognized in the financial statements.In accordance with the terms of the merger agreement between Chimerix and Oncoceutics, Inc., the achievement of the 20% overall response rate (ORR) via Blinded Independent Central Review (BICR) will result in a success milestone payment of $20 million to the former Oncoceutics, Inc. shareholders to be paid prior to year-end.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of the Company’s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.
Fair Value of Financial Instruments
Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.
 
For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.
 
The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:
 
•Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
•Level 2 — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.
•Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

At September 30, 2021 and December 31, 2020, the Company had cash equivalents including money market funds, whose value is based on quoted market prices. At September 30, 2021 and December 31, 2020, the Company had short-term investments, including U.S. Treasury securities, whose value is based on quoted market prices. At September 30, 2021, the Company had long-term investments including U.S. Treasury securities, whose value is based on quoted market prices. Accordingly, these securities are classified as Level 1.
 
At September 30, 2021, the Company had short-term investments, including commercial paper, and corporate bonds, and on December 31, 2020, the Company had short-term investments including corporate bonds. As quoted prices are not available for these securities, they are valued using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security’s credit rating, prepayment assumptions and other factors such as credit loss assumptions. Accordingly, these securities are classified as Level 2.
 
There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company's investments, please refer to Note 2, "Investments."
Inventories
Inventories

The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories.
At September 30, 2021, the Company’s inventory is related to TEMBEXA, which is being manufactured for the treatment of smallpox and potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.

The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The Company's inventories at September 30, 2021 consisted of $1.6 million of work-in-process and no finished goods.
The Company’s assessment of market value requires the use of estimates regarding the net realizable value of its inventory balances, including an assessment of excess or obsolete inventory. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. The Company determines excess or obsolete inventory based on multiple factors, including an estimate of the future demand for its products, product expiration dates and current sales levels. The Company’s assumptions of future demand for its products are inherently uncertain and if the Company were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that the Company reports in a particular period. In addition, the Company's inventory may experience expiration of its shelf-life stability. During the nine months ended September 30, 2021, the Company did not record a reserve for inventory as the Company assumes TEMBEXA will be sold to the US government under a procurement contract with Biomedical Advanced Research and Development Authority (BARDA) or could be sold to other governmental agencies. Should no procurement contract be secured in the future, the Company may reserve part or all of our inventory balance, which would be included in cost of sales.
Revenue Recognition
Revenue Recognition

Policy
The Company’s revenues generally consist of (i) contract and grant revenue - revenue generated under federal and private foundation grants and contracts, and (ii) collaboration and licensing revenue - revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.
Research and Development Prepaids and Accruals
Research and Development Prepaids and Accruals

As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.

The Company’s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2021, there had been no material adjustments to the Company’s prior period estimates of prepaid and accruals for research and development expenses. The Company’s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
Basic and Diluted Net Loss Per Share of Common Stock
Basic and Diluted Net Loss Per Share of Common Stock 

Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net loss per share of common stock is computed by dividing net loss by
the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three and nine months ended September 30, 2021 and 2020.
Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Segments SegmentsThe Company operates in only one segment, pharmaceuticals.
Impact of Recently Issued Accounting Standards Impact of Recently Issued Accounting StandardsIn June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of certain assets measured at fair value on a recurring basis
Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):
 
Fair Value Measurements
September 30, 2021
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$20,165 $20,165 $— $— 
          Total cash equivalents20,165 20,165 — — 
Short-term investments
     U.S. treasury securities7,534 7,534 — — 
     Commercial paper51,277 — 51,277 — 
     Corporate bonds37,573 — 37,573 — 
          Total short-term investments96,384 7,534 88,850 — 
Long-term investments
     U.S. treasury securities2,035 2,035 — — 
          Total long-term investments2,035 2,035 — — 
               Total assets$118,584 $29,734 $88,850 $— 
Fair Value Measurements
December 31, 2020
 TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
Cash equivalents
     Money market funds$1,503 $1,503 $— $— 
          Total cash equivalents1,503 1,503 — — 
Short-term investments
     U.S. treasury securities28,715 28,715 — — 
     Corporate bonds3,258 — 3,258 — 
          Total short-term investments31,973 28,715 3,258 — 
               Total assets$33,476 $30,218 $3,258 $— 
Schedule of accrued liabilities
Accrued liabilities consisted of the following (in thousands):
September 30, 2021December 31, 2020
Accrued research and development expenses$3,276 $1,375 
Accrued compensation4,502 4,473 
Accrued legal expenses213 651 
Other accrued liabilities2,507 751 
Total accrued liabilities$10,498 $7,250 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Summary of short-term and long-term investments
The following tables summarize the Company's debt investments (in thousands):
 September 30, 2021
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$37,579 $1 $(7)$37,573 
U.S. treasury securities9,568 2 (1)9,569 
Commercial paper51,272 7 (2)51,277 
Total investments$98,419 $10 $(10)$98,419 
 December 31, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate bonds$3,256 $2 $— $3,258 
U.S. treasury securities28,717 1 (3)28,715 
Total investments$31,973 $3 $(3)$31,973 
Summary of investments with unrealized losses, aggregated by investment type and the length of time
The following tables summarize the Company's debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):

September 30, 2021
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
Corporate bonds$27,554 $(7)$— $— $27,554 $(7)
Commercial paper10,491 (2)— — 10,491 (2)
U.S. treasury securities7,034 (1)— — 7,034 (1)
Total$45,079 $(10)$— $— $45,079 $(10)
Number of securities with unrealized losses16 — 16 
December 31, 2020
Less than 12 MonthsGreater than 12 MonthsTotal
Fair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized Loss
U.S. treasury securities$16,598 $(3)$— $— $16,598 $(3)
Total$16,598 $(3)$— $— $16,598 $(3)
Number of securities with unrealized losses6 — 6 
Summary of the scheduled maturity of company investments
The following table summarizes the scheduled maturity for the Company's debt investments at September 30, 2021 (in thousands):
Maturing in one year or less$96,384 
Maturing after one year through two years2,035 
     Total debt investments$98,419 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Operating lease right-of-use assets and liabilities
The following table sets forth the operating lease right-of-use assets and liabilities as of September 30, 2021 (in thousands):
Assets
Operating lease right-of-use assets $2,509 
Liabilities
Operating lease short-term liabilities (recorded within Accrued liabilities)$416 
Operating lease long-term liabilities (recorded within Lease-related obligations)2,525 
     Total operating lease liabilities$2,941 
Operating lease maturity
Operating lease payments over the remainder of the lease terms are as follows (in thousands):
Years Ending December 31,As of September 30, 2021
2021 (1)$97 
2022715 
2023736 
2024759 
2025781 
All remaining years467 
Total future minimum rental payments$3,555 
     Less amount of lease payments representing interest614 
Total present value of lease payments$2,941 

(1)The Company entered into the Ninth Amendment of its lease for the Company's headquarters in Durham, North Carolina, which extended the term of the lease by 65 months to July 31, 2026. As part of the amendment, the Company is entitled to receive a rent abatement of the first five months of the new lease term which began on March 1, 2021. Additionally, the Ninth Amendment grants the Company a refurbishment allowance, which the Company expects to receive in 2021 after the refurbishment has been completed.

As of December 31, 2020, operating lease payments over the remainder of the lease terms were as follows (in thousands):
Years Ending December 31,As of December 31, 2020
2021$260 
2022715 
2023736 
2024759 
2025781 
Thereafter467 
Total future minimum rental payments$3,718 
     Less amount of lease payments representing interest792 
Total present value of lease payments$2,926 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions and Share-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of employee and non-employee share-based compensation expense recognized related to stock options, the ESPP and RSUs Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Research and development expense$1,853 $625 $4,995 $2,090 
General and administrative expense1,578 657 4,132 1,910 
          Total share-based compensation expense$3,431 $1,282 $9,127 $4,000 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Oncoceutics Acquisition (Tables)
 9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Asset acquisition
The following represents the consideration paid and purchase price allocation for the acquisition of Oncoceutics (in thousands, except for per share data):

Cash$23,836 
One-year closing anniversary payment14,000 
Shares common stock issued as consideration8,723,769 
Stock price per share on effective date4.98 
Value of estimated common stock consideration43,445 
Total consideration$81,281 
Net assets acquired$(1,310)
IPR&D assets expensed82,591 
Total purchase price allocated$81,281 
Transaction costs expensed to IPR&D(1)
$299 
Total IPR&D expensed$82,890 
(1) As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired. The primary asset acquired, the IPR&D asset, was expensed and the transaction related costs were included with and expensed with this asset. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses. Additionally, there were $0.6 million of expenses related to this acquisition recorded in the fourth quarter of 2020 to general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies - Narrative (Details)
 9 Months Ended
Sep. 30, 2021
USD ($)
segment
product
Accounting Policies [Abstract]  
Number of product candidates | product 2
Number of segments | segment 1
Inventory, work in process $ 1,600,000
Inventory, finished goods $ 0
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale $ 96,384 $ 31,973
Long-term investments 2,035 0
Fair value, measurements, recurring    
Fair Value, Separate Account Investment    
Cash equivalents 20,165 1,503
Short-term investments, available-for-sale 96,384 31,973
Long-term investments 2,035  
Total assets 118,584 33,476
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Separate Account Investment    
Cash equivalents 20,165 1,503
Short-term investments, available-for-sale 7,534 28,715
Long-term investments 2,035  
Total assets 29,734 30,218
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Separate Account Investment    
Cash equivalents 0 0
Short-term investments, available-for-sale 88,850 3,258
Long-term investments 0  
Total assets 88,850 3,258
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Separate Account Investment    
Cash equivalents 0 0
Short-term investments, available-for-sale 0 0
Long-term investments 0  
Total assets 0 0
U.S. treasury securities | Fair value, measurements, recurring    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 7,534 28,715
Long-term investments 2,035  
U.S. treasury securities | Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 7,534 28,715
Long-term investments 2,035  
U.S. treasury securities | Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0 0
Long-term investments 0  
U.S. treasury securities | Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0 0
Long-term investments 0  
Commercial paper | Fair value, measurements, recurring    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 51,277  
Commercial paper | Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0  
Commercial paper | Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 51,277  
Commercial paper | Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0  
Corporate bonds | Fair value, measurements, recurring    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 37,573 3,258
Corporate bonds | Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0 0
Corporate bonds | Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 37,573 3,258
Corporate bonds | Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Separate Account Investment    
Short-term investments, available-for-sale 0 0
Money market funds | Fair value, measurements, recurring    
Fair Value, Separate Account Investment    
Cash equivalents 20,165 1,503
Money market funds | Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Separate Account Investment    
Cash equivalents 20,165 1,503
Money market funds | Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Separate Account Investment    
Cash equivalents 0 0
Money market funds | Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Separate Account Investment    
Cash equivalents $ 0 $ 0
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Accrued research and development expenses $ 3,276 $ 1,375
Accrued compensation 4,502 4,473
Accrued legal expenses 213 651
Other accrued liabilities 2,507 751
Total accrued liabilities $ 10,498 $ 7,250
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.2
The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 127 Months Ended
Oct. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2021
USD ($)
grant
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
grant
Sep. 30, 2020
USD ($)
Sep. 01, 2021
USD ($)
contract
segment
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues     $ 107,000 $ 1,609,000 $ 1,933,000 $ 4,252,000  
SymBio Pharmaceuticals              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues $ 5,000,000            
Grant | Oncoceutics, Inc.              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues     18,000   400,000    
Deferred revenue     200,000   200,000    
BARDA              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues     $ 100,000 $ 1,600,000 $ 1,600,000 $ 4,200,000  
Total number of base segments | segment             1
Total number of option segments | segment             4
Total number of separate contracts | contract             5
BARDA | Expense reimbursement              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues             $ 72,500,000
BARDA | Fees              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues             $ 4,600,000
Federal Goverment | Oncoceutics, Inc.              
Collaborative Arrangement and Arrangement Other than Collaborative              
Number of grants | grant     2   2    
Private Foundations | Oncoceutics, Inc.              
Collaborative Arrangement and Arrangement Other than Collaborative              
Number of grants | grant     2   2    
SymBio Pharmaceuticals              
Collaborative Arrangement and Arrangement Other than Collaborative              
Total revenues   $ 5,000,000          
Payment to be received upon achievement of milestones   $ 180,000,000          
License agreement cost $ 5,000,000            
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Summary of Available-for-Sale securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Schedule of Investments    
Amortized Cost $ 98,419 $ 31,973
Gross Unrealized Gains 10 3
Gross Unrealized Losses (10) (3)
Estimated Fair Value 98,419 31,973
Corporate bonds    
Schedule of Investments    
Amortized Cost 37,579 3,256
Gross Unrealized Gains 1 2
Gross Unrealized Losses (7) 0
Estimated Fair Value 37,573 3,258
U.S. treasury securities    
Schedule of Investments    
Amortized Cost 9,568 28,717
Gross Unrealized Gains 2 1
Gross Unrealized Losses (1) (3)
Estimated Fair Value 9,569 $ 28,715
Commercial paper    
Schedule of Investments    
Amortized Cost 51,272  
Gross Unrealized Gains 7  
Gross Unrealized Losses (2)  
Estimated Fair Value $ 51,277  
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
security
Dec. 31, 2020
USD ($)
security
Debt Securities, Available-for-sale    
Fair value, less than 12 months $ 45,079 $ 16,598
Unrealized loss, less than 12 months (10) (3)
Fair value, greater than 12 months 0 0
Unrealized loss, greater than 12 months 0 0
Fair value, total 45,079 16,598
Unrealized loss, total $ (10) $ (3)
Number of securities with unrealized losses, less than 12 months | security 16 6
Number of securities with unrealized losses, greater than 12 months | security 0 0
Number of securities with unrealized losses, total | security 16 6
Corporate bonds    
Debt Securities, Available-for-sale    
Fair value, less than 12 months $ 27,554  
Unrealized loss, less than 12 months (7)  
Fair value, greater than 12 months 0  
Unrealized loss, greater than 12 months 0  
Fair value, total 27,554  
Unrealized loss, total (7)  
Commercial paper    
Debt Securities, Available-for-sale    
Fair value, less than 12 months 10,491  
Unrealized loss, less than 12 months (2)  
Fair value, greater than 12 months 0  
Unrealized loss, greater than 12 months 0  
Fair value, total 10,491  
Unrealized loss, total (2)  
U.S. treasury securities    
Debt Securities, Available-for-sale    
Fair value, less than 12 months 7,034 $ 16,598
Unrealized loss, less than 12 months (1) (3)
Fair value, greater than 12 months 0 0
Unrealized loss, greater than 12 months 0 0
Fair value, total 7,034 16,598
Unrealized loss, total $ (1) $ (3)
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Schedule of Investment Maturity (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value    
Maturing in one year or less $ 96,384  
Maturing after one year through two years 2,035  
Total debt investments $ 98,419 $ 31,973
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
ft²
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
ft²
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Commitments and Contingencies Disclosure [Abstract]          
Weighted average remaining lease term 4 years 10 months 2 days   4 years 10 months 2 days    
Rent expense under non-cancelable operating leases $ 200 $ 200 $ 500 $ 600  
Weighted average discount rate 7.89%   7.89%    
Lease payments $ 122 181 $ 292 538  
Area of sublease space (in sq ft) | ft² 3,537   3,537    
Sublease income $ 0 $ 18 $ 12 $ 53  
BARDA | Refundable Agreements          
Disaggregation of Revenue          
Provision for refundable amounts $ 52   $ 52   $ 38
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Assets    
Operating lease right-of-use assets $ 2,509 $ 2,825
Liabilities    
Operating lease short-term liabilities (recorded within Accrued liabilities) 416  
Operating lease long-term liabilities (recorded within Lease-related obligations) 2,525 2,814
Total present value of lease payments $ 2,941 $ 2,926
Operating lease, liability, current, statement of financial position [extensible list] Accrued Liabilities, Current Accrued Liabilities, Current
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due    
Remainder of fiscal year $ 97  
Year one 715 $ 260
Year two 736 715
Year three 759 736
Year four 781 759
Year five   781
Thereafter   467
All remaining years 467  
Total future minimum rental payments 3,555 3,718
Less amount of lease payments representing interest 614 792
Total present value of lease payments $ 2,941 $ 2,926
Lease extension term 65 months  
Rent abatement term 5 months  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions and Share-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Jan. 20, 2021
Jan. 01, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award              
Common stock, par value (in dollars per share) $ 0.001   $ 0.001   $ 0.001   $ 0.001
Shares issued for restricted stock units (in shares)     241,000 277,000 410,000 440,000  
Public Stock Offering              
Share-based Compensation Arrangement by Share-based Payment Award              
Number of shares sold (in shares) 11,765,000            
Price of shares sold (in dollars per share) $ 8.50            
Proceeds from shares sold $ 107.8            
Underwriter's Option              
Share-based Compensation Arrangement by Share-based Payment Award              
Number of shares sold (in shares) 1,764,750            
Price of shares sold (in dollars per share) $ 7.99            
Purchase option term 30 days            
The 2013 Plan              
Share-based Compensation Arrangement by Share-based Payment Award              
Evergreen option provision, equity increase         4.00%    
Additional shares authorized (in shares)   2,500,000          
Number of shares reserved for future issuance (in shares)     2,200,000   2,200,000    
Shares issued pursuant to the exercise of stock options (in shares)     75,000 21,000 826,000 263,000  
The 2013 Employee Stock Purchase Plan              
Share-based Compensation Arrangement by Share-based Payment Award              
Evergreen option provision, equity increase         1.00%    
Additional shares authorized (in shares)   422,535          
Number of shares reserved for future issuance (in shares)     2,300,000   2,300,000    
Number of shares authorized to be granted (in shares)     3,900,000   3,900,000    
Number of shares reserved for issuance, annual increase (in shares)         422,535    
Participation term         24 months    
Percentage of pay that employee can contribute, maximum     15.00%   15.00%    
Discounted purchase price from market price, offering date         15.00%    
Discounted purchase price from market price, purchase date         15.00%    
Purchase interval         6 months    
Shares issued pursuant to employee stock purchase plan (in shares)     283,000 160,000 543,000 337,000  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount        
Total share-based compensation expense $ 3,431 $ 1,282 $ 9,127 $ 4,000
Research and development expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount        
Total share-based compensation expense 1,853 625 4,995 2,090
General and administrative expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount        
Total share-based compensation expense $ 1,578 $ 657 $ 4,132 $ 1,910
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Income Tax Contingency    
Federal or state income taxes $ 0  
Unrecognized tax benefits $ 0  
Scenario, Forecast    
Income Tax Contingency    
Estimated annual effective tax rate   0.00%
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 127 Months Ended
Dec. 31, 2020
USD ($)
Oct. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Feb. 28, 2011
extension
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 01, 2021
USD ($)
Dec. 31, 2019
USD ($)
Jul. 26, 2019
USD ($)
Long-term Purchase Commitment                      
Total revenues         $ 107,000 $ 1,609,000 $ 1,933,000 $ 4,252,000      
SymBio Pharmaceuticals                      
Long-term Purchase Commitment                      
Total revenues   $ 5,000,000                  
BARDA                      
Long-term Purchase Commitment                      
Number of extension periods | extension       4              
Total revenues         $ 100,000 $ 1,600,000 $ 1,600,000 $ 4,200,000      
BARDA | Expense reimbursement                      
Long-term Purchase Commitment                      
Total revenues                 $ 72,500,000    
BARDA | Fees                      
Long-term Purchase Commitment                      
Total revenues                 $ 4,600,000    
Cantex Pharmaceuticals Inc.                      
Long-term Purchase Commitment                      
Payments to be made for regulatory milestones (up to)                     $ 202,500,000
Payments to be made upon achievement of specified net sales levels (up to)                     $ 385,000,000
Royalty percentage to be paid (at least)                     10.00%
SymBio Pharmaceuticals                      
Long-term Purchase Commitment                      
Total revenues     $ 5,000,000                
Termination notice period     90 days                
Payment to be received upon achievement of milestones     $ 180,000,000                
Ohara Pharmaceutical Co., Ltd.                      
Long-term Purchase Commitment                      
License agreement, nonrefundable regulatory milestone payment to be received                   $ 2,500,000  
CR Sanjui | Oncoceutics, Inc.                      
Long-term Purchase Commitment                      
Total revenues $ 5,000,000                    
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Oncoceutics Acquisition - Narrative (Details) - Oncoceutics, Inc. - USD ($)
$ in Thousands
Jan. 07, 2021
Sep. 30, 2021
Asset Acquisition    
Cash payment for acquisition $ 25,000  
Number of shares issued for acquisition 8,723,769  
Debt issued for acquisition $ 14,000  
Contingent consideration for acquisition $ 360,000  
Liability for closing payment adjustments   $ 200
Accounts and notes receivable net   $ 600
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Jan. 07, 2021
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Asset Acquisition            
IPR&D assets expensed   $ 0   $ 0 $ 82,890 $ 0
Oncoceutics, Inc.            
Asset Acquisition            
Cash $ 23,836          
One-year closing anniversary payment $ 14,000          
Shares common stock issued as consideration (in shares) 8,723,769          
Stock price per share on effective date (in USD per share) $ 4.98          
Value of estimated common stock consideration $ 43,445          
Total consideration 81,281          
Net assets acquired (1,310)          
IPR&D assets expensed 82,591          
Total purchase price allocated 81,281          
Transaction costs expensed to IPR&D 299          
Transaction costs expensed to IPR&D $ 82,890          
Transaction expenses     $ 600      
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details)
$ in Thousands
 3 Months Ended
Dec. 31, 2021
USD ($)
Subsequent Event | Scenario, Forecast  
Subsequent Event  
Milestone payments for ORR $ 20,000
EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 175 300 1 false 36 0 false 11 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.chimerix.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets Sheet http://www.chimerix.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - The Business and Summary of Significant Accounting Policies Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies The Business and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2108102 - Disclosure - Investments Sheet http://www.chimerix.com/role/Investments Investments Notes 9 false false R10.htm 2113103 - Disclosure - Commitments and Contingencies Sheet http://www.chimerix.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 10 false false R11.htm 2118104 - Disclosure - Equity Transactions and Share-based Compensation Sheet http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation Equity Transactions and Share-based Compensation Notes 11 false false R12.htm 2122105 - Disclosure - Income Taxes Sheet http://www.chimerix.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 2124106 - Disclosure - Significant Agreements Sheet http://www.chimerix.com/role/SignificantAgreements Significant Agreements Notes 13 false false R14.htm 2126107 - Disclosure - Oncoceutics Acquisition Sheet http://www.chimerix.com/role/OncoceuticsAcquisition Oncoceutics Acquisition Notes 14 false false R15.htm 2130108 - Disclosure - Subsequent Events Sheet http://www.chimerix.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 2202201 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies The Business and Summary of Significant Accounting Policies (Policies) Policies http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies 16 false false R17.htm 2303301 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables The Business and Summary of Significant Accounting Policies (Tables) Tables http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies 17 false false R18.htm 2309302 - Disclosure - Investments (Tables) Sheet http://www.chimerix.com/role/InvestmentsTables Investments (Tables) Tables http://www.chimerix.com/role/Investments 18 false false R19.htm 2314303 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.chimerix.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.chimerix.com/role/CommitmentsandContingencies 19 false false R20.htm 2319304 - Disclosure - Equity Transactions and Share-based Compensation (Tables) Sheet http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables Equity Transactions and Share-based Compensation (Tables) Tables http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation 20 false false R21.htm 2327305 - Disclosure - Oncoceutics Acquisition (Tables) Sheet http://www.chimerix.com/role/OncoceuticsAcquisitionTables Oncoceutics Acquisition (Tables) Tables http://www.chimerix.com/role/OncoceuticsAcquisition 21 false false R22.htm 2404401 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails The Business and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables 22 false false R23.htm 2405402 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 23 false false R24.htm 2406403 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) Details 24 false false R25.htm 2407404 - Disclosure - The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 25 false false R26.htm 2410405 - Disclosure - Investments - Summary of Available-for-Sale securities (Details) Sheet http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails Investments - Summary of Available-for-Sale securities (Details) Details 26 false false R27.htm 2411406 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details) Sheet http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details) Details 27 false false R28.htm 2412407 - Disclosure - Investments - Schedule of Investment Maturity (Details) Sheet http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails Investments - Schedule of Investment Maturity (Details) Details 28 false false R29.htm 2415408 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 29 false false R30.htm 2416409 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details) Sheet http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details) Details 30 false false R31.htm 2417410 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) Sheet http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) Details 31 false false R32.htm 2420411 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details) Sheet http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails Equity Transactions and Share-based Compensation - Narrative (Details) Details http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables 32 false false R33.htm 2421412 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details) Sheet http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details) Details 33 false false R34.htm 2423413 - Disclosure - Income Taxes (Details) Sheet http://www.chimerix.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.chimerix.com/role/IncomeTaxes 34 false false R35.htm 2425414 - Disclosure - Significant Agreements (Details) Sheet http://www.chimerix.com/role/SignificantAgreementsDetails Significant Agreements (Details) Details http://www.chimerix.com/role/SignificantAgreements 35 false false R36.htm 2428415 - Disclosure - Oncoceutics Acquisition - Narrative (Details) Sheet http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails Oncoceutics Acquisition - Narrative (Details) Details 36 false false R37.htm 2429416 - Disclosure - Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details) Sheet http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details) Details 37 false false R38.htm 2431417 - Disclosure - Subsequent Events (Details) Sheet http://www.chimerix.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.chimerix.com/role/SubsequentEvents 38 false false All Reports Book All Reports cmrx-20210930.htm a20210930cmrxex-101.htm a20210930cmrxex-102.htm a20210930cmrxex-311.htm a20210930cmrxex-312.htm a20210930cmrxex-321.htm a20210930cmrxex-322.htm cmrx-20210930.xsd cmrx-20210930_cal.xml cmrx-20210930_def.xml cmrx-20210930_lab.xml cmrx-20210930_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cmrx-20210930.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 175, "dts": { "calculationLink": { "local": [ "cmrx-20210930_cal.xml" ] }, "definitionLink": { "local": [ "cmrx-20210930_def.xml" ] }, "inline": { "local": [ "cmrx-20210930.htm" ] }, "labelLink": { "local": [ "cmrx-20210930_lab.xml" ] }, "presentationLink": { "local": [ "cmrx-20210930_pre.xml" ] }, "schema": { "local": [ "cmrx-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 353, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021": 5, "total": 7 }, "keyCustom": 36, "keyStandard": 264, "memberCustom": 15, "memberStandard": 19, "nsprefix": "cmrx", "nsuri": "http://www.chimerix.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.chimerix.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113103 - Disclosure - Commitments and Contingencies", "role": "http://www.chimerix.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118104 - Disclosure - Equity Transactions and Share-based Compensation", "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation", "shortName": "Equity Transactions and Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122105 - Disclosure - Income Taxes", "role": "http://www.chimerix.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Significant Agreements", "role": "http://www.chimerix.com/role/SignificantAgreements", "shortName": "Significant Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Oncoceutics Acquisition", "role": "http://www.chimerix.com/role/OncoceuticsAcquisition", "shortName": "Oncoceutics Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Subsequent Events", "role": "http://www.chimerix.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "The Business and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables", "shortName": "The Business and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Investments (Tables)", "role": "http://www.chimerix.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.chimerix.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Equity Transactions and Share-based Compensation (Tables)", "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables", "shortName": "Equity Transactions and Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Oncoceutics Acquisition (Tables)", "role": "http://www.chimerix.com/role/OncoceuticsAcquisitionTables", "shortName": "Oncoceutics Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "cmrx:NumberOfProductCandidates", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "The Business and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "cmrx:NumberOfProductCandidates", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i02b68ce9da52419faeed2169a2b6fdd6_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "cmrx:AccruedDevelopmentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails", "shortName": "The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "cmrx:AccruedDevelopmentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ieb5c8971bea0439ab7e090651594487f_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Investments - Summary of Available-for-Sale securities (Details)", "role": "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "shortName": "Investments - Summary of Available-for-Sale securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)", "role": "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "shortName": "Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Investments - Schedule of Investment Maturity (Details)", "role": "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails", "shortName": "Investments - Schedule of Investment Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)", "role": "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails", "shortName": "Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)", "role": "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i452384937bb34a4daa87555bb4b408f2_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i14635248530041409cf85c8c81269dfa_I20210120", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details)", "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails", "shortName": "Equity Transactions and Share-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i14635248530041409cf85c8c81269dfa_I20210120", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)", "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails", "shortName": "Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Income Taxes (Details)", "role": "http://www.chimerix.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Significant Agreements (Details)", "role": "http://www.chimerix.com/role/SignificantAgreementsDetails", "shortName": "Significant Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ic92f2d7889154583927aaeb9a607c894_D20110201-20110228", "decimals": "INF", "lang": "en-US", "name": "cmrx:NumberOfExtensionPeriods", "reportCount": 1, "unique": true, "unitRef": "extension", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "iaacd01ce80ea4c8c9642213003673541_D20210107-20210107", "decimals": "-5", "first": true, "lang": "en-US", "name": "cmrx:PaymentsToAcquireProductiveAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Oncoceutics Acquisition - Narrative (Details)", "role": "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails", "shortName": "Oncoceutics Acquisition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "iaacd01ce80ea4c8c9642213003673541_D20210107-20210107", "decimals": "-5", "first": true, "lang": "en-US", "name": "cmrx:PaymentsToAcquireProductiveAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details)", "role": "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "shortName": "Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "iaacd01ce80ea4c8c9642213003673541_D20210107-20210107", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ib5f90f994cd74d2eba93c7cf640d526f_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "cmrx:AssetAcquisitionContingentConsiderationMilestonePaymentsORR", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Subsequent Events (Details)", "role": "http://www.chimerix.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ib5f90f994cd74d2eba93c7cf640d526f_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "cmrx:AssetAcquisitionContingentConsiderationMilestonePaymentsORR", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i32554e4db06f4ceeaa201a00ded40cee_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i6b0d70ad4d9f4842a238fe7ed9916953_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i6b0d70ad4d9f4842a238fe7ed9916953_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ic3b711f0cd3648fe960414ee74bd4630_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "ic3b711f0cd3648fe960414ee74bd4630_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - The Business and Summary of Significant Accounting Policies", "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies", "shortName": "The Business and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108102 - Disclosure - Investments", "role": "http://www.chimerix.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cmrx-20210930.htm", "contextRef": "i0864adbfdf744d899e6e26399a9ddad6_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "cmrx_AccruedDevelopmentLiabilities": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued development liabilities.", "label": "Accrued Development Liabilities", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedDevelopmentLiabilities", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "cmrx_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNetAndResearchAndDevelopmentInProgress", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Net assets acquired" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNetAndResearchAndDevelopmentInProgress": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net and Research and Development in Progress", "label": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net and Research and Development in Progress", "totalLabel": "Total purchase price allocated" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNetAndResearchAndDevelopmentInProgress", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionClosingPaymentAdjustmentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Closing Payment Adjustment Liability", "label": "Asset Acquisition, Closing Payment Adjustment Liability", "terseLabel": "Liability for closing payment adjustments" } } }, "localname": "AssetAcquisitionClosingPaymentAdjustmentLiability", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number of Shares", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number of Shares", "terseLabel": "Number of shares issued for acquisition", "verboseLabel": "Shares common stock issued as consideration (in shares)" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cmrx_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Equity Interests Issued and Issuable", "label": "Asset Acquisition, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Value of estimated common stock consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Liabilities Incurred", "label": "Asset Acquisition, Consideration Transferred, Liabilities Incurred", "terseLabel": "Debt issued for acquisition", "verboseLabel": "One-year closing anniversary payment" } } }, "localname": "AssetAcquisitionConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionContingentConsiderationMilestonePaymentsORR": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Milestone Payments ORR", "label": "Asset Acquisition, Contingent Consideration, Milestone Payments ORR", "terseLabel": "Milestone payments for ORR" } } }, "localname": "AssetAcquisitionContingentConsiderationMilestonePaymentsORR", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_AssetAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Share Price", "label": "Asset Acquisition, Share Price", "terseLabel": "Stock price per share on effective date (in USD per share)" } } }, "localname": "AssetAcquisitionSharePrice", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "perShareItemType" }, "cmrx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Operating lease right-of-use assets and liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "cmrx_BARDAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BARDA [Member]", "label": "BARDA [Member]", "terseLabel": "BARDA", "verboseLabel": "BARDA" } } }, "localname": "BARDAMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_CantexPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantex Pharmaceuticals [Member]", "label": "Cantex Pharmaceuticals [Member]", "terseLabel": "Cantex Pharmaceuticals Inc." } } }, "localname": "CantexPharmaceuticalsMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "domainItemType" }, "cmrx_ContractAndGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract and Grant", "label": "Contract and Grant [Member]", "terseLabel": "Contract and grant revenue" } } }, "localname": "ContractAndGrantMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two", "terseLabel": "Maturing after one year through two years" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_ExpenseReimbursementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense Reimbursement [Member]", "label": "Expense Reimbursement [Member]", "terseLabel": "Expense reimbursement" } } }, "localname": "ExpenseReimbursementMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_FederalGovermentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Goverment", "label": "Federal Goverment [Member]", "terseLabel": "Federal Goverment" } } }, "localname": "FederalGovermentMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_FeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fees", "label": "Fees [Member]", "terseLabel": "Fees" } } }, "localname": "FeesMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_IncreaseDecreaseInNumberOfSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in number of shares authorized.", "label": "Increase (Decrease) In Number of Shares Authorized", "verboseLabel": "Number of shares reserved for issuance, annual increase (in shares)" } } }, "localname": "IncreaseDecreaseInNumberOfSharesAuthorized", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cmrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "All remaining years" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LesseeOperatingLeaseRentAbatementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Rent Abatement Term", "label": "Lessee, Operating Lease, Rent Abatement Term", "terseLabel": "Rent abatement term" } } }, "localname": "LesseeOperatingLeaseRentAbatementTerm", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "cmrx_LesseeOperatingSubleaseAreaOfSubleaseProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Sublease, Area Of Sublease Property", "label": "Lessee, Operating Sublease, Area Of Sublease Property", "terseLabel": "Area of sublease space (in sq ft)" } } }, "localname": "LesseeOperatingSubleaseAreaOfSubleaseProperty", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "areaItemType" }, "cmrx_LicenseAgreementAmountToBePaidUponAchievementOfSpecifiedSalesLevels": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Amount To Be Paid Upon Achievement Of Specified Sales Levels", "label": "License Agreement, Amount To Be Paid Upon Achievement Of Specified Sales Levels", "terseLabel": "Payments to be made upon achievement of specified net sales levels (up to)" } } }, "localname": "LicenseAgreementAmountToBePaidUponAchievementOfSpecifiedSalesLevels", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LicenseAgreementAmountToBePaidUponReceiptOfProductApprovals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Amount To Be Paid Upon Receipt Of Product Approvals", "label": "License Agreement, Amount To Be Paid Upon Receipt Of Product Approvals", "terseLabel": "Payments to be made for regulatory milestones (up to)" } } }, "localname": "LicenseAgreementAmountToBePaidUponReceiptOfProductApprovals", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LicenseAgreementCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement Cost", "label": "License Agreement Cost", "terseLabel": "License agreement cost" } } }, "localname": "LicenseAgreementCost", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Nonrefundable Regulatory Milestone Payment to be Received", "label": "License Agreement, Nonrefundable Regulatory Milestone Payment to be Received", "terseLabel": "License agreement, nonrefundable regulatory milestone payment to be received" } } }, "localname": "LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LicenseAgreementPaymentToBeReceivedUponMilestonesAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Payment To Be Received Upon Milestones Achieved", "label": "License Agreement, Payment To Be Received Upon Milestones Achieved", "terseLabel": "Payment to be received upon achievement of milestones" } } }, "localname": "LicenseAgreementPaymentToBeReceivedUponMilestonesAchieved", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_LicenseAgreementRoyaltyPercentageToBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Royalty Percentage To Be Paid", "label": "License Agreement, Royalty Percentage To Be Paid", "terseLabel": "Royalty percentage to be paid (at least)" } } }, "localname": "LicenseAgreementRoyaltyPercentageToBePaid", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "percentItemType" }, "cmrx_LicenseAgreementTerminationNoticeTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Termination Notice Term", "label": "License Agreement, Termination Notice Term", "terseLabel": "Termination notice period" } } }, "localname": "LicenseAgreementTerminationNoticeTerm", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "durationItemType" }, "cmrx_NumberOfExtensionPeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of extension periods.", "label": "Number Of Extension Periods", "verboseLabel": "Number of extension periods" } } }, "localname": "NumberOfExtensionPeriods", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "integerItemType" }, "cmrx_NumberOfGrantsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Grants Acquired", "label": "Number of Grants Acquired", "terseLabel": "Number of grants" } } }, "localname": "NumberOfGrantsAcquired", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "integerItemType" }, "cmrx_NumberOfProductCandidates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Product Candidates", "label": "Number Of Product Candidates", "terseLabel": "Number of product candidates" } } }, "localname": "NumberOfProductCandidates", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cmrx_OharaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ohara Pharmaceutical Co., Ltd.", "label": "Ohara Pharmaceutical Co., Ltd. [Member]", "terseLabel": "Ohara Pharmaceutical Co., Ltd." } } }, "localname": "OharaPharmaceuticalCoLtdMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "domainItemType" }, "cmrx_OncoceuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oncoceutics, Inc.", "label": "Oncoceutics, Inc. [Member]", "terseLabel": "Oncoceutics, Inc." } } }, "localname": "OncoceuticsIncMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent", "terseLabel": "Lease-related amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cmrx_PaymentsToAcquireProductiveAssetsGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Productive Assets, Gross", "label": "Payments to Acquire Productive Assets, Gross", "terseLabel": "Cash payment for acquisition" } } }, "localname": "PaymentsToAcquireProductiveAssetsGross", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_PrivateFoundationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Foundations", "label": "Private Foundations [Member]", "terseLabel": "Private Foundations" } } }, "localname": "PrivateFoundationsMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering", "label": "Public Stock Offering [Member]", "terseLabel": "Public Stock Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cmrx_RefundableAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refundable Agreements [Member]", "label": "Refundable Agreements [Member]", "terseLabel": "Refundable Agreements" } } }, "localname": "RefundableAgreementsMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cmrx_ResearchAndDevelopmentInProgressIncludingTransactionCosts": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development in Progress, Including Transaction Costs", "label": "Research and Development in Progress, Including Transaction Costs", "totalLabel": "Transaction costs expensed to IPR&D" } } }, "localname": "ResearchAndDevelopmentInProgressIncludingTransactionCosts", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_ResearchAndDevelopmentInProgressTransactionCosts": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "cmrx_ResearchAndDevelopmentInProgressIncludingTransactionCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development in Progress, Transaction Costs", "label": "Research and Development in Progress, Transaction Costs", "terseLabel": "Transaction costs expensed to IPR&D" } } }, "localname": "ResearchAndDevelopmentInProgressTransactionCosts", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cmrx_RevenuePerformanceObligationTotalNumberOfBaseSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Total Number Of Base Segments", "label": "Revenue, Performance Obligation, Total Number Of Base Segments", "terseLabel": "Total number of base segments" } } }, "localname": "RevenuePerformanceObligationTotalNumberOfBaseSegments", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "integerItemType" }, "cmrx_RevenuePerformanceObligationTotalNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Total Number Of Contracts", "label": "Revenue, Performance Obligation, Total Number Of Contracts", "terseLabel": "Total number of separate contracts" } } }, "localname": "RevenuePerformanceObligationTotalNumberOfContracts", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "integerItemType" }, "cmrx_RevenuePerformanceObligationTotalNumberOfOptionSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Total Number Of Option Segments", "label": "Revenue, Performance Obligation, Total Number Of Option Segments", "terseLabel": "Total number of option segments" } } }, "localname": "RevenuePerformanceObligationTotalNumberOfOptionSegments", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "integerItemType" }, "cmrx_SaleOfStockPurchaseOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Purchase Option Term", "label": "Sale of Stock, Purchase Option Term", "terseLabel": "Purchase option term" } } }, "localname": "SaleOfStockPurchaseOptionTerm", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cmrx_SanjiuMedicalPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanjiu Medical & Pharmaceutical Co., Ltd.", "label": "Sanjiu Medical & Pharmaceutical Co., Ltd. [Member]", "terseLabel": "CR Sanjui" } } }, "localname": "SanjiuMedicalPharmaceuticalCoLtdMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "domainItemType" }, "cmrx_ShareBasedCompensationEvergreenOptionProvisionEquityIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Evergreen Option Provision, Equity Increase", "label": "Share-Based Compensation, Evergreen Option Provision, Equity Increase", "terseLabel": "Evergreen option provision, equity increase" } } }, "localname": "ShareBasedCompensationEvergreenOptionProvisionEquityIncrease", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Participation Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Participation Term", "terseLabel": "Participation term" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval", "terseLabel": "Purchase interval" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cmrx_SymBioPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SymBio Pharmaceuticals [Member]", "label": "SymBio Pharmaceuticals [Member]", "terseLabel": "SymBio Pharmaceuticals" } } }, "localname": "SymBioPharmaceuticalsMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "cmrx_The2013EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The 2013 Employee Stock Purchase Plan Member.", "label": "The 2013 Employee Stock Purchase Plan [Member]", "terseLabel": "The 2013 Employee Stock Purchase Plan" } } }, "localname": "The2013EmployeeStockPurchasePlanMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cmrx_The2013PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The 2013 Plan [Member]", "label": "The 2013 Plan [Member]", "terseLabel": "The 2013 Plan" } } }, "localname": "The2013PlanMember", "nsuri": "http://www.chimerix.com/20210930", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chimerix.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r35", "r37", "r76", "r77", "r199", "r205" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r134", "r221", "r223", "r362", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r134", "r221", "r223", "r362", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r36", "r37", "r76", "r77", "r199", "r205" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r87", "r239" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails", "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r87", "r92", "r239" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails", "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r87", "r92", "r185", "r239", "r329" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails", "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNotesReceivableNet": { "auth_ref": [ "r14", "r137", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts and notes receivable net" } } }, "localname": "AccountsAndNotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r14", "r137", "r138" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of discount/premium on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued liabilities", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r27" ], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "auth_ref": [ "r367", "r383" ], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.", "label": "Accrued Salaries", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedSalariesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r41", "r42", "r43", "r379", "r395", "r396" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss, net" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r49", "r50", "r51", "r79", "r80", "r81", "r288", "r391", "r392", "r416" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated\u00a0Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r252", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r79", "r80", "r81", "r249", "r250", "r251", "r292" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in\u00a0Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r240", "r241", "r254", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r241", "r246", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r281", "r282", "r283", "r284" ], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "totalLabel": "Total consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "auth_ref": [ "r281", "r282", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration for acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r281", "r282", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction expenses" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]", "terseLabel": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails", "http://www.chimerix.com/role/OncoceuticsAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of asset acquisition.", "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Asset acquisition" } } }, "localname": "AssetAcquisitionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "Asset Acquisition [Text Block]", "terseLabel": "Oncoceutics Acquisition" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r72", "r117", "r126", "r132", "r159", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r286", "r289", "r303", "r324", "r326", "r364", "r378" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails", "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r34", "r72", "r159", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r286", "r289", "r303", "r324", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r295" ], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r144" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r145" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r142", "r166" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r146", "r147", "r373" ], "calculation": { "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Maturing in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r140", "r143", "r166", "r366" ], "calculation": { "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Total debt investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails", "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r141", "r166" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term investments, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r141", "r166" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "The Business and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r68", "r69" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r304" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r182", "r183", "r184", "r186", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r79", "r80", "r292" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r13" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020; 86,848,426 and 62,816,039 shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r53", "r369", "r385" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r209", "r211", "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r209", "r210", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Provision for refundable amounts" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds", "verboseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r154", "r171", "r174" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Fair value, greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r154", "r171" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Unrealized loss, greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r169" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of securities with unrealized losses, greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r154", "r171", "r174" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Fair value, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r154", "r171" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Unrealized loss, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r169" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of securities with unrealized losses, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "verboseLabel": "Summary of short-term and long-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r150", "r167", "r174" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Fair value, total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r151", "r168" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Unrealized loss, total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r152", "r169" ], "calculation": { "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "totalLabel": "Number of securities with unrealized losses, total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r66", "r178" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Equity Transactions and Share-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Per share information:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r54", "r84", "r85", "r86", "r87", "r88", "r93", "r95", "r97", "r98", "r99", "r102", "r103", "r293", "r294", "r370", "r386" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r54", "r84", "r85", "r86", "r87", "r88", "r95", "r97", "r98", "r99", "r102", "r103", "r293", "r294", "r370", "r386" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Loss Per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Estimated annual effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r79", "r80", "r81", "r83", "r89", "r91", "r105", "r160", "r207", "r208", "r249", "r250", "r251", "r271", "r272", "r292", "r305", "r306", "r307", "r308", "r309", "r310", "r391", "r392", "r393", "r416" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r200", "r202", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r296", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r295", "r296", "r297", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r200", "r231", "r232", "r237", "r238", "r296", "r334" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0Prices\u00a0in Active\u00a0Markets for\u00a0Identical\u00a0Assets (Level\u00a01)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r200", "r202", "r203", "r231", "r232", "r237", "r238", "r296", "r335" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant\u00a0Other Observable\u00a0Inputs (Level\u00a02)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r200", "r202", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r296", "r336" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable\u00a0Inputs (Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r200", "r202", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value, measurements, recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r148", "r149", "r156", "r157", "r158", "r161", "r162", "r163", "r164", "r165", "r170", "r172", "r173", "r174", "r201", "r206", "r291", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "verboseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Gain on sale of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r264", "r266", "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r73", "r263", "r267", "r269", "r273", "r275", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r74", "r90", "r91", "r116", "r261", "r274", "r276", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Federal or state income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Increase (Decrease) in Notes Payable, Current", "terseLabel": "Note payable related to asset acquisition" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r371" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income and other, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r32", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r33", "r70", "r104", "r175", "r176", "r177", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Inventory, work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of the scheduled maturity of company investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r155", "r363", "r374", "r400", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r66" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Fair value of common stock issued related to asset acquisition" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating lease maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum rental payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year one" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of fiscal year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r322" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r72", "r127", "r159", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r287", "r289", "r290", "r303", "r324", "r325" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r72", "r159", "r303", "r326", "r365", "r381" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r72", "r159", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r287", "r289", "r290", "r303", "r324", "r325", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "verboseLabel": "Licensing revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r64", "r67" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r44", "r46", "r51", "r52", "r67", "r72", "r82", "r84", "r85", "r86", "r87", "r90", "r91", "r96", "r117", "r125", "r128", "r131", "r133", "r159", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r294", "r303", "r368", "r384" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows", "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Impact of Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r117", "r125", "r128", "r131", "r133" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense under non-cancelable operating leases" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r313" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total present value of lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails", "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease short-term liabilities (recorded within Accrued liabilities)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, liability, current, statement of financial position [extensible list]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease-related obligations", "verboseLabel": "Operating lease long-term liabilities (recorded within Lease-related obligations)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails", "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r316", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r312" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails", "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r320", "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r27" ], "calculation": { "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r38", "r39", "r41" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on debt investments, net", "verboseLabel": "Unrealized loss on investments, net" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonrecurringIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonrecurring (Income) Expense [Abstract]", "terseLabel": "Other income:" } } }, "localname": "OtherNonrecurringIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriter's Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "auth_ref": [ "r60" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.", "label": "Payments to Acquire Long-term Investments", "negatedTerseLabel": "Purchases of long-term investments" } } }, "localname": "PaymentsToAcquireLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r59", "r281", "r282", "r283" ], "calculation": { "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "verboseLabel": "Cash" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r60" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r242", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r204" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r204" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r12" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "verboseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020; no shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r21", "r22" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r61", "r248" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r58", "r60" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments", "verboseLabel": "Proceeds from maturities of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r58" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-term Investments", "terseLabel": "Proceeds from sales of short-term investments" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r248" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r179", "r326", "r375", "r382" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r388" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Gain on sale of investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.", "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]", "terseLabel": "Significant Agreements" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SignificantAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r257" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Prepaids and Accruals" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "cmrx_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNetAndResearchAndDevelopmentInProgress", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development", "verboseLabel": "IPR&D assets expensed" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/OncoceuticsAcquisitionConsiderationPaidandPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r208", "r252", "r326", "r380", "r394", "r396" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r79", "r80", "r81", "r83", "r89", "r91", "r160", "r249", "r250", "r251", "r271", "r272", "r292", "r391", "r393" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r114", "r115", "r124", "r129", "r130", "r134", "r135", "r136", "r220", "r221", "r362" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/SignificantAgreementsDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r71", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]", "terseLabel": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from shares sold" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price of shares sold (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of employee and non-employee share-based compensation expense recognized related to stock options, the ESPP and RSUs" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r241", "r245", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of certain assets measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Separate Account Investment [Line Items]", "terseLabel": "Fair Value, Separate Account Investment" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": { "auth_ref": [ "r376", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table]", "terseLabel": "Fair Value, Separate Account Investment [Table]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r242", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of investments with unrealized losses, aggregated by investment type and the length of time" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date", "terseLabel": "Discounted purchase price from market price, offering date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Discounted purchase price from market price, purchase date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Percentage of pay that employee can contribute, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of shares authorized to be granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares reserved for future issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "terseLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r49", "r50", "r51", "r79", "r80", "r81", "r83", "r89", "r91", "r105", "r160", "r207", "r208", "r249", "r250", "r251", "r271", "r272", "r292", "r305", "r306", "r307", "r308", "r309", "r310", "r391", "r392", "r393", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r105", "r362" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r12", "r13", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock related to asset acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r12", "r13", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued pursuant to employee stock purchase plan (in shares)", "verboseLabel": "Employee stock purchase plan purchases (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs $7.2 million (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares issued for restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "RSU stock issuance (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r207", "r208", "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued pursuant to the exercise of stock options (in shares)", "verboseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit", "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r29", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock related to asset acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r12", "r13", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Employee stock purchase plan purchases" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs of $7.2\u00a0million" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r29", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r18", "r19", "r72", "r139", "r159", "r303", "r326" ], "calculation": { "http://www.chimerix.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets", "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r318", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r311", "r328" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r311", "r328" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r311", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r311", "r328" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r148", "r149", "r156", "r157", "r158", "r201", "r206", "r291", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]", "verboseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r75", "r231", "r238", "r372" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails", "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails", "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r260", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r99" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r403": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r404": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r405": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r406": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r407": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r408": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r409": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r410": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r411": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r412": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r415": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 58 0001117480-21-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001117480-21-000025-xbrl.zip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�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